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The wind was flapping a temple flag, and two monks started an 
argument. One said the flag moved, the other said the wind 
moved. 
The sixth patriarch said:” It is not the wind that moves, it is not 
the flag that moves; it is your mind that moves.” 
Mumonkan, Case 29 
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Abstract 
In this thesis, two projects involving the total synthesis of natural products are presented. 
The first chapter gives a general introduction to natural product total synthesis and its 
impact on human society. 
The second chapter gives an overview on neurodegenerative diseases and introduces the 
neuritogenic pyridopolyene natural product (–)-pyridovericin. The enantioselective total 
synthesis of (–)-pyridovericin is presented. The key steps were an enantioselective, 
iridium-catalyzed hydrogenation of an enoate and an E-selective Horner-Wadsworth-
Emmons reaction. The complex pyridopolyene structure was then truncated and the 
neuritogenic core structure identified. Truncated natural product analogs were 
synthesized and successfully implemented in a neuritogenic surface material. 
The third chapter reviews the current state of research on HIV and AIDS. Our efforts 
towards the total synthesis of the recently isolated HIV-inhibitory natural product 
aetheramide B are reported. Three advanced building blocks were synthesized 
enantioselectively in good yields. The key steps involved the enantioselective 
hydrogenation of an enamide to form an amino ester, the diastereoselective alkynylation 
of a homobenzylic aldehyde and the enantioselective reduction of a bromoenone. The 
building blocks were then successfully coupled to form the macrocyclic depsipeptide 
core structure. The macrocyclic core of aetheramide B was then synthesized in a 
macrolactonization reaction.  
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Kurzbeschreibung 
Diese Doktorarbeit umfasst zwei Projekte, die sich mit der Totalsynthese von 
Naturstoffen und deren Anwendungen befassen. Im ersten Kapitel wird an einigen 
historischen und modernen Beispielen die Bedeutung der Naturstoffsynthese illustriert.  
Im zweiten Kapitel wird die enantioselektive Totalsynthese von (–)-Pyridovericin 
beschrieben. Die Schlüsselschritte umfassen eine enantioselektive, asymmetrische 
Hydrierung eines ungesättigten Esters und eine Horner-Wadsworth-Emmons Reaktion 
zur Verknüpfung der Hauptfragmente. Die neuritogene Grundstruktur wurde mithilfe 
von PC-12 Assays ermittelt, und das erhaltene Naturstoffanalogon wurde zur 
Herstellung einer biokompatiblen, neuritogenen Oberfläche verwendet.  
Eine Einleitung zum Status Quo der HIV-Pandemie und AIDS-Therapie bildet den 
Auftakt zu Kapitel drei. Die Fortschritte in der Totalsynthese des HIV-inhibierenden 
Depsipeptids Aetheramid B werden präsentiert. Drei Hauptfragmente wurden in guter 
Ausbeute und hoher Enantiomerenreinheit synthetisiert. Die Schlüsselschritte umfassten 
eine Rhodium-katalysierte, enantioselektive Hydrierung zur Herstellung des Dipeptid-
fragments, eine diastereoselektive Alkynylierung zur Darstellung des Diol-fragments 
und eine enantioselektive Reduktion eines labilen Bromenons. Die Fragmente wurden 
erfolgreich zusammengefügt, und die markozyklische Grundstrunktur von Aetheramid B 
wurde in einer Macrolaktonisierungsreaktion synthetisiert. 
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1 Introduction 
1.1 Natural Product Chemistry in Human History 
Throughout history, biological matter (e.g. animals, plants, fungi, microorganisms) has 
been a great source of materials beneficial to human society. This general introduction 
aims to highlight a selection of historic applications and discoveries of natural products 
in several fields relevant to human society. 
Indigo (1.03) is a blue dye used in textile dying obtained from the extracts of plants from 
the genus Indigofera (Scheme 1.1). Historically, indigo production has been performed 
in Asia (especially India) for centuries, and the first reports of the dye being used in 
Europe date back to the Greco-Roman era.1 In general, dyes were highly scarce until the 
19th century, and one of the economical driving forces of the colonization and 
exploitation of south and Southeast Asia has been the export of indigo.2 In the pre-
industrialization era, indigo was the only available blue dye and, even today, denim blue 
jeans derive their characteristic color from indigo.  
Scheme 1.1: Formation of Indigo (1.03) from indican (1.01). 
The Indigofera plants are rich in the water-soluble and colorless indol-substituted sugar, 
indican (1.01), which is extracted from the plant and hydrolyzed to give the colorless 
and water-soluble indoxyl (Scheme 1.1). When exposed to the oxygen present in air, 
indol 1.02 undergoes an oxidative dimerization to form the water-insoluble indigo 
(1.03).3 Since 1897, an industrial chemical process developed by BASF has largely 
replaced the extraction route to indigo.  
                                                
 
1 E. Steingruber, Indigo and Indigo Colorants, Ullmann's Encyclopedia of Industrial Chemistry, 2004, 
Wiley-VCH, Weinheim. 
2 D. H. Rembert, Jr. Economic Botany, 1979, 33, 128. 
3 M. Sequin-Frey, J. Chem. Educ. 1981, 58, 301. 
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 2 
The initial syntheses reported by Adolf von Baeyer in 1882 proved to be too impractical 
for industrial scale, and a modified process based on the method by Heumann and 
Hegler is still applied today, producing about 17,000 tons per year.4 
Figure 1.1: Stripping sperm whale of blubber (left) and extraction of spermaceti from the 
whale’s head (right).5 
Before the advent of the petrol industry and electrification, people relied on other 
sources of energy for the generation of light. The organic oils and waxes found in 
Cetaceans proved to be highly useful for this purpose, and especially Physeter 
macrocephalus, commonly known as sperm whale, suffered tremendously due to this 
fact. The main sought after component of the sperm whale was on one hand the blubber. 
This greasy adipose tissue under the skin of the whale was peeled off (Figure 1.1, left) 
and boiled  to give the refined whale or tran oil, which was used to fuel lamps for 
example.6 On the other hand, the product that distinguished the sperm whale from other 
Cetaceans is the spermaceti or sperm oil found in the whale’s head (Figure 1.1, right and 
Figure 1.2). This colorless waxy substance (M.p. ~ 40°C) consists mainly of wax esters 
such as cetyl palmitate (1.04, Figure 1.2),7 which gives a very bright light when 
manufactured into candles.  
                                                
 
4 A. von Baeyer, V. Drewsen, Ber. 1882, 15, 2856; H. Schmidt, Chemie unseres Zeit, 1997, 3, 121. 
5 W. M. Davis, Nimrod of the Sea; or, The American Whaleman,1874, public domain. 
6 W. F. Perrin, B. Würsig, J. G. M. Thewissen, Encyclopedia of Marine Mammals, 2002, Oxford 
Academic press, 2nd edition, Oxford. 
7 M. R. Clarke, Nature 1970, 228, 873. 
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Even early standardization protocols for the definition of luminous intensity relied on 
the use of a pure spermaceti candle.8 Nowadays, jojoba oil and synthetic cetyl palmitate 
(1.04) replace the products of whale origin in cosmetics, lubricants etc. 
Figure 1.2: Cross section of sperm whale head (left) with spermaceti in gold and its main 
constituent cetyl palmitate (1.04, right).9 
These two historic examples clearly illustrate some of the many merits of organic 
synthesis. Both the extraction of indigo and whaling of sperm whales have negative 
impact on the ecosystem. While the production of indigo largely proceeded under 
miserable conditions for the indigenous work force, also sperm whaling was a risky and 
strenuous undertaking for the crew and also nearly lead to the extinction of sperm 
whales. The processes were also economically unattractive, since the products usually 
had to be shipped over large distances. The synthetic preparation of indigo (1.03) and 
cetyl palmitate (1.04) allowed for production on-site and eliminated the drawbacks of 
the classical fabrication. 
1.2 Natural Products in Medicinal Applications 
One of the most distinguished uses of natural products has been their application in a 
medicinal context. The earliest documented case of plants applied as medicine date back 
to 60’000 BC, found in the grave of a Neanderthal in the Shanidar cave.10 Several 
written documents detail the preparation of plant tinctures and extracts, such as clay 
tablets from Mesopotamia (2600 BC), the Chinese “Wushi’er Bingfang” (1100 BC) or 
the Ebers papyrus (2900 BC).11 The Ebers papyrus lists extracts of willow barks with an 
analgesic and anti-inflammatory properties, and willow extracts have also been used in 
                                                
 
8 "Chartered Gas Light and Coke Company". London Metropolitan Archives. The National Archives. 
1823–1894. pp. LMA/4438. 
9 http://commons.wikimedia.org/wiki/File:Cross_section_of_a_sperm_whale_head.png, CC0-1.0 
universal public domain dedication license. 
10 A. Lerio-Gourhan, Science, 1975, 190, 562. 
11 G. M. Cragg, D. J. Newman, Pure Appl. Chem. 2005, 77, 7. 
O
O
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Europe since 4000 BC.12 With the emergence of modern scientific methodology in the 
19th century, the pharmacologically active constituents of the willow formulations were 
further investigated. Salicin (1.05) was isolated in 1828 by Joseph Buchner13 and, by 
1874, salicylic acid (1.07) was produced industrially via the Kolbe-Schmitt process 
(Scheme 1.2).14  
Scheme 1.2: Structure of salicin (1.05) and the synthesis of Aspirin (1.08). 
Although glycoside 1.05 possesses analgesic and anti-inflammatory properties, it was 
found that acetyl salicylic acid (1.08, trade name Aspirin) had less side effects, 
especially gastric irritation, and was patented in the U.S. in 1900 by Bayer.15 In the 
production process, phenol (1.06) is oxidized to salicylic acid (1.07) in the presence of 
sodium hydroxide and carbon dioxide. Acid 1.07 is then acetylated with acetic 
anhydride in the presence of either catalytic amounts of sulfuric acid or pyridine to give 
aspirin (Scheme 1.2). Aspirin (1.08) also possesses further modes of action than 
glycoside 1.05, and Bergström, Samuelsson and Vane, the investigators of the 
prostaglandin inhibiting properties of Aspirin, were awarded with the Nobel Prize in 
medicine and physiology in 1982.16 
For centuries, the barks of Cinchona trees have been used by the indigenous Peruvian 
Quechua people as a muscle relaxant.17 The bark was then brought to Europe in the 16th 
century by Jesuit priests for the treatment of malaria and called Jesuit’s or Peruvian 
bark. It is argued that the discovery of the Peruvian bark fuelled the colonization of the 
                                                
 
12 K.-C. Bergmann, J. Ring, History of Allergy 2014, Karger Medical and Scientific Publishers, Basel. 
13 O. Lafont, Rev. Hist. Pharm. 2007, 55, 209. 
14 H. Kolbe, E. Lautemann, Liebigs Ann. Chem. 1860, 113, 125; H. Kolbe, E. Lautemann, Liebigs Ann. 
Chem. 1860, 115, 157; .Patent US334290: Manufacture of salicylic acid. Published January12. 1886, 
Inventor: R. Schmitt. 
15 W. Sneader, BMJ, 2001, 321, 7276. 
16 J. R. Vane, Nat. New Biol. 1971, 231, 232. 
17 R. Fiametta, Quinine: malaria and the quest for a cure that changed the world 2004, NY: Perennial, 
New York. 
HO O O
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sub-Saharan African continent and allowed for permanent establishment of settlements 
in the malaria-endemic regions.18 
The antimalarial agent in Cinchona barks was first isolated in 1820 by Pelletier and 
Caventou and called quinine (1.10),19 but it wasn’t until 1908 when the correct structure 
of compound 1.10 was determined by Rabe (Scheme 1.3).20 Until the 1940’s, quinine 
(1.10) remained the treatment of choice for malaria. When the U.S. supply line of 
Cinchona bark from Javanese plantations run by the Dutch monopoly was cut during the 
German occupation of the Netherlands, it caused the death of thousands of U.S. soldiers 
stationed in the Pacific due to malaria infection. This devastation motivated 
investigations towards a synthetic route to quinine (1.10) and related Cinchona 
alkaloids, which culminated in the historic formal synthesis of (–)-quinine (1.10) from 
precursor 1.09 by Woodward and Doering in 1944 (Scheme 1.3).21  
Scheme 1.3: Total synthesis of d-quinotoxine (1.09) and formal synthesis of (–)-quinine 
(1.10) by Woodward and Doering. 
Since then, Cinchona alkaloids have found widespread application in asymmetric 
organic synthesis.22 Despite the controversy surrounding the original report,23 it served 
as a benchmark for other synthetic organic chemists, as did many of Woodward’s 
                                                
 
18 J. Achan, A. O. Talisuna, A. Erhart, A. Yeka, J. K. Tibenderana, F. N. Baliraine, P. J. Rosenthal, U. 
D'Alessandro, Malaria Journal 2011, 10, 144. 
19 P. J. Pelletier, J. B. Caventou, Annales de Chimie et de Physique 1820, 15, 337. 
20 P. Rabe, Ber. 1908, 41, 62. 
21 R. B. Woodward, W. E. Doering, J. Am. Chem. Soc. 1945, 66, 849; R. B. Woodward, W. E. Doering, J. 
Am. Chem. Soc. 1945, 67, 860. 
22 C. E. Song (Ed.), Cinchona Alkaloids in Synthesis and Catalysis: Ligands, Immobilization and 
Organocatalysis, 2009, Wiley-VCH, Weinheim. 
23 A. C. Smith, R. M. Williams, Angew. Chem. Int. Ed. 2008, 47, 1736;  J. I. Seeman, Angew. Chem. Int. 
Ed. 2007, 46, 1378. 
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works.24 It further shifted the expectation of the amount molecular complexity able to be 
achieved by total synthesis, especially in a medicinal chemistry context. 
1.3 Total Synthesis of Natural Products and Drug Development 
In 1929, Scottish biologist Alexander Fleming observed the inhibition of bacterial 
growth in a Staphylococcus culture by a contaminant mold, which was identified to be 
the fungus Penicillium notatum (Figure 1.3).25 The structure of the antibacterial 
compound was proposed in 1941 and confirmed in 1944 by X-ray crystallographic 
analysis of penicillin G.26 The β-lactam core 1.12 was later also found to be present in 
cephalosporin type antibiotic natural products (1.13, Figure 1.4).27 It was found that β-
lactam antibiotics inhibit cell wall synthesis in the bacterium by binding to penicillin-
binding transpeptidases.28 Since the first commercial production of penicillin by 
fermentation during the Second World War, the emergence of penicillin resistant 
bacterial strains posed a severe health threat. In resistant strains, the bacteria are able to 
produce penicillin-degrading β-lactamases or have developed modified transpeptidases 
to which penicillins cannot bind anymore.29 While biologists identified further β-lactam 
antibiotics from the penicillin and cephalosporin families, chemists investigated 
synthetic routes to β-lactam antibiotics. The first total synthesis of penicillin V (1.11) by 
Sheehan and co-workers was reported in 1952.30 The synthesis of all stereoisomers was 
reported, and the proposed structure could be confirmed experimentally. Furthermore, 
the synthesis indicated that the site most amenable for modification was the amide side 
chain.   
                                                
 
24 R. B. Woodward, M. P. Cava, W. D. Ollis, A. Hunger, H. U. Daeniker, K. Schenker, Tetrahedron 1963, 
19, 247; E. C. Kornfeld, E. J. Fornefeld, G. B. Kline, M. J. Mann, D. E. Morrison, R. G. Jones, R.B. 
Woodward, J. Am. Chem. Soc. 1956, 78, 3087; R. B. Woodward, Pure & Appl. Chem. 1968, 17, 519; R. 
B. Woodward, Pure & Appl. Chem. 1971, 25, 283; R. B. Woodward, Pure & Appl. Chem. 1973, 33, 145; 
A. Eschenmoser, C. E. Wintner, Science 1977, 196, 1410. 
25 C. H. Steffee, N.C.Med. J. 1992, 53, 308; A. Fleming, Br. J. Exp. Pathol. 1929, 10, 226; R. Hare, Med. 
His. 1982, 26, 1. 
26 E P. Abraham, E. Chain, C. M. Fletcher, Lancet 1941, 16, 177; D. Crowfoot, C. W. Bunn, B. W. 
Rogers-Low, A. Turner-Jones, "X-ray crystallographic investigation of the structure of penicillin" in 
Clarke, H. T.; Johnson, J. R.; Robinson, R. (ed). Chemistry of Penicillin. 1949, Princeton University Press, 
Princeton. 
27 E. P. Abraham, G. G. F. Newton, Biochemical Journal, 1961, 79, 377. 
28 K. F. Kong, L. Schneper, K. Mathee, Acta Pathol. Microbiol. Immunol. Scand. 2010, 118, 1. 
29 K. Lewis, Nat. Rev. Drug Discov. 2013, 12, 371. 
30 J. C. Sheehan, K. R. Henery-Logan, J. Am. Chem. Soc. 1957, 79, 1262. 
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Figure 1.3: Collection of Penicillium molds (left) and an original mold sample from 
Alexander Fleming (right).31 
This synthesis can also be seen as one of the earlier examples of biomimetic synthesis, 
as the side chains are introduced via acylation of the amide in the last steps similar to the 
biosynthesis of penicillins.32 The key intermediate in Sheenan’s synthesis is (+)-6-
aminopenicillanic acid (6-APA) containing the penicillin core structure (1.12, Figure 
1.4). In 1959, researchers at Beecham reported the isolation of 6-APA from penicillin 
fermentation mold,33 and the synthesis of structural analogs of natural penicillins started 
from this intermediate. By simple acylation of the primary amino group of the β-lactam 
a myriad of analogs could be synthesized and their biological activity compared with 
other penicillins. These new semi-synthetic penicillin analogs could be fine-tuned to 
fulfill specific demands, such as lactamase stability, improved uptake and metabolic 
stability.34 The knowledge gained from penicillins could then be applied to the 
cephalosporin class of β-lactam antibiotics. Cephalosporin C (1.14) was isolated in 1961 
and its core structure 7-aminocephalosporanic acid (7-ACA, 1.13, Figure 1.4), also 
proved to be amenable in the semi-synthesis of antibiotic cephalosporin derivatives.35 
The development of penicillins and cephalosporins as antibacterial drugs helped to 
establish new methodologies in biochemistry and drug discovery.  
                                                
 
31 http://en.wikipedia.org/wiki/Penicillium#/media/File:Ascomycetes.jpg; Photo by: Dr. David Midgley 
Cultures: Dr. David Midgley, University of Sydney, Australia, Creative Commons BY-SA 2.5 license; 
http://commons.wikimedia.org/wiki/File:Sample_of_penicillin_mould_presented_by_Alexander_Fleming
_to_Douglas_Macleod,_1935_(9672239344).jpg; Science Museum Photo Studio; Science Museum 
London, Creative Commons BY-SA 2.0 license. 
32 A. Brakhage, P. Spröte, Q. Al-Abdallah, A. Gehrke, H. Plattner, A. Tüncher, Advances in Biochemical 
Engineering, 2004, Springer Berlin; C. J. Schofield, J. E. Baldwin, M. F. Byford, I. Clifton, J. Hajdu, C. 
Hensgens, P. Roach, Curr. Op. Struct. Biol. 2004, 7, 857. 
33 F. R. Batchelor, F. P. Doyle, J. H. C. Nayler, G. N. Rolinson, Nature 1959, 183, 257. 
34 A. M. Hujer, M. Kania, T. Gerken, V. E. Anderson, J. D. Buynak, X. Ge, P. Caspers, M. G. P. Page, L. 
B. Rice, R. A. Bonomo, Antimicrob. Agents Chemother. 2005, 49, 612. 
35 J. M. T. Hamilton-Miller, Int. J. Antimicrob. A. 2008, 31, 189. 
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Figure 1.4: Structures of penicillins (left) and cephalosporins (right). 
The controlled variation of fermentation conditions led to the isolation of new structures, 
which helped to elucidate the mechanisms of action of the β-lactam antibiotics in return. 
These are also some of the earliest examples of a drug accessed by fermentation of a 
fungi culture, and the identification and genetic modification of suitable fungal strains 
was unprecedented at the time.36 From a total synthesis point of view, penicillins and 
cephalosporin’s were formidable targets due to their complex structure. As in the case of 
paclitaxel (vide infra), the total syntheses were not able to compete with the 
fermentation process in terms of yield, but proved indispensable for the structural 
elucidation and mode of action investigations of the natural products. The large-scale 
production of 6-APA (1.12) and 7-ACA (1.14) gave rise to early examples of thorough 
structure-activity relationship (SAR) studies, a method that is now standard in medicinal 
chemistry. It can be argued that the greatest strengths of total synthesis are characterized 
by interplay with other disciplines, but foremost biology, where the coalescence of the 
research fields gives rise to synergies to a sum much greater than its individual parts. 
Figure 1.5: Pacific yew with characteristic berries (left) and debarking of the trunk 
(right).37 
  
                                                
 
36 H. A. Roslan, C. S. Ngo, S. Muid, J. Cell Mol. Biol. 2010, 7, 13. 
37 http://commons.wikimedia.org/wiki/File:Taxus_brevifolia_Blue_Mts_WA.jpg, Jason Hollinger, 
Creative Commons licence CC BY 2.0; 
http://en.wikipedia.org/wiki/Paclitaxel#/media/File:Yew_bark_Taxol_PD.jpg; cancer.gov, Public Domain. 
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In 1963, a bioactivity-guided plant isolation program of the US government revealed 
extracts of the pacific yew Taxus brevifolia to possess anti-tumor activity (Figure 1.5).38 
By 1968, the active compound had been purified and the structure of paclitaxel (1.17) 
was assigned in 1971 ( Scheme 1.4).39 Clinical trials conducted in the 1980s led to the 
FDA approval of paclitaxel (1.17) as a treatment of several cancers, such as ovarian, 
breast, and lung cancer.40 Paclitaxel (1.17) was found to act as a microtubule-stabilizing 
agent and affects the cytoskeletal system. It blocks mitosis and arrests the uncontrolled 
cell division of the cancer cells.41 Paclitaxel (1.17) was mainly extracted from the bark 
of the yew. Initial clinical trials in the 1980s required several tons of yew bark. This 
posed a threat to the ecosystem, as the plant is rather slow growing and killed during 
bark harvest (Figure 1.5, right). The initial isolation method gave only about 10 g of 
pure paclitaxel (1.17) from 1,200 kg of bark, and a typical treatment requires about 2 g 
of the drug per patient. Current annual demand is in the range of 200 kg per year (50,000 
treatments) and rising.42 The intricate structure of paclitaxel proved to be a challenging 
target for synthetic chemists, and indeed since the first syntheses by the groups of 
Holden and Nikolaou in 1994, several others have been reported.43 While these 
syntheses cannot compete with the extraction route in terms of yield, they provided 
essential information for the production of paclitaxel on a commercial scale. One of 
these critical findings was the use of the Ojima lactam 1.1544 for the introduction of the 
side chain to the tetracyclic 10-deacetylbaccatin III derivative 1.16. Indeed, most of the 
total syntheses mentioned above rely on this method, and so did the first semi-synthetic 
route to paclitaxel developed by Holton and commercialized by Bristol-Myers Squibb 
                                                
 
38 G. M. Cragg, Med. Res. Rev. 1998, 18, 315. 
39 M. Wani, H. Taylor, M. Wall, P. Coggon, A. McPhail , J. Am. Chem. Soc. 1971, 93, 2325. 
40 L. J. Cseke, A. Kirakosyan, P. B. Kaufmann, S. L. Warber, J. A. Duke, H. L. Brielmann, Natural 
Products from Plants, 2006, Taylor and Francis, Boca Raton. 
41 G. A. Orr, P. Verdier-Pinard, H. McDaid, S. B. Horwitz, Oncogene 2003, 22, 7280. 
42 P. M. Dewick, Medicinal Natural Products:A Biosynthentic Approach 2002, John Wiley and Son, West 
Sussex. 
43 R. A. Holton, C. Somoza, H. B. Kim, F. Liang, R. J. Biediger, P. D. Boatman, M. Shindo, C. C. Smith, 
S. Kim, H. Nadizadeh, Y. Suzuki, C. Tao, P. Vu, S. Tang, P. Zhang, K. K. Murthi, L. N. Gentile, J. H. 
Liu, J. Am. Chem. Soc. 1994, 116, 1597; K. C. Nicolaou, Z. Yang, J. J. Liu, H. Ueno, P. G. Nantermet, R. 
K. Guy, C. F. Claiborne, J. Renaud, Nature 1994, 367, 630; S. J. Danishefsky, J. J. Masters, W. B. Young, 
J. T. Link, L. B. Snyder, T. V. Magee, D. K. Jung, R. C. A. Isaacs, W. G. Bornmann, C. A. Alaimo, C. A. 
Coburn, M. J. Di Grandi, J. Am. Chem. Soc. 1996, 118, 2843; P. A. Wender, N. F. Badham, S. P. Conway, 
P. E. Floreancig, T. E. Glass, J. B. Houze, N. E. Krauss, D. Lee, D. G. Marquess, P. L. McGrane, J. Am. 
Chem. Soc. 1997, 119, 2757; K. Morihira, R. Hara, S. Kawahara, T. Nishimori, N. Nakamura, H. Kusama, 
I. Kuwajima, J. Am. Chem. Soc. 1998, 120, 12980. 
44 I. Ojima, I. Habus, M. Zhao, M. Zucco, Y. H. Park, C. M. Sun, T. Brigaud, Tetrahedron 1992, 48, 6985. 
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from 1993 onwards.45 The advantages of using derivative 1.16 as an advanced 
intermediate are twofold: 10-deacetylbaccatin (precursor of 1.16) is found in the more 
abundant European yew (Taxus baccata) and in a higher concentration than paclitaxel, 
and the process is sustainable, as only twigs and leaves are used for the extraction, 
which regrow after a season. This rendered the approach more environmentally friendly 
and cost effective. Since 2004, the semi synthetic route has been replaced by a plant-cell 
fermentation process, where paclitaxel is directly extracted from a fermentation broth of 
Taxus chinensis cells.46 
 Scheme 1.4: Industrial semi-synthetic route to paclitaxel (1.17) by Bristol-Myers Squibb. 
The development of paclitaxel into a drug illustrates the advantage of using organic 
synthesis to produce natural products. While total synthesis could not compete with the 
extraction route in terms of yield in this case, isolated natural products often are 
extremely scarce. Reasons for this include that the samples are hard to obtain (e.g. from 
marine environment), or general rarity of the specimen in the biosphere. The production 
of secondary metabolites is also highly dependent of environmental factors such as 
climate, pH, nutrient supply and can render repeated isolation difficult.47 Total synthesis 
can turn a ‘once in a lifetime’-isolation of a small amount of a natural product into a 
reproducible route to the target compound. As absolute structural determination is 
difficult with only small quantities of substance available, total synthesis often serves as 
a final proof in structural assignment. As the commercial semi-synthetic route to 
paclitaxel illustrates, the combination of total synthesis with a suitable precursor 
obtained from natural sources can give much more ecologically and economically 
sustainable routes to a target.  
                                                
 
45 J. Goodman, V. Walsh, The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug, 
2001, Cambridge University Press, Cambridge. 
46 P. G. Mountford, Green Chemistry in the Pharmaceutical Industry, 2010, Wiley-VCH, Weinheim. 
47 D. J. Kliebenstein, Plant, Cell Environ., 2004, 27, 675; A. Ramakrishna, G. A. Ravishankar, Plant 
Signal. Behav. 2014, 6, 1720. 
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1.4 The Educational Value of Total Synthesis 
While the many medicinal, ecological and economical benefits have been highlighted in 
the previous section, the educational value of total synthesis for chemistry students 
cannot be neglected and will be briefly discussed in this section. 
Total synthesis starts by choosing a suitable target. This usually involves the thorough 
literature study of total syntheses of related natural products, if there are any. The 
student thereby gains an understanding of the research field and the key challenges 
involved, and this allows the student to assess their own intellectual- and practical 
capabilities with respect to the task. Once a target is chosen, the next step is the 
retrosynthetic analysis. This usually involves several reiterations, and often the student 
has to choose between a more novel, risky and challenging route and a more 
conventional, but “safer”, route. During the process, the student already gains a greater 
theoretical knowledge about the general reactivity of the planned intermediates and the 
corresponding synthetic transformations. This stage also promotes communicational 
skills by scientific discussions with more experienced co-workers about the envisaged 
route. After a route has been decided upon, the student bears the (often unforeseeable) 
consequences and enters the next stage of performing actual synthesis. 
The most apparent gain of knowledge from the second stage is of practical nature. Total 
synthesis usually involves a wide range of chemical reactions, and the student thereby 
learns how to handle reactive reagents, quenching and disposal of reactive or toxic 
materials, and the proper setup of the reaction apparatuses. Sooner than later, the student 
will encounter a step in the sequence which will fail to deliver acceptable yield, purity, 
selectivity or poses other challenges. 
It his here where one of the great values of total synthesis emerges: the art of scientific 
and creative problem solving. The scientific aspect forms the backbone of the problem 
solving process; it is the rigorous monitoring and variation of reaction parameters 
usually in reference to the relevant literature to overcome the synthetic challenge. The 
ability to develop and conduct a methodical plan for problem solving is fostered in this 
process. The creative aspect of the problem solving often involves the application of an 
unconventional or questionable concept or methodology to the problem at hand, and it is 
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undoubtedly here where greatest sources of satisfaction and inspiration of total synthesis 
lie. 
Of course, not all encountered problems can be solved to satisfaction on every level, and 
the student eventually has to re-evaluate the possible alternatives in a synthetic route to 
circumvent the barriers blocking progress. With the experience gained from previous 
work, the student is ready for the next iteration of observing, learning and reflection on 
the process.  
During this practice outlined above, the student will learn to deal with the inevitable 
failure and rejection of total synthesis, and will hopefully be able to observe the 
vanishing of barriers and the emergence of stepping-stones. Therefore, total synthesis is 
not only a great practice of mastering the intellectual and experimental challenges of 
organic chemistry, but also can be a way towards personal growth of the student. 
1.5 Conclusions and Outlook 
In this chapter, we have briefly touched upon the several influences natural products had 
on human society. The historic examples of indigo dye (1.03) and cetyl palmitate (1.04) 
illustrate the great benefits for the eco system by replacing natural sources with synthetic 
materials. The Baeyer synthesis of indigo at BASF is an early example of the industrial 
production of a compound previously obtained from natural sources. 
The more modern example of the Aspirin (1.08) synthesis demonstrates the power of 
organic chemistry in drug development, where an easily introduced acetyl group greatly 
reduced undesired side effects and improved efficacy of the drug. It also is a prime 
example of drug discovery from a biological source, as was the isolation and structural 
assignment of quinine (1.10) from Cinchona bark. The 1944 formal synthesis of 
compound 1.10 by Woodward and Doering is now regarded as a milestone in total 
synthesis. This synthesis and later works by Woodward pushed the boundaries of 
synthetic organic chemistry, and today even the most complex molecules seem to be 
within reach given the required expertise, funding and time.48  
                                                
 
48 K. C. Nicolaou, R. J. Aversa, Isr. J. Chem. 2011, 51, 359; K. C. Nicolaou, K. P. Cole, M. O. Frederick, 
R. J. Aversa, R. M. Denton, Angew. Chem. Int. Ed. 2007, 46, 8875; K. C. Nicolaou, M. O. Frederick, A. 
C. B. Burtoloso, R. M. Denton, F. Rivas, K. P. Cole, R. J. Aversa, R. Gibe, T. Umezawa, T. Suzuki, J. 
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The discovery of penicillin opened new ways for the treatments of otherwise lethal 
bacterial infections and is a great example of the synergy between organic synthesis and 
biology. Thorough optimization led to the development of industrial scale fermentation 
of penicillins, which could then be further functionalized by chemical means to form 
structural analogs. This provided material for SAR studies to investigate biochemical 
pathways. 
The account of paclitaxel (1.17) from a crude extract of yew bark to a prestigious total 
synthesis target and a top selling anti-cancer drug illustrates the scale to which drug 
discovery programs might develop. The account also demonstrates that the benefits of 
total synthesis are often not immediately apparent, but might prove beneficial in another 
context. An example of this is the total synthetic efforts of the Holton group, which 
eventually culminated in an industrial production of paclitaxel via semi-synthesis from 
the more abundant advanced intermediate, 10-deacetylbaccatin, extracted from 
European yew. This process has then been replaced by a plant cell fermentation process 
to an even greater relief of the eco system. Once again the greatest merits of total 
synthesis was achieved in synergy with biological methods. 
The last section discussed the great value of total synthesis for the education of students. 
Total synthesis is a great environment for acquiring deep and diverse knowledge of 
synthetic transformations and practical execution in the lab. Methodical and creative 
problem-solving processes are among the key aspects to be learned. 
Looking forward, the rise and fall in popularity of combinatorial chemistry or high 
throughput screening have shown that the “next big thing” in organic and medicinal 
chemistry is hard to predict, and that encouraging initial results might not stand the test 
of time.49 A statement about the required foundation for a philanthropic and charitable 
development of organic chemistry and the pharmaceutical industry is more easily made. 
In many of the largest pharmaccutical companies, the expenses on marketing surpass the 
                                                                                                                                          
 
Am. Chem. Soc. 2008, 130, 7466; K. C. Nicolaou, P. Heretsch, T. Nakamura, A. Rudo, M. Murata, K. 
Konoki, J. Am. Chem. Soc. 2014, 136, 16444; K. C. Nicolaou, R. J. Aversa, J. Jin, F. Rivas, J. Am. Chem. 
Soc. 2010, 132, 6855. 
49 T. Kodadek, Chem. Commun. 2011, 47, 9757; J.-Y. Ortholand, A. Ganesan, Curr. Opin. Chem. Biol. 
2004, 8, 271; H. Kubinyi, Nat. Rev. Drug Discov. 2003, 2, 665. 
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investment in research and development.50 In combination with questionable handling of 
patent law,51 this sheds a negative light on the industry. Investment into basic research 
facilities, in industry or academia, still seems to be a valuable approach for a steady 
development of new discoveries and drugs beneficial for society, both in an 
economically valuable and ethically justifiable fashion. 
 
                                                
 
50 https://openpaymentsdata.cms.gov/; http://www.washingtonpost.com/blogs/wonkblog/wp/2015/ 02/11/ 
big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/; accessed 07.4.2015. 
51 S. Kadidal, IDEA 1996, 7, 371; T. Caulfield, T. Bubela, C. J. Murdoch, Genet. Med. 2007, 9, 850; J. M. 
Mueller, N. Engl. J. Med. 2007, 356, 541 
Total Synthesis of (–)-Pyridovericin 
15 
2 Total Synthesis of (–)-Pyridovericin 
2.1 Alzheimer’s Disease – a Neurodegenerative Disorder 
During the course of the 20th century, the average life expectancy in developed regions 
has increased substantially.52 In parallel, the occurrence of neurodegenerative diseases is 
now much more common, as these diseases are mostly prevalent in the elderly. 
Examples of neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s 
disease (PD), and Huntington’s disease (HD). The common pathology observed in the 
aforementioned diseases is the gradual loss and degradation of neuronal structure and 
function.53 As of today, there is no cure for any neurodegenerative disease, and 
treatments are of a palliative nature. The following section will discuss AD as one of the 
most prominent and intensively investigated examples of a neurodegenerative disease. 
German psychiatrist Alois Alzheimer reported the first case of AD in 1907.54 Since then, 
the disorder has become widespread in aging, developed societies. Estimations indicate 
that the disease affects 5% of 65 year olds,55 and that this number increases to about 
40% for 80 year olds.56  
The underlying intricate mechanisms of the disease have been the subject of great 
discussion in the scientific community. Already in 1911, Alois Alzheimer reported the 
observation of neurofibrillary anomalies in the brains of diseased patients.57 A hundred 
years later, protein aggregation and plaque formation are recognized as one of the 
hallmarks of neurodegenerative diseases and AD especially. In Alzheimer patients, the 
plaque consists of extracellular aggregated amyloid β (Aβ) protein.58 Aβ protein is 
formed by proteolysis of amyloid β precursor protein (APP) by the proteins β- and 
γ-secretase.59 The primary function of APP is not known, but the membrane protein is 
mainly found in neurons. The released Aβ monomers initially form oligomers, which 
then aggregate further to form the Aβ plaque (Figure 2.1). The formation of Aβ plaque 
                                                
 
52 J. Oeppel, J. W. Vaupel, Science, 2002, 296, 1031. 
53 S. Sheikh, Safia, E. Haque, S. S. Mir, J.  Neurodeg. Dis. 2013, 2013, 1. 
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55 R. Bullock, Expert. Opin. Investig. Drugs 2004, 13, 303. 
56 E. Forsyth, P. D. Ritzline, Phys Ther. 1998, 78, 1325. 
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58 D. J. Selkoe, Neuron 1991, 6, 487. 
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has been shown to cause neuronal inflammation, eventually leading to programmed cell 
death and loss of neuronal structure and function.60 However, some studies argue that 
the Aβ plaque merely acts as a reservoir for the smaller Aβ oligomers, which themselves 
have been shown to be neurotoxic.61 
Figure 2.1: Proteolysis of APP (left) to give Aβ plaque (right).62 
A second common pathology found in AD patients is the formation of aggregates of 
hyperphosphorylated tau protein.63 Tau is a microtubule stabilizing protein. 
Microtubules are key structural elements of cells forming the cytoskeleton.64 When tau 
is excessively phosphorylated, it detaches from the rest of the microtubule forming tau 
oligomers. In the process, the microtubules start to disintegrate and the neuron looses its 
cytoskeleton, leading to cell death.65 Underlying these biomolecular irregularities are 
several genetic mutations associated with AD. So far, the identified genetic mutations 
have only been found to be associated with Aβ overexpression in mutations of the genes 
encoding APP and presinilins 1 and 2.66  
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Although these mutations not necessarily evoke AD, they have been identified as risk 
factors.67 
While this was a general overview over the most prevalent processes involved in AD, 
the complexity and scale of the research field would exceed the scope of this 
introduction, but several reviews are available for further reading.68 The next section 
briefly discusses possible therapeutic targets of AD. 
2.2 Therapeutic Targets of Alzheimer’s Disease 
Figure 2.2: AChE inhibitors Rivastigmine (2.01) and Tacrine (2.02). 
The currently available medications for the treatment of AD are acetylcholinesterase 
(AChE) inhibitors, such as Rivastigmine (2.01) or Tacrine (2.02, Figure 2.2). First 
reports of an unbalanced acetylcholine metabolism in AD date back to the 1970s,69 and 
while AChE inhibitors have been shown to delay the course of the disease, unfortunately 
the effects seem to be marginal.70 The elucidation of the role of Aβ plaque, tau 
aggregation and genetic risk factors gave rise to several new therapeutic approaches, 
which have been proposed and tested. 
In the case of Aβ plaque formation, several pathways are potentially amenable for 
intervention. These involve for example the inhibition of β− and γ− secretase, giving 
lower concentrations of Aβ monomers.71 The inhibition of Aβ plaque formation was 
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also investigated,72 and seminal immunotherapeutic approaches by immunization with 
Aβ gave promising results.73 
As mentioned previously, hyperphosphorylation of tau gives rise to the decomposition 
of microtubule and collapse of the cytoskeleton of the neuron. Tau kinase, the enzyme 
transferring the phosphate group to the tau protein, is therefore currently under 
investigation as a therapeutic target,74 as is the activation of tau phosphatase, which 
could reverse the process and could cause the degradation of tau aggregates by 
dephosphorylation.75 
Other compound classes under investigation are anti inflammatory drugs76 and 
cholesterol regulating agents, as it has been shown that the proteolysis of APP to Aβ is 
dependent of cholesterol plasma levels.77 
The described therapeutic approaches all focus on the inhibition of destructive 
biochemical processes. However, the cellular repair of damaged nerve tissue would 
certainly be beneficial for successful treatment of neurodegenerative disorders. Many 
natural products have shown to possess neuritogenic activity in cell and animal 
models,78 and in the following section our studies of truncated neuritogenic natural 
product analogs are presented.  
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2.3 Truncation of Natural Products 
As described in chapter 1, biologically active compounds from natural sources have laid 
the foundation of human medicine throughout history. With the development of 
advanced analytical and synthetic methodologies in the 20th century, the identification 
and preparation of natural products and analogs has become more feasible. Combined 
with the advances in chemical biology for the biological evaluation of the compounds, 
several concepts, such as structure-activity relationships (SAR), function-oriented 
synthesis (FOS)79 or diversity-oriented synthesis (DOS),80 provide now a solid 
foundation for the identification and structural optimization of bioactive compounds. 
One focus of our research is the truncation of natural products, a concept that involves 
the preparative and structural simplification of a target structure while retaining or even 
improving its biological activity. Several reviews on the subject are also available.81 
Figure 2.3: Halochondrin B (2.03) and truncated analog eribulin (2.04). 
A prominent example of a truncated natural product is halichondrin B (2.03) and its 
truncated analog eribulin (2.04) (Figure 2.3). Halochondrin B (2.03) is a polyether 
macrolide from marine sponges isolated by Umura (1986)82 and Pettit (1991).83 Initial 
biological studies showed that the compound possessed promising anti-tumor activities, 
and later investigations revealed the mechanism to involve the inhibition of tubulin 
polymerization and microtubule formation.84 As the isolation of the compound from 
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biological matrices did not yield the required amounts for further clinical studies, several 
groups approached the total synthesis of target 2.03 and structural analogs thereof. The 
group of Kishi reported the first total synthesis of halichondrin B (2.03) in 1992,85 but 
still the synthesis was not able to deliver substantial amounts of the target compound. In 
2001, it was reported that the structural analog eribulin (2.04) possessed a similar 
biological profile to the parent molecule 2.03,86 and the synthetic route has been further 
optimized to a multi-kilogram scale.87 Eribulin mesylate (Halaven) has recently been 
approved by the FDA for metastatic breast cancer.88 This example clearly demonstrates 
the power of truncation of natural products, as totally synthetic halichondrin B will 
probably not be accessible in clinically useful quantities in the near future. 
Figure 2.4: Dynemicin A (2.05) and truncated analog (2.06). 
Dynemicin A (2.05) is another natural product that gave rise to bioactive truncated 
analogs such as 2.06 (Figure 2.4). The isolation of dynemicin A (2.05) was reported in 
1989 by the group of Clardy.89 Fermentation of Micromonospora chersina followed by 
bioassay-guided isolation gave compound 2.06, bearing a characteristic strained 10-
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membered ring with a 1,5-diyn-3-ene system. Seminal biological studies revealed the 
compound to be highly potent against several cancer cell lines. The intricate structure 
caused considerable synthetic effort in the community, and the first total synthesis of 
dynemicin A (2.05) by the Myers group was reported in 1995.90 From a mechanistic 
point of view, it was found that the anthraquinone core intercalated with DNA, and it is 
proposed that the 1,5-diyn-3-ene system forms a phenyl diradical by a reaction cascade 
involving two one-electron reductions followed by tautomerization, epoxide opening 
and finally Bergman cyclization. The phenyl diradical then cleaves the 2-deoxyribose-
phosphate backbone of the DNA, resulting in a double strand cleavage. Dynemicin A 
binds preferentially to B-DNA, and currently truncated analogs such as compound 2.06 
are under investigation for treatment of various cancers.91 While many analogs have 
been reported in the literature and their cytotoxic properties were studied, the hope is 
that a compound with a higher specificity for certain cancer cell lines is found, as the 
current analogs unfortunately also display high cytotoxicity towards healthy cells. 
Figure 2.5: Farinosone C (2.07) and truncated analogs (2.08-2.09). 
Examples by our group of a successfully truncated natural product with neuritogenic 
activity are the derivatives of farinosone C (2.07, Figure 2.5). Farinosone C (2.07) was 
first isolated by the group of Hamburger and showed neuritogenic activity in the 
pheochromacytoma-12 (PC-12) cell assay.92 Biosynthetically, it was proposed that 
farinosone C (2.07) actually is a side product of the biosynthesis of the vast family of 
pyridone alkaloid natural products (see section 2.5), as the primary alcohol in compound 
2.07 is unable to undergo the cyclization to form the pyridone. The proposed 
biosynthesis of the corresponding pyridone alkaloids requires a carboxylic acid in this 
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position.93 Farinosone C (2.07) was isolated from the entomopathogenic fungus 
Paecylomyces farinosus, and the total synthesis was concluded by our group in 2009 
along with several structural analogs (2.08 and 2.09, Figure 2.5).94 The stereodivergent 
approach allowed for assignment of the absolute configuration of the natural product, as 
well as truncation of the side chain. Biological evaluation in the PC-12 cell assay led to 
the identification of a truncated analog 2.09, and further studies in collaboration with the 
Gertsch group indicated the CB1 receptor as a possible target of truncated analog 2.09.95 
This project also sparked our interest in the synthesis of pyridone alkaloids and their 
neuritogenic properties. 
2.4 (–)-Pyridovericin – a Pyridone Alkaloid from the 
Entomopathogenic Fungus Beauveria Bassiana 
Entomopathogenic fungi rely on a host insect for reproduction, to which they cause 
severe harm or death during the process. They have been shown to be a great source of 
biologically active natural products.96 Their intricate multi-stage life cycle and its 
dependence on environmental factors is described in the next paragraphs.97 
Generally, the long term persistence and infective fungal spores called conidia rest in the 
environment such as soil, a plant surface or in the rhizosphere (plant root system).98 This 
period of the life cycle is called saprophytic phase, and the conidia can be spread by 
wind, rain or through contact with insects.99 When the conidia come in contact with a 
host insect, they enter the body through the cuticle by a combination of mechanical force 
applied by the germ tube of the conidia and cuticle degrading enzymes such as 
chitinases and proteases.100 Once the cuticle has been successfully penetrated, the fungus 
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forms a multicellular tissue of blastosphores, which infests the whole host through the 
haemocoel.101 The fungal tissue secretes a wide range of bioactive compounds in the 
process, with toxins to weaken the host’s immune system and antimicrobial compounds 
preventing secondary infections of competing microbes.102  
As the fungus consumes the host’s tissue for nutrients, several behavioral changes in 
host insects have been reported. In insects living in colonies, the abandonment of the 
hive has been reported, and it is speculated that this is a countermeasure against further 
spreading of the infection.103 In some cases, the infection causes increased sexual 
attractiveness towards mates by up-regulation of pheromone production, helping the 
sporulating fungus to spread.104 In many cases, the final and ultimately lethal phase of 
infection is accompanied by so called “classic summit disease”, where the host relocates 
to a point of higher elevation, for example by moving to the soil surface in root feeding 
hosts or climbing on plant stems for superterranean insects. It is argued that this 
behavioral change is also a mechanism beneficial for the dispersion of fungal spores into 
the environment.105 Finally, the host is completely consumed and covered by fungal 
tissue, and the last step of the reproductive cycle is the release of infective conidia from 
the fungal fruit body into the environment. 
The elucidation of these fascinating biological interactions between fungi and host have 
led to application of entomopathogenic fungi as pest control agents, and the species 
Beauveria bassiana (B.b.) has gained special attention in this field.106 This species is a 
fungus of the order hypocreales and has been shown to be able to infect over 700 
different host species.  
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The excessive use of chemical pest control agents has given rise to resistant insect 
strains, and the application of entomopathogenic fungi could prove a viable additional 
method for crop protection.107 Several studies have shown that application of 
formulations of B.b. with or without additional pesticides has beneficial effects on pest 
mortality. Additionally, it should be mentioned that B.b. and related fungi have been 
reported to show essentially no toxicity whatsoever against vertebrates.108 
Figure 2.6: Militarinone D (2.10) and farinosone A (2.11). 
While the application of B.b. formulations is certainly attractive, the investigation of the 
biochemical mechanisms involved in infection has proven equally promising. The 
constant battle between the host and the fungi for survival and adaptation has been 
called an “evolutionary arms race”,109 and several key agents produced by the fungi 
have been identified and studied, such as cuticle degrading proteins or 
immunosuppressive agents.110 This insight could give rise to the identification of new 
biochemical pathways amenable for pest control. Among the isolated compounds are 
also pyridone alkaloids, such as militarinone D (2.10) or farinosone A (2.11) (Figure 
2.6).111 While their exact role in the fungal interaction with the host is not yet clarified, 
they have certainly received considerable attention in the biological and chemical 
community, the results of which are presented in the next sections. 
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2.5 Occurrence, Classification and Biosynthetic Pathways of Pyridone 
Alkaloids 
Figure 2.7: Representative members of the pyridone natural product family. 
Pyridone alkaloid natural products are a vast and diverse class of mainly fungal 
metabolites.112 Three selected members of the family are presented in Figure 2.7. The 
natural products can be further divided into three subclasses depending on their 
substitution pattern. The first class consists of 4-hydroxy-3-acyl substituted compounds, 
such as ilicicolin H (2.12). This group has received the greatest attention with respect to 
biosynthetic pathway investigation and total synthesis efforts. The second class has a 4-
hydroxy-3-ether substitution pattern as in (+)-sambutoxin (2.13). The third class consists 
of natural products such as 8-methylpyridoxatin (2.14), bearing a 4-hydroxy-3-alkyl 
substituted 2-pyridone fragment. 
Scheme 2.1: Biosynthesis of pretenellin (2.18). 
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Scheme 2.1 shows the biosynthetic pathway of pretenellin (2.18) as proposed by the 
Simpson group.113 The pathway was elucidated by genome sequencing, knockout 
experiments and database comparison with similar non-ribosomal peptide synthetase 
(NRPS)-polyketide synthase (PKS) complexes. Initially, the activated polyene 2.17 is 
produced by a PKS. A NRPS affords the peptide carrier protein (PCP) bound tyrosine 
derivative 2.16. The building blocks 2.16 and 2.17 are then condensed, the thioester is 
reduced and, upon elimination of water, pretenelin (2.18) is obtained. 
In another study, the group further reported the biosynthesis of tetramic acid 2.19 and 
further skeletal oxidative rearrangements to form the characteristic 4-hydroxy-3-acyl-2-
pyridone core of tenellin (2.25, Scheme 2.2). The process involves an initial oxidation of 
enone 2.19 to the epoxide 2.20 by cytochrome P450.114 A sequential addition and 
elimination of water gives tetramic acid 2.21. Hydrogen abstraction and rearrangement 
gives the radical 2.24, which upon hydroxyl radical addition and elimination of water 
gives the natural product tenellin (2.25). In the next section, a few selected examples of 
total syntheses of 4-hydroxypyridone natural products will be discussed. 
Scheme 2.2: Biosynthesis of tenellin (2.25). 
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2.6 Previous Synthetic Studies on Pyridone Alkaloids 
The synthesis of 4-hydroxypyridone natural products has been reviewed,112 and this 
section will focus on representative examples from the three main groups described in 
section 2.5. 
Scheme 2.3: Racemic synthesis of ilicicolin H (2.12). a) KOtBu, -40 °C, THF, 4 h, 72%; 
b) o-dichlorobenzene, reflux, 5 min, 80%; c) LDA, THF, -78 °C, 20 min, then HOAc–
H2O; d) BCl3, DCM, -78 °C, 1 min, then MeOH, 60% over two steps. 
Ilicicolin H (2.12) was isolated in 1971 from Cylindrocladium ilicicola and was found to 
possess antifungal and antibiotic properties.115 The absolute configuration and the 
biosynthesis have also been investigated.116 The Williams group reported a racemic 
synthesis of compound 2.12117 starting from the known advanced intermediate 2.26 
(Scheme 2.3).118 An aldol condensation between ketone 2.26 and aldehyde 2.27 using 
potassium tert-butanonlate gave enone 2.28, which underwent a thermal Diels-Alder 
reaction119 to establish the trans-decalin substituted side chain. Subsequent deprotection 
gave racemic ilicolin H (2.12). 
(–)-Sambutoxin (2.13) was isolated in 1994,120 and its enantiomer was synthesized in 
2000 by Williams and co-workers (Scheme 2.4).121 Isolated from Fusarium sambucium, 
the compound was found to cause toxic effects in rats. The intermediate 2.29 was 
synthesized via an asymmetric conjugate addition and anti-aldol reaction, and then the 
enolate of 2.29 added to aldehyde 2.30. Fmoc deprotection caused spontaneous 
cyclization to form a dihydropyridone, which was then oxidized to give pyridone 2.32.  
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Scheme 2.4: Synthesis of (+)-sambutoxin (2.13). a) LDA, THF, HMPA, -78 °C, 71%; b) 
DMSO, DCC, pyridinium chloride, 89%; c) DBU, DCM, r.t., then BrCCl3, 0 °C, 92%; d) 
TBAF, THF; e) Pd(OAc)2, K2CO3, MeCN, 44% over 2 steps; f) NaI, HCl, acetone, 82%. 
After TBS deprotection, an intermediate quinone methide was formed and trapped by 
the hydroxyl group, giving natural product antipode (+)-sambutoxin (2.13). 
Scheme 2.5: Synthesis of racemic 8-methylpyridoxatin (2.14). a) Rh-catalyst on β-75 
zeolite, H2, EtOH, 100 bar, 175 °C, 1 h, 82%; b) LDA, TMSCl, THF, -78 °C, 86%; c) 
GaCl3, THF, ethynyltrimethylsilane, r.t., 5 min, 87%; d) NBS, MeCN, reflux; e) MeI, 
Ag2CO3, CHCl3, 3 d, 42% over 2 steps; f) n-BuLi, THF, -78 °C; chlorooxoacetate, 1 h, 
61%; g) AIBN, Bu3SnH, toluene, heat, 18 h, 86%; h) MeMgI, neat, 165 °C, 2h, 72%; i) 
HMDS, TMSCl, reflux, 24 h; j) MoO5pyHMPA, DCM, 24 h; k) Na4EDTA, H2O-
EtOAc, r.t., 2 h, 61% over three steps. 
8-Methylpyridoxatin (2.14) was initially isolated as an atropisomeric mixture in 1999,122 
but the atropoisomers were later separated and the configurations assigned.123 Reports 
on a possible antimalarial activity of the compounds were not conclusive, and a racemic 
synthesis with subsequent separation of the atropisomers has been reported by the Chai 
group (Scheme 2.5).124 The synthesis started from phenol 2.33 with a hydrogenation 
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reaction using a zeolite supported rhodium catalyst to give a meso-ketone, which was 
then converted to the diastereomerically pure ketone 2.34. In parallel, the 4-hydroxy 
pyridone 2.35 was brominated and methylated to give aryl bromide 2.36, which was 
deprotonated with n-BuLi and quenched with ketone 2.34, and the formed alkoxide was 
trapped with chlorooxoacetate to allow for a MacMillan deoxygenation.125 Removal of 
the protecting groups and N-oxidation with Vedej’s reagent126 gave the natural product 
2.14. 
In our labs we have also reported several total syntheses of pyridopolyene natural 
products,127 and the next chapter details the total synthesis of (–)-pyridovericin (2.46). 
2.7 Total Synthesis of (–)-Pyridovericin – a Neuritogenic Pyridone 
Alkaloid 
2.7.1 Previous Synthetic Contributions 
Since its isolation in 1988 by Nakagawa and co-workers,128 pyridovericin (2.46) has 
received considerable attention from the synthetic community. In 2002, the Curran 
group reported a quasiracemic synthesis of both enantiomers of pyridovericin (2.46 and 
2.47, Scheme 2.6).129 Quasiracemic synthesis shares concepts of both racemic and 
enantioselective synthesis. In quasiracemic synthesis, both enantiomers are obtained in a 
single synthetic sequence, but like in enantioselective synthesis, the final compounds are 
obtained in enantioenriched form. This is achieved by initially tagging the two 
enantiomerically pure starting materials 2.38 and 2.42 separately at the beginning of the 
synthesis with two distinguishable tags and then mixing them.130   
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The ideal pair of tags should behave identically throughout the synthesis (e.g. reactivity, 
solubility, polarity, spectral characteristics, chromatography). In the end, the two tags 
must be able to be differentiated by at least one orthogonal reaction or separation 
methodology (e.g. fluourous HPLC) to separate the quasiracemic mixture and give 
enantiopure products. 
Scheme 2.6: Synthesis of both enantiomers of pyridovericin (2.46 and 2.47). a) TiCl4, 
NEt3, BOMCl, 78%; b) H2, Pd/C, quant. c) BrSi(iPr2)CH2CH2C6F13, NEt3, DMAP, 89% 
or BrSi(iPr2)CH2CH2C8F17, NEt3, DMAP, 89% d) LiBH4, 71%; e) equimolar mixing of 
2.39 and 2.43; f) (COCl)2, DMSO; g) Ph3PC(CH3)CO2Et, 73% over two steps; h) 
DIBAL-H; i) (COCl)2, DMSO, 95% over two steps; j) (EtO)2P(O)CH2C(O)CH2CO2Et, 
LDA, 83%; k) MEMOC6H4CH=NCO, NaH, 58%; l) Ph2O, 250 °C, 50%; m) separation 
by fluorous HPLC; n) TMSCl, NaI, 90%, 25% e.e. 
In the pyridovericin synthesis of Curran, the orthogonal tags applied were two very 
similar silyl protecting groups with perfluorinated chains of slightly different length 
(C6F13 vs. C8F17).131 These perfluorinated protecting groups were anticipated to behave 
similarly throughout the performed chemical transformations, but would be separable at 
a later stage by HPLC using a perfluorated stationary phase.132 The synthesis of the side 
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chain started from acylated Evans auxiliary 2.37, which was enantioselectively alkylated 
with BOMCl, and the benzylic group was cleaved hydrogenolytically133 to give the two 
enantiomeric alcohols 2.38 and 2.42 (Scheme 2.6). These were then protected with 
BrSi(iPr2)CH2CH2C6F13 or BrSi(iPr2)CH2CH2C8F17 respectively134 to give the 
quasienantiomers 2.39 and 2.43, which where then mixed in equimolar amounts to give 
the quasiracemate M-2.40. With the quasiracemic mixture prepared, the rest of the 
synthesis was performed according to an adapted literature procedure. The quasiracemic 
alcohol M-2.40 was oxidized to the corresponding aldehyde by Swern oxidation135 and 
subjected to a Wittig reaction. After an additional reduction-oxidation-Horner-
Wadsworth-Emmons (HWE) reaction sequence,136 the quasiracemic β-keto ester M-2.44 
was obtained. The formation of the pyridone cycle M-2.45 was then achieved by 
acylation of β-keto ester M-2.44 with a vinyl isocyanate followed by thermal ring 
closure.137 At this stage, the quasiracemic mixture of M-2.45 was resolved by semi-
preparative fluorous HPLC, and the obtained enantiomerically enriched pyridones were 
treated with TMSCl and NaI to afford the deprotected enantiomers 2.46 and 2.47 of 
pyridovericin. The group then applied Mosher ester 1H NMR analysis for the 
determination of the enantiomeric excess, as no chiral HPLC conditions for the 
separation of the racemate were found. Unfortunately, it was found that the e.e. had 
eroded from an enantiopure compound 2.39 to a low e.e. of 25% for 2.46 during the 
course of the synthesis. However, this synthetic approach still allowed for proof of 
concept of quasiracemic synthesis, and an example where a different enantiopure natural 
product is prepared with excellent e.e. via a quasiracemic synthesis was given in the 
same publication. Nevertheless, the main drawback of the synthesis was racemization of 
the intermediates during the sequence.  
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Scheme 2.7: Racemic synthesis of pyridovericin (2.56). a) LAH, THF; b) TBSCl, NaH, 
THF, 60% over two steps; c) Swern oxidation; d) Ph3P=C(CH3)CO2Et, toluene, 90% over  
two steps; e) DIBAL-H, THF f) Swern oxidation g) Ph3P=CHCO2Et, toluene, 78% over 
three steps; h) DIBAL-H, THF; i) Swern oxidation, 97% over two steps; j) Br2, conc. aq. 
HBr; k) MeI, Ag2CO3, DCM, 45% over two steps; l) BnOC6H4B(OH)2, Pd(PPh3)4, 
Na2CO3, toluene/ethanol, 44%; m) t-BuLi, THF, 59%; n) MnO2, DCM, 71%; o) TMSCl, 
NaI, MeCN, 53%; p) BBr3, DCM, 75%. 
The Baldwin group reported a total synthesis of racemic pyridovericin (2.56) in 2002.138 
The strategy was based on a two-fold functionalization of the protected dibromopyridine 
(2.53, Scheme 2.7). The synthesis of the side chain started from malonate 2.48, which 
was reduced to the diol with lithium aluminum hydride, mono-TBS-protected139 and 
oxidized to give aldehyde 2.49. A Wittig-reduction-oxidation sequence gave enal 2.50, 
which underwent another Wittig-reduction-oxidation sequence to give dienal 2.51. The 
synthesis of the biaryl fragment 2.54 started from commercially available pyridine 
derivative 2.52, which was brominated twice140 and methylated with methyl iodide in 
the presence of silver carbonate.141 The following Suzuki–Miyaura coupling142 under 
conditions reported in the literature143 proceeded in a moderate yield of 44%, as the 
double-arylation product and the positional isomer was also obtained in considerable 
amounts. The key step to couple the fragments 2.54 and 2.51 consisted of first 
performing a lithium-bromine exchange with t-BuLi and then quenching the obtained 
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aryllithium species with the aldehyde 2.51. The corresponding alcohol was obtained in 
59% yield, along with 20% of the quenched aryllithium species bearing an H-atom in 
the C(3)-position. The authors attribute this to either deprotonation of the ε-position of 
the aldehyde 2.51 by the aryllithium species or deprotonation of the formed tert-butyl 
bromide. The alcohol was then oxidized with activated manganese dioxide to the 
arylenone 2.55, and cleavage of the methyl- and benzylic ethers with TMSCl/NaI144 and 
boron tribromide,145 respectively, gave racemic pyridovericin (2.56). The route involved 
13 linear steps starting from the malonate 2.48 and gave the target in 7% overall yield. 
The established synthesis allowed the authors to further investigate the biomimetic 
synthesis of related natural products.146 
Both reported syntheses relied upon a Wittig/HWE-reduction-oxidation sequence for the 
construction of the side chain. Curran’s approach required equimolar amounts of a chiral 
auxiliary for the introduction of asymmetry, whereas the Baldwin group chose a racemic 
route. With respect to our synthesis, we found it highly desirable to apply a catalytic 
enantioselective transformation for introduction of the chiral element. We also would 
have to take special care to detect and avoid racemization observed in Curran’s 
synthesis. The formation of the biaryl moiety was achieved in a thermal [4+2] 
cycloaddition in Curran’s synthesis and via sequential functionalization of the 
dibromopyridine 2.53 in Baldwin’s synthesis. While the latter approach was of a more 
modular and convergent nature, problems arose due to only moderate positional 
selectivity in the Suzuki reaction. Ideally, we would be able to implement two 
orthogonal activating groups to avoid these issues. Our retrosynthetic analysis for (–)-
pyridovericin (2.46) is presented in the next section.  
                                                
 
144 K. E. Henegar, S. W. Ashford, T. A. Baughman, J. C. Sih, R. L. Gu, J. Org. Chem. 1997, 62, 6588. 
145 D. E. Ward, Y. Gai, B. F. Kaller, J. Org. Chem. 1995, 60, 7830. 
146 N. R. Irlapati, J. E. Baldwin, R. M. Adlington, G. J. Pritchard, A. Cowley, Org. Lett. 2003, 5, 2351. 
   Chapter 2 
 34 
2.7.2 Retrosynthetic Analysis 
Scheme 2.8: Retrosynthetic analysis of (R)-(–)-pyridovericin 2.46 and the fragments 2.57 
and 2.58. 
Our retrosynthetic analysis (Scheme 2.8) was based on our previously reported 
syntheses.127 The building blocks 2.57 and 2.58 would be connected via an HWE 
reaction. The biaryl fragment 2.57 would be synthesized via a Suzuki-Miyaura coupling 
reaction and nucleophilic phosphonation of an ester. The enantiomerically enriched 
aldehyde 2.58 would be synthesized with a Wittig reaction and an enantioselective 
hydrogenation of a protected β-hydroxy enoate. This approach had proven to be 
synthetically useful before and should give high enantiomeric ratios. Judging from our 
previous experiences with similar targets, we should also be able to deliver the natural 
product in a similarly concise fashion to Baldwin’s synthesis. 
2.8 Results and Discussion 
2.8.1 Synthesis of the Biaryl Fragment 
For the synthesis of the phosphonate building block 2.57, we relied upon a procedure 
developed in our group as (Scheme 2.9).127 The synthesis of the known heterocycle 
2.64147 started with a Knoevenagel condensation148 between ethyl cyanoacetate 2.59 and 
1,1,1-trimethoxy methane to give the enol ether 2.60. Condensation with DMF-dimethyl 
acetale followed by cyclization under acidic conditions gave the pyridone 2.62. 
Although the yield was rather low (25–41% over three steps), only one chromatographic 
purification was required in this sequence, and decagram amounts of intermediate 2.62 
were readily obtainable. The yield of the subsequent electrophilic aromatic substitution 
with NBS to give compound 2.63 seemed to be dependent of the quality of the NBS, 
with freshly crystallized reagent performing best.  
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Scheme 2.9: Synthesis of the phosphonate 2.57. a) CH3(OCH3)3, reflux, 6 h; b) N,N-
dimethylformamide dimethyl acetal, reflux, 2 h; c) AcOH, H2O, reflux, 1 h, 25–41% over 
three steps; d) NBS, NH4NO3, MeCN, reflux, 45 min, 68–87%; e) SEMCl, NEt3, DCM, 0 
°C, 1 h, N-SEM 58%, O-SEM 42%; f) (4-[{4- methoxybenzyl}oxy]phenyl)boronic acid, 
Pd(PPh3)4, K2CO3, DME/H2O/DMF, 60 °C; 12–24 h, quant. g) for N-SEM pyridone: 
TBAF, THF, 60 °C, 4 h, 80%; for O-SEM pyridine: TFA, DCM, r.t., 30 min, quant.; h) 
MePO(OMe)2, n-BuLi, -78 °C, THF; 2.64, THF, -78 °C, 93%. 
The pyridone core was then SEM-protected, giving a separable mixture of N-SEM 
pyridone and O-SEM protected pyridine. The introduction of the protecting group was 
found to be necessary, as presumably the free pyridone moiety coordinates to the 
catalyst and deactivates it during the Suzuki-Miyaura coupling reaction. It was also 
found that the O-SEM pyridine rearranges to the N-SEM pyridone to a 4:5 ratio when 
stored at 5 °C. This could prevented by storing the compound at -20 °C. We also tried to 
improve the chemoselectivity of the SEM protection by introduction of silver salts in the 
reaction,149 but with no success (data not shown). The Suzuki coupling reaction to 
introduce the PMB-protected phenol moiety gave quantitative yield, even if the 
regioisomeric mixture of SEM-protected compounds was applied, but thorough 
degassing of the solvents (freeze-pump-thaw cycle, 3x) is mandatory. Formation of 
black palladium precipitate indicated completion of the reaction or that reaction had 
stalled. The SEM groups where then removed with TBAF (for N-SEM derivative) or 
TFA in DCM (for O-SEM derivative) in good yields. The following formation of the 
phosphonate 2.57 from the ester 2.64 gave very good yields, however several parameters 
had to be controlled rigorously. The initial deprotonation of the dimethyl 
methylphosphonate had to be performed at -78 °C, and an off-white suspension 
indicated formation of the organolithium species. Therefore, the phosphonate solution 
was precooled and the n-BuLi solution was let run down the vessel wall in order to also 
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precool it. If no suspension was formed, the reagent proved to be insufficiently reactive 
for the phosphonation to occur. Furthermore, a threefold excess of reagent was required, 
one equivalent for the nucleophilic attack, one for the deprotonation of the pyridone and 
one for the deprotonation of the β-keto phosphonate. The solution of the pyridone was 
then also added slowly to the phosphonate suspension, as a fast addition also diminished 
the yield. Ideally, the rate of addition was adjusted so that the lithiated phosphonate 
suspension did not transform to a homogenous solution. When these requirements were 
met, the reaction gave reproducible yields of >90%. 
2.8.2 Synthesis of the Side Chain  
Scheme 2.10: Synthesis of the aldehyde 2.58. a) Acetaldehyde, DABCO, r.t., 7 d, 80%; 
b) NBS, DMS, DCM, r.t., 16 h, 91%; c) NaOAc, MeOH, 80 °C, 4 h; K2CO3, MeOH, r.t., 
18 h, 82%; d) TBDPSCl, Im, DCM, 0 °C to r.t., 1h, 89%; e) [Ir(L)(cod)]{B[3,5-
(CF3)2C6H3]4} 1 mol%, H2, DCM, 0 °C, 16 h, 99%, 92:8 e.r.; f) DIBAL-H, DCM, -78 °C 
1 h, 82%; g) ethyl 2- (triphenylphosphoranylidene)propanoate, DCM, reflux, 48 h, 95%; 
E/Z >30:1; h) DIBAL-H, THF, -78 °C to r.t., 2 h, 88%; i) TPAP, NMO, DCM, r.t., 1 h, 
99%; j) TBAF, THF, r.t., 2 h, 95%. 
With building block 2.57 in hand, we commenced the synthesis of aldehyde 2.58 
(Scheme 2.10). The synthesis started from methacrylate 2.66, initially following a 
previously reported procedure.150 A Morita-Baylis-Hillman reaction151 with 
acetaldehyde in the presence of DABCO gave the β-hydroxy ester 2.67, which was 
converted under modified base-free Corey-Kim conditions152 to give the vinyl bromide 
2.68. We only observed formation of the E-isomer, which was crucial for the 
enantioselective hydrogenation later on, as the Z-isomer would yield the opposite 
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enantiomer.153 Bromide 2.68 underwent substitution with sodium acetate, and the acetate 
intermediate was subjected to methanolysis in a one-pot procedure. The resulting allylic 
alcohol was TBDPS protected to give ester 2.69. This ester was then subjected to 
enantioselective hydrogenation conditions developed in collaboration with the Pfaltz 
group. The investigations of this reaction have been extensively described elsewhere,154 
however a few key points shall be mentioned here for the sake of completeness. 
The introduction of a silyl protecting group was found to be necessary, and it is 
proposed that for an unprotected alcohol, the hydrogenation product irreversibly binds to 
the catalyst, shutting down the catalytic cycle.155 TBDPS-protected alcohol 2.69 was 
found to be superior to the TIPS- or TBS-protected analogs in terms of 
enantioselectivity. It was also observed that performing the reaction at a concentration of 
0.2 M gave better selectivity than at 0.4 M. Therefore, the reaction was run in several 
batches on lower concentration to obtain the best enantiomeric ratios.  
Ester 2.70 was obtained in good yield and e.r. and, after reduction and oxidation to the 
aldehyde, subjected to a Wittig reaction, which gave enoate 2.71 in excellent yield and 
E/Z selectivity. Attempted direct DIBAL-H reduction to the corresponding aldehyde 
only gave low yields, and we therefore applied a DIBAL-H reduction/Ley-Griffith 
oxidation156 protocol/deprotection to furnish the aldehyde 2.58. For the subsequent 
HWE-reaction, it was found necessary to remove the sterically demanding TBDPS 
group, as otherwise only low yields were observed. 
In some cases we obtained Knoevenagel-type products such as 2.74 in the HWE 
reaction. We performed a screening on a test substrate 2.72 to minimize formation of 
this product as detailed in Table 2.1. The reactions were monitored by UPLC-MS 
analysis. As the absorption coefficients of the reactants were not known, this allowed 
only for a rough quantitative analysis. Nevertheless, this approach proved to be 
sufficient for optimization of the reaction.  
                                                
 
153 A. Lightfoot, P. Schnider, A. Pfaltz, Angew. Chem. Int. Ed. 1998, 37, 2897; S. J. Roseblade, A. Pfaltz, 
Acc. Chem. Res. 2007, 40, 1402. 
154 A. Schumacher, Ph.D. Thesis; University of Basel, Switzerland, 2012, ISBN 978–3-95404-059-9. 
155 J. Zhou, W. Oegle, Y. Fan, V. Banphavichit, Y. Zhu, K. Burgess, Chem. Eur. J. 2007, 13, 7162. 
156 A. C. Dengel, R. A. Hudson, W. P. Griffith, Transit. Metal Chem. 1985, 10, 98; W. P. Griffith, S. V. 
Ley , G. P. Whitcombe, A. D. White, J. Chem. Soc., Chem. Commun. 1987, 1625. 
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Table 2.1: Screening of HWE conditions.  
Entry Conditions (eq.) Conversion (%) 
to 2.73 
 
to 2.74 
1 DBU (1.2), THF <50 <50 
2 DBU (1.2), THF-H2O (4:1) <50 <50 
3 DBU (1.2), LiCl (2.0), THF <50 – 
4 DBU (1.2), LiCl (2.0), THF-H2O (4:1) >50 – 
5 LiOH (1.2), THF <50 traces 
6 LiOH (1.2), THF-H2O (4:1) >50 – 
General conditions: Phosphonate 2.57 (1.0 eq.), aldehyde 2.72 (1.0 eq.), r.t. 0.2 M, exclusion of light. 
We quickly noticed that the undesired product 2.74 was only formed in the absence of 
lithium salts (entries 1 and 2). We also observed decomposition of the product 2.74 upon 
adding aqueous LiOH to the reaction mixture. Lithium chloride in the presence of water 
proved to be beneficial for formation of the desired product 2.73 (entry 4) compared to 
the anhydrous conditions in entry 3. When lithium hydroxide was used as a combination 
of base and lithium-ion source in a THF-H2O mixture, we observed the best results in 
terms of product formation and side reaction suppression (entry 6). We contribute this to 
a solubility effect of the lithium salt as deduced from comparison with entry 5. 
2.8.3 Coupling of the Fragments 
We then applied the optimized conditions to the enantiomerically enriched aldehyde 
2.58 (Scheme 2.11). Although the HWE reaction required a long reaction time (6 d), we 
obtained the desired pyridopolyene in good yield and excellent E/Z selectivity. It should 
be noted that the formed pyridopolyenes are light sensitive and are prone to E/Z 
isomerization.  
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Scheme 2.11: Synthesis of the (–)-Pyridovericin 2.46 .a) 2.58, LiOH, THF-H2O, 
exclusion of light, r.t., 6 d, 77%, E/Z >30:1; b) LiI, pyridinium chloride, THF, 60 °C, 4 h; 
c) TFA, DCM, r.t., 30 min, 83% over to steps, 93:7 e.r.,  E/Z >6:1, E/Z >30:1 after 
recrystallization. 
The reactions were therefore carried out under exclusion of light, and light exposure was 
also minimized during workup and storage. After removal of the protecting groups we 
obtained (–)-pyridovericin (2.46) in good yield and in a moderate E/Z ratio of about 6:1 
after flash chromatography. However, we were able to increase this ratio to >30:1 upon 
repeated fractional crystallization. The e.r. was determined to be 93:7 by comparison of 
chiral HPLC traces with the racemic compound (Figure 2.8). 
Figure 2.8: Chiral HPLC trace of the racemic compound (up) and (–)-pyridovericin 
(below). 
In summary, the natural R-(–)-isomer of pyridovericin (2.46) was synthesized in 13 
linear steps and in 22% yield from methyl acrylate (2.66). The key steps involved the 
enantioselective hydrogenation of TBDPS-protected enoate 2.69 and the coupling of 
phosphonate fragment 2.57 to the aldehyde 2.58. In comparison to the other reported 
syntheses of pyridovericin (section 2.71), we could successfully avoid racemization 
during the route, as proven by analysis of chiral HPLC traces of several intermediates 
(see SI).  
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2.9 Pyridopolyene Natural Products as Light-Triggered Molecular 
Switches 
As already discussed in section 2.4, pyridone natural products have been shown to 
possess neuritogenic activity, and we have confirmed these results independently with 
our synthetic material of several natural products.127 As mentioned in the previous 
section, the polyene side chains of these pyridopolyenes were found to be 
configurationally labile, and E/Z isomerization was observed when the samples were 
exposed to ambient and UV light. While the rate of isomerization under ambient light 
was found to be slow, care had to be taken when samples were exposed to UV 
irradiation (e.g. UV detection in semi-preparative HPLC), as mixtures of E/Z-isomers 
were obtained within minutes. 
Figure 2.9: Ophiocordyceps growing from a dead ant attached to a leaf.157 
Enthomopathogenic fungi have been shown to induce behavioral changes in the host 
organism (see section 2.4). Ophiocordyceps unilateralis for example was found to cause 
host ants to leave their hive and let them seek areas with suitable humidity and 
temperature for fungal growth, where the fungal infection then would cause the ant to 
irreversibly attach to the major vein on the underside of leaves (Figure 2.9). The infected 
ant would now remain attached to the leaf until death, while the fruiting body would 
begin to protrude from the host and distribute spores from the newly gained vantage 
point (classical summit disease, section 2.4).158 
                                                
 
157 M. B. Pontoppidan, W. Himaman, N. L. Hywel-Jones, J. J. Boomsma, D. P. Hughes, PLoS ONE  2009, 
4, e4835; used under permission of creative commons license CC-BY 2.5. 
158 S. Mongkolsamrit, N. Kobmoo, K. Tasanathai, A. Khonsanit, W. Noisripoom, P. Srikitikulchai, R. 
Somnuk, J. J. Luangsa-ard, J. Inv. Pat. 2012, 111, 217. 
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Scheme 2.12: Isomerization of the model substrate 2.75 upon UV irradiation. 
We therefore hypothesized that the polyene side chain could function as a molecular 
switch, whereupon light exposure and conformational change a biological response 
might be triggered, as it has been shown for some host insects.159 We decided to further 
investigate the isomerization behavior of these pyridopolyene natural products on the 
model substrate 2.75 (Scheme 2.12). 
 
Figure 2.10: UV-Vis spectrum (left) and determination of ε (right) of 2.75. 
We began our studies by recording UV-Vis spectra, identifying the absorption maxima 
and calculating the corresponding molar absorption coefficients ε (Figure 2.10). The 
absorption maxima λmax were detected at 254 nm and 345 nm, with the corresponding 
molar absorption coefficients of 15685 M-1cm-1 and 22613 M-1cm-1 respectively. In 
order to further characterize the spectroscopic properties of model substrate 2.75, we 
measured emission spectra of the identified λmax. The sample was irradiated with a 
constant wavelength of 260 nm or 345 nm and the corresponding emission spectra were 
recorded (Figure 2.10). Compound 2.75 exhibited an emission at 481 nm when 
irradiated at 260 nm, and another emission maximum at 575 nm when irradiated at 345 
nm, which matched well with the observed yellow-orange color of the pyridopolyene 
natural products.  
                                                
 
159 R. J. Milner, D. G. Holdom, T. R. Glare, Entomol. Exp. Appl. 1984, 36, 37; T. Ohbayashi, K. Iwabuchi, 
Appl. Entomol. Zool. 1991, 26, 479. 
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Figure 2.11: Emission spectra of 2.75 at 260 nm (left) and 345 nm (right). 
We then designed an experiment to quantify the rate and extent of E/Z isomerization. A 
solution of 2.75 in deuterated chloroform in a 1H NMR tube was irradiated at 366 nm 
and the 1H NMR spectra were recorded at several intervals, monitoring the 
isomerization. The initial E/Z ratios for the three double bonds DB1, DB2 and DB3 were 
determined to be 19:1, 20:1 and 17:1 respectively (Scheme 2.12, left). The obtained data 
is represented in an E/Z vs. time plot (Figure 2.11, right) and an overlay of the change in 
1H NMR spectra over time (Figure 2.11, left). 
Figure 2.12: Selected 1H NMR signals of 2.75 at different times (left) and development 
of E/Z ratio with time (right). 
The compounds underwent isomerization to an E/Z ratio of about 2:1 within ten minutes 
for all double bonds DB1, DB2 and DB3. During our syntheses of pyridopolyene natural 
products, we mainly observed the isomerization of DB3, but we were not able to identify 
any preferential site of isomerization in our UV-NMR experiments. Although these 
findings did not disprove our hypothesis of the polyene side chain acting as a molecular 
switch, we found the compounds proved to be challenging to handle, as for example the 
starting E/Z ratios varied from batch to batch (17:1 to 24:1). This would have rendered 
prospect bioassays difficult to reproduce. Our further investigations involving truncation 
of pyridopolyene natural products and their application in a bioactive surface material 
are presented in the next section.  
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2.10 Truncated Pyridone Natural Products in a Neuritogenic 
Functional Material 
As described in section 2.3, the truncation of natural products is a powerful method for 
the generation of biologically active structural analogs while decreasing molecular- and 
synthetic complexity. Our group had already demonstrated the successful 
implementation of biologically active natural product-related compounds into functional 
surfaces and materials.160 Therefore, we initiated a two-phase project consisting of the 
truncation and identification of the neuritogenic core structure of the pyridopolyene 
natural products, and, in a secondary stage, the application of the truncated compound in 
a biologically active functional material. 
2.10.1 Truncation of Neuritogenic Pyridopolyene Natural Products 
Scheme 2.13: Neuritogenic truncated analogs 2.78 and 2.79 and synthesis of methylated 
derivatives 2.80-2.86. a) LiI, THF, reflux; b) MeI, K2CO3, MeCN; c) TFA (5% in DCM), 
r.t., 30 min. 
The synthesis and identification of the neuritogenic core structures has been extensively 
described elsewhere.161 The major conclusions of these investigations are summarized in 
this section. As described in section 2.72, our synthetic approach allowed for easy 
variation of the aryl substituent by Suzuki coupling. Using this approach, we 
synthesized a small library and identified the hydroxy substituted compounds 2.78 and 
2.79 as the most active in the PC-12 assay.   
                                                
 
160 J.-Y. Wach, S. Bonazzi, K. Gademann, Angew. Chem. Int. Ed. 2008, 47, 7123; R. Wehlauch, J. 
Hoecker, K. Gademann, ChemPlusChem 2012, 77, 1071; J. Gomes, A. Grunau, A. K. Lawrence, L. Eberl, 
K. Gademann, Chimia 2013, 67, 275. 
161 F. Schmid, H. J. Jessen, P. Burch, K. Gademann, Med. Chem. Commun. 2012, 4, 135. 
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The polyene side chain was found to be unrequired for the induction of neurite 
outgrowth. Thereby, we had already achieved a major simplification of the biologically 
active structure. We then tried to further elucidate the role of the three H-bond donor- 
and acceptor substituents for biological activity and synthesized all combinations of 
methylated derivatives to block the specific positions (compounds 2.80-2.86, Scheme 
2.13). 
Figure 2.13: Screening of H-bond substituents (left) and dilution series of 2.79 (right). 
Errors are indicated as standard error of the mean. 
We then evaluated the neuritogenic activity of compounds 2.80-2.86 in the PC-12 
assay.162 The summarized results of the study are presented in Figure 2.13. The 4’-
methoxy substituted analogs 2.80 and 2.82 did not induce neurite outgrowth at 20 µM, 
whereas compounds 2.84-2.86 and 2.78 were all active at this concentration (Figure 
2.13, left). This indicated the necessity of a 4’-hydroxy substituent for neuritogenic 
activity, whereas blocking the 1- and 4-positions with a methyl group did not reduce 
neuritogenic activity (compounds 2.80-2.83). We also identified compound 2.79 as the 
most active of our library, with neuritogenic activity observed at a minimal 
concentration of 1 µM, whereas the natural product prebassianin B did not display any 
activity at this concentration (Figure 2.13, right). 
Through these studies we have been truncate the neuritogenic core structure of the 
pyridopolyene natural products and even identifying a more active analog 2.79. This 
was only possible due to our modular synthetic approach, which allowed for the 
synthesis of described analogs in scales useful for application in a bioactive functional 
material as described in the next section.  
                                                
 
162 Cell culture experiments were performed by Dr. Henning Jessen and Dr. Patrick Burch. 
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2.10.2 Neuritogenic Surfaces Using Truncated Natural Product Analogs 
With the truncated and highly neuritogenic compound 2.79 in hand, we sought out to 
implement it in a biocompatible material, giving access to a neuritogenic surface 
material. The summary of our detailed study163 is presented in this section. 
Our group had extensive knowledge of the preparation and functionalization of 
biologically active surfaces.160 Since the introduction of an anchoring group often 
elongates the synthetic sequence, we intended to incorporate compounds such as 2.78 or 
2.79 directly into the functional surface without further synthetic modification. The 
method should also be compatible with the setup of the PC-12 assay. Although the assay 
was usually performed in commercial pre-coated collagen 24-well plates, such plates 
can readily be coated with various polymer supports.164 We therefore sought to find a 
suitable method for adding our truncated neuritogenic compound 2.79 to the standard 
collagen coating procedures described in the literature. The general experimental setup 
is depicted in Figure 2.14. The process involved coating of the glass cover slides with 
the standard collagen solution (Figure 2.14 right, labeled blank in graphs below) and a 
collagen solution with a neuritogenic additive (Figure 2.14, left). After thorough rinsing, 
the coated glass slides were subjected to our standard PC-12 assay procedure in 24-well 
plates. After two days, the cells were fixed, stained and micrographs were recorded and 
statistically evaluated in order to assess neuritogenic activity.165 The main parameters to 
be optimized were the coating temperature and time, and the concentration and solvent 
of the neuritogenic compound solution applied in the coating process. We decided to 
perform the seminal studies with the highly neuritogenic model compound tetradecyl 
2,3-dihydroxybenzoate (2.87, Scheme 2.13).166  
                                                
 
163 P. Burch, F. Schmid, K. Gademann, Adv. Healthc. Mater. 2014, 3, 1415. 
164 M. Buttiglione, F. Vitiello, E. Sardella, L. Petrone, M. Nardulli, P. Favia, R. d’Agostino, R. Gristina, 
Biomaterials 2007, 28, 2932. 
165 Cell experiments were performed by Dr. Patrick Burch. Further details are avaialble in “Synthesis, 
Biological Evaluation and Surface Applications of Neuritogenic Compounds”, Patrick Burch, PhD Thesis, 
2014, University of Basel. 
166 L. Gao, J. Li, J. Qi, Bioorg. Med. Chem. 2010, 18, 2131; L. Gao, L. Xiang, Y. Luo, G. Wang, J. Li, J. 
Qi, Bioorg. Med. Chem. 2010, 18, 6995; Y. Luo, K. Sun, L. Li, L. Gao, G. Wang, Y. Qu, L. Xiang, L. 
Chen, Y. Hu, J. Qi, ChemMedChem 2011, 6, 1986. 
   Chapter 2 
 46 
Figure 2.14: Experimental setup of the surface coating experiments for the generation of 
neuritogenic surfaces. 
We identified a concentration range from 1 mM to 100 nM to significantly induce 
neurite outgrowth (Figure 2.15, left). Further experiments were then conducted with a 
1 µM coating solution (10 µM stock solution diluted 1:10 v/v), and we observed 
increased detachment of the cells from the surface for higher concentrations. In parallel, 
we performed a screening of the optimal coating temperature and time and found that a 
coating time of 16 h at 36 °C gave the highest rate of differentiated cells (Figure 2.15, 
right). 
Figure 2.15: Screening of concentrations (left) and coating conditions (right). Errors are 
indicated as standard error of the mean. *Compound positive control: Surfaces coated 
without the active compound 2.87, and 2.87 was subsequently added to the growth 
medium as DMSO solution to give a final concentration of 1 µM.  
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Figure 2.16: Screening of solvents (left) and co-incubation experiments (right). Errors are 
indicated as standard error of the mean. *Compound positive control: Surfaces coated 
without the active compound 2.87, and 2.87 was subsequently added to the growth 
medium as DMSO solution to give a final concentration of 1 µM. 
We then investigated the influence of the solvent of the stock solution in the coating 
process (Figure 2.16, left). We obtained positive results for all water-miscible solvents 
that were tested and prepared further stock solutions in DMSO, as it is available in 
sterile cell culture grade and widely applied in cell culture experiments. We then tried to 
gain further insight into the mechanism of neurite growth induction. Usually, control 
blank experiments with collagen-coated glass slides without a neuritogenic additive 
were performed in separate wells of the 24 well plate. Leeching of the neuritogenic 
compounds from the collagen surface into the medium could be a possible mechanism 
of distribution of the compound. Therefore, we performed co-incubation experiments 
with the blank glass slides and the slides coated with the neuritogenic compound in the 
same well on a six well plate (Figure 2.16, right). We were not able to detect increased 
neuron differentiation on the blank slides placed adjacent to the neuritogenic coated 
slides, and UPLC analysis gave no indication of the compound 2.87 being present in the 
cell medium within the limits of detection (1 µM). We then tested whether the coated 
slides would retain their neuritogenic properties throughout several cycles of cell 
incubation (Figure 2.17, left). After the first cycle of cell incubation (2 d), the cells were 
detached from the glass slides using trypsin solution, the slides were washed and 
sterilized and subjected to another cycle of incubation (2 d) with new cells. Although a 
significant induction of neurite outgrowth was still observable after three cycles, the 
activity of the slides had clearly decreased. 
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Figure 2.17: Screening of truncated natural products (left) and recycling of the covered 
slides experiments (right). Errors are indicated as standard error of the mean. *Compound 
positive control: Surfaces coated without the indicated active compound, and the 
indicated active compound was subsequently added to the growth medium as a DMSO 
solution to give the final concentration indicated. 
Finally, we concluded the project by the application of the truncated natural product 
analogs 2.78 and 2.79 in the surface material (Figure 2.17, right). Although we had to 
raise the concentration of neuritogenic compound in the coating solution, we observed 
significant induction of neurite outgrowth. We were also able to even further broaden 
the scope of the developed methodology by replacing collagen by polylysine, another 
widely applied coating material in cell biology experiments, in the coating solution (data 
not shown). 
In summary, we have successfully truncated the pyridopolyene natural products and 
identified the neuritogenic core. We were then able to integrate the truncated analog into 
a newly developed neuritogenic functional material with a robust and general approach. 
2.11 Conclusion and Outlook 
We were able to enantioselectively synthesize the pyridopolyene natural product (–)-
pyridovericin (2.46) based upon our previously developed modular and convergent 
approach in good yield and enantiomeric ratio. 
Our biological investigations of the pyridopolyene natural products commenced with the 
study of the light-triggered E/Z isomerization of model substrate 2.75 by UV-Vis, 
fluorescence and 1H NMR spectroscopy. Measuring the degree of neuron differentiation 
in the PC-12 assay, we then continued with the identification of the neuritogenic core 
and truncation of the natural products. This was accomplished by varying the aryl 
substituent in the C(4) position by Suzuki coupling and selectively blocking hydrogen 
bonding sites by methylation, which eventually yielded neuritogenic truncated analogs 
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2.78 and 2.79. These analogs were more easily accessed and showed higher neuritogenic 
activity as compared to the natural products. Our final project involved incorporation of 
the truncated analogs 2.78 and 2.79 onto a neuritogenic surface material. By adaption of 
a standard collagen coating protocol for cell assays, we had optimized coating 
concentrations, temperatures and times, and identified suitable solvents and other 
coating matrices than collagen. 
Looking forward, the pyridopolyene natural products surely hold more undiscovered 
potential, especially from a biological point of view. While our research has mainly been 
focused on the neuritogenic properties of these compounds, we are and other groups are 
also investigating other biological targets.167 In the next chapter, we will further dwell 
into the synthesis of another family of natural products, the aetheramides. 
                                                
 
167 M. de Souza Santos, W. J. Andrioli, M. P. F. de Morais Del Lama, J. K. Bastos, N. P. D. Nanayakkara, 
R. M. Z. G. Naal, International Immunopharmacology, 2013, 1. 
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3  SYNTHETIC STUDIES TOWARDS 
AETHERAMIDE B 
3.1 HIV and AIDS 
The human immunodeficiency virus (HIV) is the cause of an accumulation of medical 
conditions summarized under the term acquired immunodeficiency disease syndrome 
(AIDS). The HI virus is the result of several cross-species virus transmissions and 
originates from simian immunodeficiency viruses (SIV) found in African primates such 
as macaques or chimpanzees.168 Phylogenetic and statistical analyses date the last 
common ancestor and modern HIV-1 with other virus sub-types between 1910 and 
1930,169 therefore taking between 50 to 70 years before being recognized as an 
individual disease in 1981.170 This delay of onset of the pandemic is explained by the 
fact that although infections in sub-Saharan Africa have occurred before the major 
global outbreak in the 1980s, the infected individuals (e.g. hunters and farmers) lived in 
secluded areas preventing further spreading of the disease. Shortly after identifying 
AIDS as a disease, the causative agent was found to be the HI virus.171 The main 
transmission pathways were identified to be via sexual transmission, percutaneous 
transmission (e.g. reuse of hypodermic needles by recreational drug addicts) and 
perinatal transmission, although sexual transmission is the major pathway for 
infection.172 As of 2008, the lowest estimations state the minimal number of infected 
individuals to be at least 60 million, with a 25 million death toll.173 Since the main group 
of infected individuals consists of young adults in developing countries, the available 
palliative treatments are often prohibitively expensive. The applied strategies and 
available treatments are discussed in the next section.  
                                                
 
168 P. M. Sharp, B. H. Hahn, Cold Spring Harbor Perspectives in Medicine 2011, 1, a006841. 
169 M. Worobey, M. L. Santiago, B. F. Keele, J. B. Ndjango, J. B. Joy, B. L. Labama, A. B. Dhed, G. M. 
Saw, Nature, 2004, 428, 820. 
170 F. P. Siegal, C. Lopez, G. S. Hammer, A. E. Brown, S. J. Kornfeld. J. Gold, S. Z, Hirschman, C. 
Cunningham-Rundles, B. R. Adelsberg, N. Engl. J. Med. 1981, 305, 1439; M. S. Gottlieb, R. Schroff, H. 
M. Schanker, J. D. Weisman, P. T. Fan, R. A. Wolf, A. Saxon, N. Engl. J. Med. 1981, 305, 1425. 
171 R. C. Gallo, P. S. Sarin, E. P. Gelmann, M. Robert-Guroff, E. Richardson, V. S. Kalyanaraman, D. 
Mann, G. D. Sidhu, R. E. Stahl, S. Zolla-Pazner, J. Leibowitch, M. Popovic, Science 1983, 220, 856; F. 
Barre-Sinoussi, J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. 
Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, L. Montagnier, Science 1983, 220, 868. 
172 M. S. Cohen, G. M. Shaw, A. J. McMichael, B. F. Haynes, N. Engl. J. Med. 2011, 364, 1943. 
173 M. H. Merson, J. O’Malley, D. Serwadda, C. Apisuk, Lancet 2008, 372, 475. 
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3.2 Current Treatments of HIV Infection and AIDS 
In order to understand the available treatment methods, the underlying cellular 
mechanisms of HIV infection are briefly outlined in the following paragraph. The HI 
virus is a retrovirus, therefore relying on replication of its single stranded RNA by 
reverse transcription in the host cell as an obligatory parasite.174 The virus effectively 
“hijacks” parts of the cellular machinery in order to replicate, killing the host cell in the 
process. HIV targets human immune cells (e.g. T helper cells or macrophages),175 and 
this results in a decrease of available immune responses of the human body leading to 
AIDS, where an otherwise moderately severe condition (e.g. pneumonia) can cause 
death. The key steps of the viral reproduction cycle are highlighted in Figure 3.1. 
Figure 3.1: Key steps of HIV reproduction cycle and points of medical intervention.176 
The first class of medication are reverse-transcriptase inhibitors. These compounds 
incorporate an unnatural nucleotide or -nucleoside into the newly formed DNA strain in 
the reverse transcriptase step, where viral RNA is translated to DNA.  
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This then terminates the DNA chain elongation, and the incomplete DNA chain is not 
able to induce viral peptide expression (vide infra). Examples of such compounds are 
Zidovudine (3.01) and Abacavir (3.02) (Figure 3.2).177 
Figure 3.2: The nucleotide transcriptase inhibitors Zidovudine (3.01) and Abacavir 
(3.02). 
Once the viral RNA is translated, the resulting viral DNA must be introduced to the 
hosts DNA in order to be translated into viral proteins. HIV integrase is the enzyme 
responsible for the incorporation of the transcripted viral DNA into the host cells DNA 
in the nucleus. A compound that is able to interfere at this stage of the viral reproduction 
cycle is Elvitegravir (3.03, Figure 3.3), which binds to the viral integrase enzymes, 
therefore inhibiting integration of viral DNA into the host cells’ DNA.178 
Figure 3.3: The integrase inhibitor Elvitegravir (3.03). 
After the translated viral DNA has been successfully merged with the host DNA in the 
nucleus by the integrase enzyme, the host cell will start with the translation of the newly 
introduced viral DNA into proteins. The resulting viral polypeptide chain is cleaved at 
the appropriate sequences to give viral enzymes. HIV achieves this process by the use of 
protease enzymes. Protease inhibitors inhibit the cleavage of the translated polypeptide 
chain and therefore decrease viral enzyme accumulation in the host cell. Darunavir 
(3.04, Figure 3.4), developed by the group of Arun K. Ghosh, is currently the 
recommended first line protease inhibitor.179  
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Figure 3.4: The protease inhibitor Darunavir (3.04). 
While all the agents described above target processes inside the host cell, there are also 
compounds that block the initial entrance of viral RNA into the host. This class of 
compounds is called fusion inhibitors, and Enfurvirtide is an example of a polypeptidic 
medication of this class with the peptide sequence: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-
Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-
Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2.180 
While all these therapeutics are effective to a certain extent, they are usually applied in a 
combined approach where at least two different stages of viral reproduction are targeted. 
This approach is known as highly active antiretroviral therapy (HAART). Since HIV has 
a rather fast reproduction cycle of 1.5 days from cell entrance to release of new virions 
and infection of other cells, it is prone to develop drug- and multidrug resistant mutants, 
which is less likely when HAART is applied.181 With the currently available treatments, 
it is possible to render HIV infection a chronic disease with life-long treatment and 
without development of AIDS, whereas no treatment usually leads to death of the 
patient within 9 to 11 years.182 It is, however, not yet possible to completely cure HIV 
infection or AIDS, although of course new medications and vaccine approaches are 
under investigation.183 The “evolutionary wisdom enshrined in natural products”184 
might help to further clarify the cellular mechanisms and biochemical aspects of HIV 
and AIDS and might even pave the way to new forms of treatment.185  
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3.3 Depsipeptides – a Class of Non-Ribosomal Peptides 
3.3.1 The Biosynthesis of Depsipeptides 
A polypeptide where one of the amide bonds is replaced by an ester bond is called a 
depsipeptide (Figure 3.5). 
Figure 3.5: Characteristic structural motif of depsipeptides. 
Depsipeptides are non-ribosomal peptides (NRP), which means they are not synthesized 
in the ribosome and, therefore, do not require an mRNA template for biosynthesis.186 
Therefore, each NRP synthetase complex can only synthesize one specific peptide. NRP 
are produced by microorganisms such as bacteria or fungi and, although NRP have been 
found in higher organisms (e.g. nudibranchs), it is believed that these were isolated from 
microorganisms living with the investigated specimen.187 The biosynthetic machinery of 
NRP synthesis (NRPS) consists of several modules, with each module containing 
distinct domains. Figure 3.6 illustrates the general biosynthetic pathway of NRPS. 
Figure 3.6: General NRPS pathway. 
As mentioned before, the biosynthetic pathway can be divided into several modules, in 
this example modules 1 to 3. Each NRPS module contains at least three domains. The 
adenylation domain (A) is responsible for substrate recognition and initial activation.188 
The activated substrate is then transferred to the peptide carrier protein domain (PCP), 
which is the transport unit shuttling the carried protein to the catalytic sites of the 
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enzyme.189 In this example, module 1 contains a condensation domain (C) as the last 
domain. In this domain, the new amide bond (as in this example) or ester bond (in 
depsipeptide synthesis) is formed, elongating the chain.190 The process is then repeated 
in module 2: the adenylation domain recognizes the dipeptide product of module 1, 
activates it and transfers is to the peptide carrier protein. In this example, module 2 
contains an additional, non-necessary domain, the epimerization domain (E).191 This 
domain is capable of epimerizing the innermost amino acid in the substrate-enzyme 
complex. There are several other non-necessary domains capable of other chemical 
transformations, such as N-methylation (NMT), cyclization (Cy) or formylation (F) 
domains.192 The final condensation domain of module 2 the gives the epimerized 
tripeptide, which is shown in Figure 3.6 attached to the PCP domain of module 3. After 
another condensation, module 3 will terminate the NRPS with the thioesterase (TE) 
domain.193 The liberated tripeptide could now undergo further post-synthetic 
transformations.194 The incorporation of polyketide synthases (PKS) into NRPS has also 
been shown to occur.195 The described biochemical process of NRPS has a large 
substrate scope, and a wide array of modifying domains gives rise to a vast number of 
natural products occupying a diverse chemical space.  
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3.3.2 Biological Activities of Depsipeptides 
Depsipeptides have been reported to possess a vast range of biological activities.196 This 
section will focus on a few selected examples in a medicinal chemistry context and 
discuss their biological profile in more detail. 
Figure 3.7: Structure of Romidepsin (3.05). 
In 2009, the FDA granted approval to the depsipeptide natural product Romidepsin 
(3.05, Figure 3.7) for the treatment of cutaneous T-cell lymphoma. Romidepsin was first 
isolated and characterized in 1994.197 It was later discovered that Romidepsin acts as an 
histone deacetylase (HDAC) inhibitor. The octameric Histone proteins are involved in 
the packing of DNA, where DNA is wrapped around the Histones.198 Therefore, these 
structures must be unwound for gene expression, and this is achieved by acylation of the 
positively charged lysine residues on the histones by the enzyme histone 
acetyltransferase (HAT). The reverse process is achieved by HDAC and causes tighter 
wrapping of the DNA around the histone octamer.199 HAT and HDAC are opposing 
forces in a dynamic system to regulate DNA translation and therefore protein 
expression. It is well known that in cancer cells, HDAC is often overexpressed, causing 
unfavorable epigenetic changes.200, therefore counteracting the effect of HDAC 
overexpression in malignant cells. Romidepsin itself is a prodrug, and it is postulated 
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that upon reduction of its disulfide bond in the organism, the formed thiol groups 
coordinate to a zinc atom present in the HDAC enzyme, thereby inhibiting its activity.201 
Since the introduction of sulfonamide antibiotics in the 1930s,202 the therapeutic efficacy 
of antibiotics has suffered from the emergence of resistant strains. For example, 
Methicillin-resistant Staphylococcus aureus (MRSA) is a multidrug resistant bacterial 
strain often found in hospitals. It is able to cause severe complications by secondary 
infections in otherwise low-risk surgeries.203 Historically, most clinically applied 
antibiotics rely upon inhibition of critical metabolic processes in bacteria. The β-lactam 
antibiotic class of penicillins and cephalosporins inhibits cell wall biosynthesis in the 
bacterium, and resistant mutants have developed β-lactamases to degrade these 
antibiotics (Section 1.3).204 Since for possibly every new antibiotic resistance will 
eventually be observed to a certain extent, antibiotics with new modes of actions are 
highly sought after. Enopeptin A (3.06, Figure 3.8) constitutes a member of a newly 
found class of antibiotics, the acyldepsipeptide (ADEP) antibiotics.205 
Figure 3.8: Structure of enopeptin A (3.06). 
Enopeptin A (3.06) and several other ADEP antibiotics activate the proteolytic 
proteasome complex caseinolytic peptidase (ClpP).205 Since ClpP is involved in the 
degradation of proteins, it is highly regulated and requires a ClpP-ATPase along with 
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other activating agents in order to hydrolyze peptides.206 The inactive heptameric ClpP 
complex itself only allows for free diffusion of small polypeptides (hexapeptides or 
smaller) into the proteolytically active chamber formed by the heptamer.207 ADEP 
antibiotics such as 3.06 bind to the same active site as the corresponding ClpP-ATPases 
and therefore cause uncontrolled peptide degradation in the bacterial cell .208 Since no 
currently marketed antibiotic drugs target ClpP activation, ADEPs are promising 
candidates for a new class of antibiotics, and even for the treatment of multidrug 
resistant strains.209 Several SAR studies have been conducted and reported for these 
compounds, underlining the unique biological profiles of depsipeptides.210 
3.4 Aetheramide A and B – HIV-Inhibitory Depsipeptides 
Several cyclic depsipeptides with HIV-inhibitory properties have been reported.211 More 
recently, the group of Müller reported the isolation and structural elucidation of two 
cyclic depsipeptides, the aetheramides A and B (3.07 and 3.08, Figure 3.9).212 The 
depsipeptides were isolated from a recently discovered genus of myxobacteria 
Aetherobacter.213 More specifically, the strain Aetherobacter rufus was cultivated in a 
yeast medium and bioassay-guided isolation gave the two compounds 3.07 and 3.08. 
Similar to other natural products before,214 it was found that the two isomers are in 
equilibrium via transesterification in a methanolic solution.   
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Figure 3.9: Structure of Aetheramide A (3.07) and B (3.08). 
The molecular structure was assigned by HRMS, NMR spectroscopy, Mosher ester 
analysis and quantum mechanical calculations. The natural products were found to 
possess a dipeptide fragment consisting of a valine- and an unusual 3-methoxy-N-
methyl-(R)-tyrosine subunit. The valine residue was identified to be connected to an 
(R,R)-configured syn-diol with a geminal phenyl-group and (E,E)-configured diene. The 
absolute configuration of the allylic methyl ether in the C(26) position and of the C(17) 
of the β-keto amide could not be determined unambiguously. From a synthetic point of 
view, the absolute conformation could be confirmed by total synthesis, and larger 
quantities of the compounds for biological studies could be obtained. Furthermore, a 
suitable retrosynthetic approach would give access to structural analogues for SAR 
studies. Therefore, we decided to start a total synthesis program to address these 
challenges. Previous synthetic efforts towards the aetheramides A (3.07) and B (3.08) 
are summarized in the next chapter.  
3.5 Previous Synthetic Contributions 
Several Groups have already published their synthetic efforts towards the Aetheramides. 
The first report of an attempted total synthesis from the Kalesse group is outlined in 
Scheme 3.1.215 Starting from the cinnamate 3.09, the syn hydroxyl groups were 
introduced via a Sharpless asymmetric dihydroxylation reaction.216 The following 
double TBS protection could render a prospective regioselective esterification on the 
diol more difficult. A reduction-oxidation-Wittig sequence followed by another 
reduction-oxidation step furnished the aldehyde 3.10.  
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Scheme 3.1: Synthesis reported by the Kalesse group. a) AD-β-mix, MeSO2NH2, 77%; b) 
TBSOTf, 2,6-lutidine, 96%; c) DIBAL-H, 87%; d) IBX; e) Wittig salt, n-BuLi, 62% over 
two steps; f) DIBAL-H, 89%; g) MnO2; h) VMA, 80% over two steps; i) Meerwein’s salt, 
proton sponge; Stryker’s Reagent, PhSiH3, 40% over two steps; j) NiCl2, NaBH4; k) 
DIBAL-H; l) MnO2, 47% over three steps; m) HWE reagent, KHMDS, 36% n) AlCl3, 
acetylchloride, 76%; o) SOCl2, MeOH, 70%; p) CbzCl, Na2CO3, 90%; q) BnBr, K2CO3, 
TBAI, 72%; r) mCPBA, DCM, K2CO3, 63%; s) NaH, MeI, quant.; t) LiOH, 
THE/MeOH/H2O; u) methyl valinate, EDC, HOBt, DIPEA, 75% over two steps; v) H2, 
Pd/C, 66%. 
This then underwent the key step, an enantioselective vinylogous Mukayama-aldol 
reaction (VMA) under conditions developed by Kalesse and co-workers.217 The obtained 
enoate 3.11 was reduced with Stryker’s reagent to the aldehyde and then subjected to a 
final HWE reaction to furnish the thioester 3.12 in 13 steps and 3% overall yield. The 
thioester was intended to be coupled to the dipeptide fragment 3.14 in a silver-mediated 
thioester coupling.218 The synthesis of the dipeptide fragment 3.14 started from 
commercially available (R)-tyrosine (3.13), which was acylated, protected and oxidized 
in a Baeyer-Villiger reaction219 to give the fully decorated aromatic system according to 
a literature procedure.220 A peptide coupling reaction followed by deprotection then 
gave the fragment 3.14 in 13 steps and 11% overall yield. Unfortunately, the silver 
mediated thioester coupling of 3.12 and 3. 14 could not be realized, as the thioester 3.12 
appeared to be too unreactive.  
                                                
 
217 S. Simsek, M. Horzella, M. Kalesse, Org. Lett. 2007, 9, 5637. 
218 S. V. Ley, P. R. Woodward, Tetrahedron Lett. 1987, 28, 3019; G. Zhou, D. Lim, D. M. Colart, Org. 
Lett. 2008, 10, 3809; M. C. Bagley, K. Chapaneri, J. W. Dale, X. Xiong, J. Bower, J. Org. Chem. 2005, 
70, 1389; L. T. Burke, D. J. Dixon, S. V. Ley, F. Rodriguez, Org. Biomol. Chem. 2005, 3, 274. 
219 A. Baeyer, V. Villiger, Ber. 1899, 32, 3625. 
220 Y.-L. Song, M. L. Peach, P. P. Roller, S. Qui, S. Wang, Y.-Q. Long, J. Med. Chem. 2006, 49, 1585. 
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Scheme 3.2: Synthesis reported by the Gosh group. a) AD-β-mix, MeSO2NH2, 82%; b) 
TBSCl, py; c) MEMCl, DIPEA, 43% over two steps; d) DIBAL-H; e) Swern oxidation; f) 
Wittig reaction, 76% over 3 steps; g) DIBAL-H; h) Wittig reaction, 83% over two steps; 
i) DIBAL-H; j) Swern oxidation; k) asymmetric allylation, 55% over three steps; l) NaH, 
MeI; m) 9-BBN, 71% over two steps; n) MsCl, NEt3; o) NaCN, DMSO, 69% over two 
steps; p) DIBAL-H; q) Wittig reaction, 65% over two steps; r) Evan’s aldol, 82%; s) 
TBSOTf, 2,6-lutidine; t) LiOH, H2O2, H2O, 70% over two steps; A) Enantioselective 
hydrogenation; B) H2, Pd/C, 75% over two steps; C) MeSO3H; D) CbzCl, NEt3; E) 
K2CO3, MeOH, 48% over three steps; F) MEMCl, DIPEA; G) MeI, Ag2O; H) H2, 
Pd(OH)2, 51% over three steps; I) BOPCl, DIPEA, 63%; J) TBAF-AcOH; K) Fmoc-Val, 
EDC, DMAP, DIPEA, 49% over two steps; L) Me3SnOH; M) MeCN, Et2NH; N) BOPCl, 
2,6-lutidine, 47% over two steps; O) TBAF-AcOH; P) DMP, 53% over two steps. 
The Ghosh group recently reported the synthesis of a MEM protected derivative 3.21 of 
Aetheramide A (3.07, Scheme 3.2).221 This synthesis also involved an asymmetric 
dihydroxylation of cinnamate 3.09 to introduce the syn-diol. The hydroxy groups were 
then selectively protected in rather low yield, but, nevertheless, this allowed for 
selectively forming one of the two possible esters later in the synthesis. After two Wittig 
reactions and the corresponding reduction-oxidation steps, the aldehyde 3.16 was 
obtained. The key step was the introduction of the vinylic stereocenter, which was 
accomplished via an asymmetric allylation with a silver(I)-(S)-BINAP complex and 
                                                
 
221 A. K. Ghosh, K. V. Rao, S. Akasapu, Tetrahedron Lett. 2014, 55, 5191. 
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allyltributylstannane.222 Furhter steps involved a hydroboration of the newly introduced 
double bond and conversion into an aldehyde. This set the stage for an Evan’s aldol 
reaction.223 After cleavage of the auxiliary and protection, the syn-configured acid 3.18 
was obtained. The necessety of the Evans aldol reaction was not entirely justified, as the 
hydroxy group would be oxidized later in the route, and it can be argued that in the 
natural product, the acidic α-position would equilibrate to the more stable epimer. 
However, the report does not comment on this. The amino acid 3.20 was synthesized 
from the known enamide 3.19224 via an asymmetric hydrogenation. Next, a cascade of 
protecting group modifications was necessary. This was followed by a final methylation 
and deprotection to furnish the free amine 3.20, which was then coupled to the acid 3.18 
with BOPCl in 63% yield. The homobenzylic TIPS group was then cleaved in order to 
introduce the valine residue, and deprotection and macroamidation furnished the 
macrocyclic core structure. Another TBS deprotection followed by oxidation then gave 
the MEM protected aetheramide A derivative 3.21. Unfortunately, the group was not 
able to remove the MEM groups under acidic conditions, as this caused elimination of 
the methyl ether followed by decomposition. We took mental note of this in reference to 
our synthesis, as this elimination might be avoided by formation of the lactone at the 
benzylic position, giving rise to Aetheramide B (3.08). In summary, the approach 
reported by Ghosh and co-workers gave the MEM protected natural product 3.21 in 36 
steps and 0.82% yield. Compared to Kalesses approach, Ghosh’s route gave rise to a 
higher step count. This was due to the linear approach, installing the two amino acid 
moieties separately, whereas Kalesse’s work described the introduction of the dipeptide 
fragment directly. Most recently, the group of Prasad reported an “expeditious” 
synthesis of the polyketide fragment of the Aetheramides as presented in Scheme 3.3.225  
  
                                                
 
222 M. Georgy, P. Lesot, J.- M. Campagne, J. Org. Chem. 2007, 72, 3543; A. Yanagisawa, H. Nakashima, 
A. Ishiba, H. Yamamoto, J. Am. Chem. Soc. 1996, 118, 4723. 
223 D. A. Evans, J. Bartroli, T. L. Shih, J. Am. Chem. Soc. 1981, 103, 2127; D. A. Evans, J. M. Takacs, L. 
R. McGee, M. D. Ennis, D. J. Mathre, J. Bartroli, Pure Appl. Chem. 1981, 53, 1109. 
224 M. S. Matta, A. Kelley, M. F. Rohde, U.S. Patent Application Publication U.S.1973/3878043 A1. 
225 O. Revu, K. Prasad, Synlett 2014, 25, 2887. 
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In this synthesis, the racemic furanol 3.22 was initially subjected to Sharpless kinetic 
resolution conditions226 to give the desired alcohol in 43% yield and 99% e.e. The 
hydroxyl group was then TBS protected and ring opening of the furan227 gave the enal 
3.23. Reaction with a Weinreb-amide substituted HWE reagent, followed by a Grignard 
addition, gave the ketone 3.24. 
Scheme 3.3: Synthesis reported by the Prasad group. a) TBHP, Ti(OiPr)4, L-(+)-DIPT, 4 
Å MS, 43%, 99% e.e; b) TBSCl, imidazole, DMAP, 95%; c) NBS, NaHCO3, 80%; d) 
HWE reaction, 91%; e) NaBH4, CeCl3, 87%; f) MOMCl, DIPEA, 93%; g) 
NHMe(OMe)HCl, iPrMgCl, 85%; h) Br(CH2)4OTHP, 83%, i) (S)-CBS catalyst, borane 
dimethyl sulfide complex, 82%; j) NaH, MeI, 80%; k) PPTS, , MeOH, 84%; l) IBX; m) 
Wittig reaction, 95% over two steps; n) DIBAL-H, 87%; o) MnO2; p) Nagao aldol 
reaction, 90% over two steps; q) TESOTf, pyridine, 92%; r) LiOH, H2O2, 60%. 
The ketone was then asymmetrically reduced in a CBS-reduction.228 The syn-diol was 
formed via a diastereoselective Luche reduction.229 THP deprotection and oxidation, 
followed by Wittig reaction and a reduction-oxidation sequence gave an aldehyde, 
which was then subjected to a Nagao aldol reaction230 to give a syn-aldol product. 
Again, the authors did not comment on the necessity of this enantio- and 
diastereoselective reaction with respect to equilibration of the configuration in the 
                                                
 
226 M. Kusakabe, Y. Kitano, Y. Kobayashi, Y. Sato, J. Org. Chem. 1989, 54, 2085. 
227 Y. Kobayashi, M. Nakano, G. B. Kumar, K. Kishihara, J. Org. Chem. 1998, 63, 7505; Y. Kobayashi, 
G. B. Kumar, T. Kurachi, H. P. Acharya, T. Yamazaki, T. Kitazume, J. Org. Chem. 2001, 66, 2011. 
228 A. Hirao, S. Itsuno, S. Nakahama, N. Yamazaki, J. Chem. Soc., Chem. Commun. 1981, 315; E. J. 
Corey, R. K. Bakshi, S. Shibata, J. Am. Chem. Soc. 1987, 109, 5551; E. J. Corey, R. K. Bakshi, S. Shibata 
J. Am. Chem. Soc. 1987, 109, 7925. 
229 J. L. Luche, J. Am. Chem. Soc. 1978, 100, 2226; J. L. Luche, L. Rodriguez-Hahn, P. Crabbe, J. Chem. 
Soc., Chem. Commun. 1978, 601; J. L. Luche, A. L. Gemal, J. Am. Chem. Soc. 1979, 101, 5848. 
230 Y. Nagao, Y. Hagiwara, T. Kumagai, M. Ochiai, T. Inoue, K. Hashimoto, E. Fujita, J. Org. Chem. 
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natural product. The auxiliary was then cleaved to give the acid 3.25 in 18 steps and 
3.8% overall yield. Prasad’s approach featured a novel way for the introduction of the 
syn-diol compared to Kalesse and Ghosh’s reports, but at the cost of a necessary kinetic 
resolution at the beginning of the synthesis. The (R)-methyl ether was accessed via a 
CBS reduction, which is probably more straightforward than the asymmetric VMA and 
asymmetric allylation in the other reports. Prasad then also applied an enantio- and 
diastereoselective Nagao aldol reaction in the late stages of the synthesis of the 
fragment, similar to Ghosh’s synthesis, whereas Kalesse’s approach relied upon 
equilibration of the configuration of the α-position in the natural product. 
In summary, the three reported routes followed a rather linear strategy, and only 
Kalesse’s approach featured a more convergent route via introduction of a dipeptide 
fragment 3.14. The syn-diol group was either introduced via asymmetric 
dihydroxylation or kinetic resolution. The β-hydroxy ester functions were introduced 
with asymmetric aldol reactions in Ghosh and Prasad’s synthesis, whereas Kalesse 
argued in favor of an eventual equilibrium of the absolute configuration in the natural 
product, rendering an enantio- and diastereoselective approach to this fragment 
unnecessary. The stereocenter of the methyl ether was accessed by enantioselective 
allylation (Ghosh), asymmetric VMA (Kalesse) or CBS reduction (Prasad). The 
unnatural amino acid fragments were accessed by enantioselective hydrogenation in 
Ghosh’s synthesis, and by functionalization of (R)-tyrosine as reported by Kalesse. 
3.6 Retrosynthetic Analysis 
Scheme 3.4 illustrates our retrosynthetic analysis of aetheramide B (3.08). Our strategy 
divides the molecule into the three major fragments. This convergent approach allows 
for a modular synthesis and more general flexibility. The dipeptide fragment 3.26 would 
be synthesized via an asymmetric hydrogenation reaction of an enamide to furnish the 
unnatural aromatic amino acid moiety. After peptide coupling to (S)-valine, the fragment 
would be attached by esterification and trapping of a ketene derived from dioxinone 
fragment 3.28. For the synthesis of fragment 3.28, we envisioned either a late stage 
dioxinone-formation of an advanced intermediate or an initial formation of a dioxinone 
and further decoration of this core.  
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Scheme 3.4: Retrosynthetic analysis of Aetheramide B (3.08) and the main fragments 
3.26-3.28. 
The beauty of dioxinones such as 3.28 lies in their reactivity: upon heating (commonly 
in toluene, reflux) they release acetone to form a ketene, which can be trapped by 
various nucleophiles.231 The dioxinone group therefore acts as an activating group and 
as a synthetic analog to labile β-keto acids, which are prone to decarboxylation. 
Although the ketene trapping reaction would be expected to show moderate 
diastereoselectivity at the most, like Kalesse we argue that the conformation in the 
natural product would equilibrate to the more stable configuration. The stereocenter of 
the methyl ether would be formed by CBS reduction of the corresponding bromo-enone. 
It could then be coupled to the stannane fragment 3.27 in a Stille-Migita cross 
coupling.232 Fragment 3.27 itself would be synthesized from known MOM protected 
(R)-mandelic aldehyde 3.83 in a Cram chelation-controlled alkynylation,233 followed by 
a hydrostannylation reaction. This chiral-pool approach has the advantage that no 
enantioselective reactions have to be carried out in the synthesis of the diol fragment 
fragment, as opposed to the syntheses described in the previous sections. The 
hydrostannylation reaction could also be replaced by a hydroboration reaction for a 
subsequent Suzuki-Miyaura coupling, allowing for alternative strategies.  
                                                
 
231 M. Sato, H. Ogasawara, S. Komatsu, T. Kato, Chem. Pharm. Bull. 1984, 32, 3848; R. J. Clemens, J. A. 
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This approach also allows the formation of the macrocycle via either intramolecular 
ketene trapping, macrolactonizaiton or Stille macrocyclization. 
3.7 Results and Discussion 
3.7.1 Synthesis of the Eastern Fragment 
3.7.1.1 Late Stage Dioxinone Formation 
Our first generation approach involved the late stage formation of the dioxinone 3.28 
from the proposed advanced intermediate 3.29, as shown in Scheme 3.5. 
Scheme 3.5: Proposed late stage dioxinone formation from the advanced intermediate 
3.29. 
The synthesis of the advanced intermediate 3.29 started from glutaraldehyde 3.30 and is 
depicted in Scheme 3.6. A Wittig reaction234 furnished the known enone 3.31235 in 
acceptable yield and excellent selectivity (E/Z > 30:1). For initial studies of the 
feasibility of our approach, we decided to continue the synthesis with racemic material. 
Aldehyde 3.31 was therefore alkynylated with trimethylsilylacetylene and n-BuLi, 
followed by methyl ether formation with methyl iodide, n-BuLi and DMSO236 to give 
ester 3.32 in good to excellent yields. Claisen condensation237 with either tert-butyl 
propionate or methyl propionate and LDA furnished the β-keto esters 3.33 decent yields. 
With the stage set for the dioxinone formation, tert-butyl ester 3.33 was subjected to 
standard dioxinone formation conditions (Ac2O, H2SO4, acetone or TFA-anhydride, 
TFA, acetone, Scheme 3.6).  
                                                
 
234 G. Wittig, G. Geissler, Ann. 1953, 580, 44; G. Wittig, G. U. Schöllkopf, Chem. Ber. 1954, 97, 1318; G. 
Wittig, W. Haag, Chem. Ber. 1955, 88, 1654. 
235 E. L. Richards, P. J. Murphy, F. Dinon, S. Fratucello, P. M. Brown, T. Gelbrich, M. B. Hursthouse, 
Tetrahedron 2001, 57, 7771. 
236 J. Gagnepain, E. Moulin, C. Nevado, M. Waser, A. Maier, G. Kelter, H.-H. Fiebig, A. Fürstner, Chem. 
Eur. J. 2011, 17, 6973. 
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Scheme 3.6: Synthesis of compound 3.33. a) Ph3P=C(Me)COOEt, DCM, r.t., 18 h, 58%; 
b) TMS-acetylene, n-BuLi, THF, -78 °C to 0 °C, 4 h, 91%; c) n-BuLi, MeI, DMSO, THF, 
-78 °C to r.t., 18 h, 79%; d) tert-butyl propionate or methyl propionate, LDA, THF, -78 
°C to 0 °C, 18 h, 57% for R = Me, 68% for R = t-Bu; e) Ac2O, H2SO4, acetone, 0 °C to 
r.t., 24 h, or TFA-anhydride, TFA, acetone, 0 °C to r.t., 24 h; R = t-Bu. 
Using sulfuric acid only, we observed TMS-deprotection and decomposition, whereas 
with TFA and TFA-anhydride, only unreacted starting material was observed, even at 
elevated temperature. Therefore, we decided to change our strategy to form the 
dioxinone fragment at an early stage of the synthesis and then further functionalize it. 
3.7.1.2 Formation and Trapping of Dioxinone Derived Homoenolates 
As previous studies have shown, certain dioxinones can undergo deprotonation in the 
allylic position, and the formed vinylogous enolates can be trapped by an electrophile to 
form silyl enol ethers, ketones and alcohols,238 or phosphonates (Scheme 3.7).239 It has 
also been reported that dioxinones can be halogenated under Wohl-Ziegler240 allylic 
bromination conditions.241 We therefore strived for the synthesis and further 
functionalization of dioxinone 3.40 bearing a vinylic methyl and ethyl group (Scheme 
3.8). 
Scheme 3.7: Reported functionalisations of dioxinones  
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Scheme 3.8: Synthesis of building block 3.40. a) MeI, K2CO3, THF, 80 °C, 36 h, 97%; b) 
KOH, MeOH/H2O, r.t. 2 h, 70-93%; c) Ac2O, H2SO4, acetone, 0 °C to r.t., 4 h, 78%; d) 
Ac2O, H2SO4, acetone, 0 °C to r.t., 2 h; propionyl chloride, pyridine, DCM, -78 °C to r.t., 
2 h, 38% over two steps; e) acetone, toluene, 190 °C (microwave), 3 h, 31%. 
The known building block 3.40242 was synthesized via two routes (Scheme 3.8). The 
first synthesis started from methyl-3-oxyvalerate (3.39), which underwent methylation 
with methyl iodide under basic conditions in quantitative yield. In the subsequent 
saponification of the methyl ester with potassium hydroxide and aqueous methanol, 
special care had to be taken to prevent decarboxylation of the labile β-keto acid during 
acidification of the reaction mixture in the aqueous workup and during rotary 
evaporation of the solvents. Due to these variables, the yields usually varied between 70-
90%, but in one case, complete decarboxylation was observed due to an excess of 
hydrochloric acid in the acidification of the reaction mixture. The obtained acid was 
usually used immediately without further purification, and standard conditions (Ac2O, 
H2SO4, acetone) gave dioxinone 3.40 in good yield.  
Due to the delicate workup after the ester hydrolysis, we investigated a possibly more 
facile second route to obtain dioxinone 3.40 (Scheme 3.8, right). Methylmalonic acid 
(3.41) was treated with acetic anhydride and acetone in the presence of a catalytic 
amount of sulfuric acid, and the obtained Meldrum’s acid derivative was acylated with 
propionyl chloride and pyridine in 38% yield over two steps. Thermal decarboxylation 
and intramolecular ketene trapping was conducted in a toluene-acetone mixture at 190 
°C in a microwave reactor. The reaction proceeded very cleanly according TLC, but the 
ratio of product/starting material could not be increased beyond 4:3, even by prolonged 
reaction times or varying solvent mixtures. Separation of the product and starting 
material by flash chromatography also proved to be challenging due to similar polarities, 
which lead to a yield of only 31% of product 3.40. Therefore, we chose to pursue our 
initial strategy for the synthesis of building block 3.40.  
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Scheme 3.9: HWE reaction to form dioxinone 3.45. a) Ozone, NaHCO3, DCM/MeOH, -
78 °C, 3 h; NEt3, Ac2O, 0 °C to r.t., 2 h, 44%; b) LDA, THF, -78 °C, 1 h; diethyl 
chlorophosphite, -78 °C to r.t.; H2O2, DCM, r.t., 1 h, 31%. 
Phosphonate 3.44243 was prepared from dioxinone 3.40 and was intended to react in a 
Horner-Wadsworth-Emmons reaction136 with aldehyde 3.43244 (Scheme 3.9). 
Cyclopentene (3.42) was first subjected to ozone in a DCM-methanol solvent mixture 
and, after solvent exchange, treated with acetic anhydride in the presence of 
triethylamine to give aldehyde 3.43 in 44% yield. Although the phosphonation of 
compound 3.40 is described in literature, we were not able to reproduce the reported 
yield of 59%.243 We therefore screened for optimal reaction conditions (Table 3.1). As 
can be deduced from the results presented in Table 3.1, it can generally be said that the 
reaction is low in conversion and yield, with a maximum yield of about 30% under 
optimized conditions (entries 3 and 7). To determine whether this was due to the nature 
of the nucleophile or the electrophile, we tried to trap the homoenolate with other 
electrophiles (Scheme 3.10). 
Scheme 3.10: Trapping of the vinylogous enolates. a) LDA, THF, -78 °C, 1h; TBSCl, -78 
°C to r.t., 2 h; b) LDA, THF, -78 °C, 1 h; 3.43, -78 °C to r.t, 1 h, 39%. 
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Table 3.1: Screening of phosphonation conditions of dioxinone 3.40.  
Entry Base (eq.) ClP(OEt)2 (eq.) Observationa Yieldb 
1 DIA (1.2), n-BuLi (1.2) 2.0 No conversion – 
2 DIA (1.5), n-BuLi (1.5) 2.0 Low conversion 31% 
3 LDA (1.5) c) 2.0 Low conversion 28% 
4 LHMDS (1.5) 2.0 Low conversion 10% 
5 HMDS (2.0), n-BuLi (2.0) 2.5 Low conversion 20% 
6 HMDS (3.0), n-BuLi (3.0) 3.5 Low conversion 18% 
7 HMDS (1.5), n-BuLi (1.5) 2.0 Low conversion 28% 
a) According to TLC and 1H NMR of the crude product. b) isolated yield. All reaction mixtures were 
quenched by addition of diethyl chlorophosphite and oxidized by an excess of aqueous H2O2. c) 
Commercial solution of LDA in THF/hexanes (1 M). 
We were not able to trap the vinylogous enolate with TBSCl, however trapping with 
aldehyde 3.43 proved to be successful. The observed yield of 39% for the formation of 
the silyl enol ether was comparable to the yields obtained in the phosphonation reactions 
(Table 3.1), and concluded that either the deprotonation does not occur readily, or that 
the vinylogous enolate itself is not reactive enough. 
Scheme 3.11: Radical bromination of dioxinone 3.40. a) NBS, AIBN, hν, CCl4, r.t., 1 h, 
complete conversion. 
This hypothesis is supported by the fact that similar reactions were reported to give 
much higher yield with sterically less hindered dioxinones.243 The formation of a gel in 
some reactions might also hint at an undesired polymerization side reaction.  
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 We then tried to brominate 3.40 under Wohl-Ziegler conditions and react the resulting 
allyl bromide 3.50 with a trialkyl phosphite in order to generate a phosphonate 3.51 in a 
Michaelis-Arbuzow reaction245 (Scheme 3.11). The bromination with NBS and AIBN 
proceeded nicely, but gave an inseparable mixture of the three species 3.48, 3.49 and 
3.50. We decided to abandon our initially proposed HWE strategy and opted for a new 
approach presented in the next section. 
3.7.1.3 Dioxinone Functionalization by Cross Metathesis 
Scheme 3.12: Functionalisation of dioxinone 3.52 via cross metathesis. 
Cross metathesis is a powerful synthetic tool to form carbon-carbon double bonds.246 
This methodology has already been successfully used on unsaturated dioxinones in the 
context of total synthesis.247 We planed implement cross metathesis in our synthesis as 
depicted in Scheme 3.12. 
Scheme 3.13: Synthesis of dioxinone 3.52. a) LDA, THF, -78 °C, 30 min; methacrolein, 
THF, -78 °C, 20 min, 88%; b) IBX, DMSO, r.t., 18 h, 98%; c) TFA, TFA-anhydride, 
acetone, 0 °C to r.t., 1.5 h, 97%. 
Scheme 3.13 illustrates the synthesis of unsaturated dioxinone 3.52. An aldol addition of 
tert-butyl propionate (3.55) to methacrolein furnished a β-hydroxy ester, which was then 
oxidized by IBX in DMSO to give the β-keto ester 3.56 in excellent yield. Ring closure 
with TFA and TFA-anhydride in acetone gave dioxinone 3.52 in quantitative yield.  
                                                
 
245 A. Michaelis, T. Becker, Chem. Ber. 1897, 30, 1003; A. Michaelis, R. Kaehne, Chem. Ber. 1898, 31, 
1048; A. Arbuzov, J. Russ. Phys. Chem. Soc. 1906, 38, 687; A. Arbuzov, J. Russ. Phys. Chem. Soc. 1910, 
42, 395. 
246 R. R. Schrock, J. Mol. Catal. 2004, 213, 21; A. H. Hoveyda, R. R. Schrock, Comprehensive 
Asymmetric Catalysis 2004, 1, 207; K. C. Nicolaou, P. G. Bulger, D. Sarlah, Angew. Chem. Int. Ed. 2005, 
44, 4490. 
247 J. Gebauer, S. Blechert, J. Org. Chem. 2006, 71, 2021; P. S. Blencowe, A. G. M. Barrett, Can. J. 
Chem. 2012, 90, 975. 
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Scheme 3.14: Synthesis of fragment 3.60. a) N,O-Dimethylhydroxylamine hydrochloride, 
pyridine, DCM, -20 °C to r.t., 2 h, 93%; b) Br2, DCM, 0 °C, 1 h; DBU, 0 °C to r.t., 2 h, 
58%; c) morpholine, pyridine, DCM, -20 °C to r.t., 2 h, 92%; d) Br2, DCM, 0 °C, 1 h; 
DBU, 0 °C to r.t., 2 h, 28%; e) 5-bromo-1-pentene, Mg, THF, r.t., 30 min; Weinreb 
amide, THF, 0 °C, 1 h, 29%. 
For the synthesis of the allyl ether fragment 3.53 we targeted ketone 3.60 (Scheme 
3.14), as it could be directly subjected to asymmetric reduction and methylation to form 
the desired methyl ether 3.53. We planned to synthesize bromo-enone 3.60 by Grignard 
addition248 of pent-4-enyl-1-magnesium bromide to Weinreb amide249 3.58 or 3.59. It 
has recently been shown that morpholine amides such as 3.59 can react with Grignard 
reagents in the same way as Weinreb amides.250 Therefore, morpholine as well as N,O-
dimethoxyhydroxylamine hydrochloride were acylated by methacryloyl chloride in the 
presence of pyridine in good yield. Bromination was achieved by a one-pot addition-
elimination procedure by first adding a solution of bromine to give the dibromide, 
followed by addition of DBU to effect β-elimination of HBr. Although these reaction 
only gave moderate yields, sufficient material for screening the Grignard addition was 
obtained. The results of this screening are presented in Table 3.2. In all Grignard 
addition reactions tested, the yield of the desired product never exceeded 30%. Varying 
the amount of Grignard reagent or changing the solvent had no influence on this 
outcome. In all cases, byproducts 3.61 and 3.62 were observed, indicating that the 
enhanced electrophilicity of the bromo enone allowed for 1,4-addition of the nucleophile 
to occur. Subjecting the morpholine derived amide 3.59 to these conditions gave similar 
results (entry 5). Additionally, the purified ketone 3.60 proved to be very labile, as it 
decomposed overnight, even when stored at -20 °C under argon. Therefore, we decided 
to perform the Grignard addition directly on the Hoecker aldehyde 3.64251 and 
investigate the cross metathesis as depicted in Scheme 3.15.  
                                                
 
248 V. Grignard, C. R. Acad. Sci. 1900, 1322; V. Grignard,. Ann. Chim. 1901, 7, 433. 
249 S. Nahm, S. M. Weinreb, Tetrahedron Lett. 1981, 22, 3815. 
250 R. Peters, P. Waldmeier, A. Joncour, Org. Process Res. Dev. 2005, 9, 508. 
251 X. Li, X. Zeng, Tetrahedron Lett. 2006, 47, 6839; Y. Murakami, M. Nakano, T. Shimofusa, N. 
Furuichi, S. Katsumura, Org. Biomol. Chem. 2005, 3, 1372; J. Hoecker, K. Gademann, Org. Lett. 2013, 
15, 670. 
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Table 3.2: Screening of Grignard addition conditions to Weinreb amides 3.58 and 3.59. 
Entry E+ RMgBr (eq.) Solvent Yield of 3.60a/b 3.60:3.61:6.62 
1 3.58 2.0 THF 30%a – 
2 3.58 5.0 THF 29%a 1:1:1 
3 3.58 3.5 THF 27%b – 
4 3.58 3.5 Et2O 24%b 1:1:1 
5 3.59 2.0 THF 30%a 1:1:1 
a) isolated yield. b) determined by 1H NMR and UPLC-MS analysis of the crude product; RMgBr = pent-
4-en-1-ylmagnesium bromide.  
The previously developed conditions for the Grignard reaction were found to be suitable 
for the conversion of aldehyde 3.64 to the alcohol in good yield. Methylation with 
sodium hydride and methyl iodide gave methyl ether 3.53 in quantitative yield.  
Scheme 3.15: Synthesis of fragment 3.53 a) Br2, DCM, 0 °C to r.t., 4 h; DBU, DCM, r.t., 
18 h, 94%; b) LiAlH4, Et2O, 0 °C to r.t., 2 h; MnO2, DCM, r.t., 2-5 d, 92%; c) 5-bromo-1-
pentene, Mg, THF, r.t., 30 min; 3.64, THF, 0 °C, 1 h, 72%; d) NaH, MeI, THF, 0 °C to 
r.t., 30 min, 97%. 
We then continued with the investigation of the cross metathesis (Table 3.3). The first 
three entries indicate an inherent inertness of the subtrates 3.52 and 3.53 in the presence 
of Grubbs-Hoveyda 2nd generation catalyst and varying alkene stoichiometry. We 
suspected two main reasons for this observation. First, the possibility of vinyl halides 
poisoning the catalyst has been reported in the literature,252 although there are examples 
                                                
 
252 I. C. Stewart, C. J. Douglas, R. H. Grubbs, Org. Lett. 2008, 10, 441; A. K. Chatterjee, J. P. Morgan, M. 
Scholl, R. H. Grubbs, J. Am. Chem. Soc. 2000, 122, 3783;	
  V. Sashuk, C. Samojłowicz, A. Szadkowska, K. 
Grela, Chem. Commun. 2008, 23, 2468. 
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where this did not inhibit reactivity.253 Secondly, sterically hindered and electron 
deficient substrates have been found to be less reactive in cross metathesis reactions in 
some cases.254 However, steric hindrance on an alkene can also have beneficial aspects 
in cross metathesis, as it can prevent homocoupling.254 Bearing in mind that cross 
metathesis on unsaturated dioxinones had been reported before,247 we continued our 
screening effort. 
Table 3.3: Screening of cross metathesis conditions to form.  
Entry Catalyst (eq.) Alkene (eq.) Alkene (eq.) Observation 
1 GH-2 (0.05) 3.53 (1.0) 3.52 (1.0) No conversion 
2 GH-2 (0.05) 3.53 (1.0) 3.52 (2.0) No conversion 
3 GH-2 (0.05) 3.53 (2.0) 3.52 (1.0) No conversion 
4 GH-2 (0.05) 3.65 (1.0) 3.52 (1.0) Dimerization of 3.65 
5 GH-2 (0.05) 3.53 (1.0)        – No conversion 
6 GH-2 (0.05) 3.65 (1.0) 3.56 (2.0) Dimerization of 3.65 
7 SF-1 (0.10) 3.53 (1.0) 3.52 (2.0) No conversion 
8 SF-1 (0.10) 3.65 (1.0) 3.52 (2.0) Dimerization of 3.65 
9 SF-1 (0.10) 3.65 (1.0) 3.56 (2.0) Dimerization of 3.65 
10 GH-1 (0.05) 3.65 (1.0) 3.52 (1.0) Dimerization of 3.65 
Abbreviations: GH-1 and GH-2: Grubbs-Hoveyda 1st and 2nd generation catalyst; SF-1: Schrock-Fürstner 
type catalyst 1. 
To prove wether the presence of a vinyl halide was detrimental for the reaction, we 
performed cross metatheses using 5-bromo-1-pentene 3.65, and only dimerization of the 
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latter was observed. This indicates that the vinyl bromide present in compound 3.53 
might poison the catalyst, as for this alkene no dimerization was observed (entry 5). To 
investigate the effect of steric hindrance in the substrates, we subjected enone 3.56 to 
our standard conditions and only observed dimerization (entry 6). Reaction with 
Grubbs-Hoveyda 1st generation catalyst gave the same result (entry 10). We then 
investigated the suitability of molybdenum-based Schrock-type catalysts.246 Recent 
developments by the Fürstner group have rendered these rather sensitive compounds 
more manageable by attaching a bipyridyl- or phenanthroline dummy ligand to give 
largely air stable pre-catalysts, which are then converted to the catalytically active 
species by the addition of dry zinc triflate.255 Unfortunately, when applied to our system, 
the same trends as for the ruthenium-based catalysts were observed (entries 7-9). 
In conclusion, our strategy to employ a dioxinone structure in fragment 3.28 proved to 
be unsuccessful. Functionalisations of the dioxinones 3.40 and 3.52 via phosphonation 
and HWE reaction, aldol addition, bromination and cross metathesis were either low-
yielding or gave no conversion at all. We attribute these findings to the high steric 
demand of the dioxinones 3.40 and 3.52. Furthermore, the vinyl bromide substituent 
proved to be detrimental to our cross metathesis reactions. Therefore, we decided to 
abandon this route completely and chose a more classical approach, which will be 
described in the next section. 
3.7.1.4 Final Approach via a Wittig-Aldol Sequence 
Scheme 3.16 depicts our revised synthetic approach towards the eastern fragment. 
Harking back to our previously gained synthetic experience, we decided to start from 
Hoecker aldehyde 3.64 and prepare intermediate 3.70 via a Grignard addition and 
further modifications. A Wittig reaction followed by an aldol addition256 would then 
give fragment 3.70, which would be coupled to the other fragments in a Stille-Migita 
coupling and peptide coupling reaction. For screening purposes, we decided to initially 
perform a racemic synthesis (Scheme 3.16).   
                                                
 
255 J. Heppekausen, A. Fürstner, Angew. Chem. Int. Ed. 2011, 50, 7829. 
256 R. Kane, J. Prakt. Chem. 1838, 15, 129; R. Kane, Ann. Phys. Chem. Ser. 2 1838, 44, 475. 
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Scheme 3.16: 3rd approach to fragment 3.70. a) DIBAL-H, DCM, -78 °C, 2 h; b) ethylene 
glycol, p-TsOH, toluene, Dean-Stark trap, reflux, 1 d, 51% over two steps; c) Mg, THF, 
r.t., 30 min; 3.69, THF, 0 °C, 2 h, 79%; d) NaH, MeI, THF, 0 °c to r.t., 30 min, 91%; e) p-
TsOH, acetone, H2O, 100 °C, microwave, 40 min, 90%; f) Ph3P=C(Me)CHO, DCM, 
toluene, 65 °C, 3 d, 50%, E/Z>30:1; g) methyl propionate, LDA, THF, -78 °C, 30 min; 
aldehyde, THF, -78 °C , 30 min, 50%. 
Protected aldehyde 3.69 was synthesized according to a literature procedure.257 Ethyl-4-
bromobutyrate (3.68) was reduced to the corresponding aldehyde with DIBAL-H and 
the crude material was directly protected as an acetale 3.69 in acceptable yield. Grignard 
addition of dioxolane 3.69 to aldehyde 3.64 proceeded in good yields. The obtained 
allylic alcohol turned out to be unstable, as partial transketalization of 3.72 to 3.73 was 
observed within two weeks of storing the compound at 5 °C (Scheme 3.17). 
Scheme 3.17: Observed transketalization of dioxolane 3.72 to 3.73. 
Thus, the methyl group was introduced preferably in direct succession of the Grignard 
addition by alkylation with methyl iodide in almost quantitative yield. The dioxolane 
group was then cleaved by a catalytic amount of para-toluenesulfonic acid in an 
acetone-water mixture under microwave heating (100 °C). Unfortunately, this 
deprotection always stalled at about 80% conversion to give an inseparable mixture of 
product and starting material. Efforts to drive the reaction to completion by adding more 
acid, prolonging reaction time or changing the solvent system proved to be ineffective. 
We then directly applied this mixture in the following Wittig reaction with a literature 
known phosphorane.258 This olefination reagent directly gave an aldehyde in moderate 
                                                
 
257 G. N. Varseev, M. E. Maier, Org. Lett. 2005, 7, 3881. 
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yield, and the usual reduction-oxidation sequence required in ester stabilized 
phosphoranes or phosphonates could be circumvented. Finally, aldol addition of methyl 
propionate to this aldehyde under our previously established conditions gave β-hydroxy 
ester 3.71 in good yields as a separable diastereomeric mixture (2:1). Reports of similar 
substrates indicate the relative configuration of the major product to be anti.259 Although 
we now finally had access to fragment 3.71 in synthetically useful quantities, we 
decided to perform one last round of optimization of this synthesis to eliminate its major 
drawbacks, e.g. the tendency of dioxolane 3.72 to undergo transketalization and the 
inseparability of some intermediates. A TES protected primary alcohol was found to be 
an ideal replacement for the acetal protecting group in the final synthetic route towards 
enantiomerically enriched building block 3.79 (Scheme 3.18). 
Scheme 3.18: Optimized synthesis of enantiomerically enriched fragment 3.80. a) allyl 
bromide, triethyl silane; PdCl2, 70 °C, 18 h, 76%; b) Mg, THF, r.t., 30 min; 3.75, THF, 0 
°C, 2 h, 68%; c) TPAP, NMO, 3 Å molecular sieve, DCM, 0 °C to r.t., 30 min, 71%, 91% 
brsm.; d) (S)-CBS catalyst, borane dimethylsulfide complex, toluene, -70 °C to 0 °C, 2 h, 
e.r. 98:2; e) NaH, MeI, THF, 0 °c to r.t., 30 min, 87% over two steps; f) TBAF, THF, r.t., 
1 h, 94%; g) IBX, DMSO, r.t., 18 h, 90%; h) Ph3P=C(Me)CHO, DCM, benzene, 90 °C, 
18 h, 95%, E/Z>30:1; i) methyl propionate, LDA, THF, -78 °C, 30 min; aldehyde, THF, -
78 °C , 30 min, 81%. 
Tetrahydrofuran (3.74) underwent a bromosilation reaction to give the TES-protected 
alcohol 3.75 in good yield.260 Palladium(II) chloride must be added last to the reaction, 
as otherwise thermal excursion of the reaction mixture ensues. Similar to our previous 
syntheses, we performed a Grignard addition to furnish the corresponding alcohol in 
good yield. Also in this case we observed decomposition of this alcohol within one week 
at 5 °C, and we identified the degradation pathway as silyl migration from the primary 
to the secondary alcohol. Therefore, the alcohol was immediately oxidized under the 
                                                
 
259 H. E. Zimmerman, M. D. Traxler, J. Am. Chem. Soc. 1957, 79, 1920; C. Palomo, M. Oiarbide, J. M. 
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conditions developed by Ley and Griffith with TPAP and NMO to give the very labile 
bromo enone 3.76 in good yield. Enone 3.76 decomposed completely when stored at 5 
°C over night. As a result, the compound 3.76 was immediately treated it with (S)-CBS 
catalyst and borane dimethylsulfide complex in dry toluene at -70 °C to give the 
enantiomerically enriched (e.r. = 98:2) R-configured alcohol 3.81 in quantitative yield. 
Since the mechanism and stereochemical outcome of this reaction have been extensively 
studied,261 we did not experimentally confirm the absolute configuration, but only 
determined the enantiomeric ratio of the alcohol. The chiral HPLC traces of the 
racemate 3.80 and enantiomerically enriched alcohol 3.81 are shown in Figure 3.10.  
Figure 3.10: Chiral HPLC traces of the racemate 3.80 (up) and enantiopure compound 
3.81 (below). 
The crude material was then directly methylated in high yield with methyl iodide in the 
presence of sodium hydride to form the stable methyl ether 3.77. The TES group of 
ether 3.77 could be cleaved in the work-up of the methylation by adjusting to pH = 1 
with aqueous hydrochloric acid, but the reaction was found to be difficult to drive to 
completion. Furthermore, we wanted to fully characterize the first stable intermediate 
after four synthetic steps, and therefore decided to remove the TES group in a separate 
step with TBAF in THF.  
                                                
 
261 B. Ganem, Chemtracts: Org. Chem. 1988, 1, 40; S. Wallbaum, J. Martens, Tetrahedron: Asymmetry 
1992, 3, 1475; L. Deloux, M. Srebnik, Chem. Rev. 1993, 93, 763; V. Nevalainen, Tetrahedron: 
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The crude primary alcohol was oxidized with IBX in DMSO to yield primary aldehyde 
3.78. The next two steps were identical to those of the racemic substrate. Nevertheless, 
we managed to improve the yield of the Wittig reaction to form the corresponding enal 
to 95% yield and with complete E-selectivity by raising the temperature and changing 
the solvent mixture from toluene to DCM-benzene. The yield of the final enolate 
addition to form the fragment 3.79 was improved to a very satisfactory 81% (2:1 d.r.), 
and we attribute this to the more reliable preparation of LDA on a larger scale (3.5 g of 
aldehyde were applied in the highest yielding batch). 
In summary, we have developed a synthesis of fragment 3.79 from methyl methacrylate 
3.63 in 11 steps with 24% overall yield and an e.r. of 98:2 on a multigram scale. Careful 
execution of the reactions allowed this to be accomplished with only three 
chromatographic purifications following the Grignard addition, Wittig reaction and the 
aldol addition. 
3.7.2 Synthesis of the Diol Fragment 
As described in the retrosynthetic analysis (section 3.6), we planned to synthesize the 
diol fragment 3.27 via a Cram chelation-controlled alkynyl anion addition to the known 
aldehyde 3.83.262  
Scheme 3.19: Synthesis of alcohol 3.84. a) MOMCl, DIPEA, DCM, 40 °C, 18 h, 93%; b) 
DIBAL-H, DCM, -78 °C, 2 h, 76-98%; c) ethynylmagnesium bromide, THF, -78 °C to 
r.t., 1 h, 81%, syn:anti 3:2. 
The sequence started from R-mandelic acid (3.82, Scheme 3.19).263 Introduction of the 
coordinating MOM group for the chelation-controlled alkynylation was conducted 
according to a literature procedure with MOMCl and Hünig’s base264 in DCM in good 
yield. 
  
                                                
 
262 E. J. Corey, F. J. Hannon, N. W. Boaz, Tetrahedron 1989, 45, 545. 
263 Parts of the described syntheses were performed by Christopher Wittwer during the course of his 
master thesis “Synthetic Studies towards Aetheramide A”, Christopher Wittwer. Master Thesis, 2014, 
University of Basel. 
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Careful monitoring of the reaction temperature in the following DIBAL-H reduction 
allowed obtaining the aldehyde 3.83 in quantitative yield after aqueous workup. In some 
cases, however, incomplete reduction or over-reduction occurred, lowering the yield to 
76% and making chromatographic purification necessary. We then proceeded with the 
Cram chelation-controlled alkynylation. 
Scheme 3.20: Stereochemical model for the diastereoselective alkynylation reaction of 
3.83. 
Our stereochemical rationale for the selectivity of this reaction is outlined in Scheme 
3.20. The key for 1,2-asymmetric induction in this reaction is the initial formation of a 
Cram-chelate as depicted in transition state 3.85, where the magnesium coordinates to 
the carbonyl function and the oxygen atoms of the α-MOM ether, bringing the two 
substituents to an eclipsed conformation. The alkynyl anion then attacks the aldehyde 
from the less hindered half space at the Bürgi-Dunitz angle.265 Next, the formed 
alkoxide 3.86 is protonated upon aqueous workup to give the desired syn-diol 3.87. The 
formation of the chelate complex can be favored by using more strongly coordinating 
zinc- or magnesium based nucleophiles (compared to Li-nucleophiles), and the presence 
of a coordinating group such as a MOM ether in the α-position is essential.  
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Table 3.4: Screening of chelation controlled alkynylation conditions of 3.88. 
Entry M =  
(additive) 
R =  Conditions Syn/antia (% yield) 
1 MgBr H THF, -78 °C to r.t., 1 h 3:2 (81 %) 
2 MgBr; (ZnBr2) H THF, -78 °C to r.t., 48 h 1:1 (–) 
3 MgBr; (ZnCl2) H THF, -78 °C to r.t., 48 h 1:1 (–) 
4 Li TIPS Et2O, -78 °C to r.t., 14 h 7:1 (–) 
5 Li; (ZnBr2) TIPS Et2O, -78 °C to r.t., 14 h 1:1 (–) 
6 Li TMS Et2O, -78 °C to r.t., 14 h 3:1 (–) 
7 Li; (ZnBr2) TMS Et2O, -78 °C to r.t., 14 h 3:1 (–) 
a) Determined by 1H NMR analysis of the crude product. 
Table 3.4 summarizes our screening efforts for this reaction. Initial experiments with 
commercially available ethynylmagnesium bromide solution gave an inseparable 3:2 
mixture of the diastereomers 3.89 and 3.90 in good yield (entry 1). It is well known that 
transmetalation from magnesium to stronger coordinating metals such as zinc can 
improve the diastereoselectivity in Cram-chelation controlled reactions.266 In this case 
transmetalation led to decreased reaction rates (48 h vs. 1h) and lower selectivity 
(entries 2 and 3 vs. entry 1). Another method to increase the syn:anti selectivity is to use 
sterically more demanding nucleophiles267 (entries 4–7). Since the corresponding 
Grignard reagents were not commercially available, the alkynes were first deprotonated 
by n-BuLi and then used directly (entries 4 and 6) or transmetalated by stirring with zinc 
bromide (entries 5 and 7). The best diastereoselectivities were observed with the 
sterically most demanding TIPS-protected alkyne, but surprisingly with the supposedly 
less chelating organolithium nucleophile as compared to the magnesium- and zinc 
nucleophiles.   
                                                
 
266 K. T. Mead, Tetrahedron 1987, 28, 1019; M. Chérest, H. Felkin, N. Prudent, Tetrahedron Lett. 1968, 
9, 2199. 
267 Review articles: A. Mengel, O. Reiser, Chem. Rev. 1999, 99, 1191; B. W. Gung, Tetrahedron 1996, 52, 
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An increased reaction time was also necessary, and ,unfortunately, the crude propargylic 
alcohols containing a silyl protecting group decomposed during chromatographic 
purification on silica gel. Albeit giving the best selectivities, the cumbersome workup 
rendered this approach less attractive, and also the diastereomers were inseparable by 
flash chromatography. We continued the synthesis with the procedure described in entry 
1 and tried to develop a method to separate the diastereomers. We chose an approach 
based on kinetic resolution with polymer-supported lipase in presence of an acyl donor, 
as these reactions are usually operationally simple, easily scalable and highly 
selective268 and thus performed a screening (Table 3.5). 
Table 3.5: Screening of reaction conditions for kinetic resolution of 3.89.  
Entry Solvent Acyl donor  Lipase Conversiona 
1 toluene vinyl acetate CAL-B 79% 
2 hexane vinyl acetate CAL-B 85% 
3 toluene isopropenyl acetate CAL-B 68% 
4 hexane isopropenyl acetate CAL-B 72% 
5 toluene vinyl acetate CAL-B 71% 
6 hexane vinyl acetate Novozyme 435 18% 
General conditions: diastereomeric mixture of alcohols 3.89 and 3.90 (0.1 mM), acyl donor (3.5 eq.), 
lipase (10 wt.% of alcohol), r.t.; CAL-B: Candida antarctica lipase B; Novozyme 435: a different brand 
of polymer bound CAL-B. a) determined by 1H NMR analysis of an aliquot after 4 d; 100% conversion 
correspond to complete consumption of protected syn diol 3.89. 
 Novozyme 435 proved to be rather unsuitable for this reaction (entry 6), although it 
should be noted that, as with CAL-B, the yield was highly dependent on the source of 
the used reagent (data not shown). This might be caused by a higher content of absorbed 
water in the older bottles, which in some cases has been reported to be detrimental for 
kinetic resolutions of alcohols.269 Degradation of the enzyme might also account for this 
observation. Varying the acyl donor or switching the solvent from toluene to hexane did 
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not change the reaction outcome considerably (entries 1–5). The obtained acetate 3.91 
and free alcohol 3.90 were readily separated by column chromatography, and the final 
reaction conditions employed are shown in Scheme 3.21 for the scale up of the reaction 
(5 g of diastereomeric alcohol mixture). 
The use of only 10 wt. % of lipase is probably the main cause for the long reaction time 
of six days, as literature procedures often describe the use of 100 wt.% of lipase resin.270 
Hydrolysis of the acetate with potassium carbonate furnished the diastereomerically 
pure alcohol 3.92 in quantitative yield (Scheme 3.21). 
Scheme 3.21: Kinetic resolution of the alcohol 3.84. a) CAL-B (10 wt. %), vinyl acetate, 
hexane, r.t. 6 d, 96% based on syn-diol in the starting material; b) K2CO3, MeOH/H2O, 
r.t., 20 min, 98 %. 
We had yet to experimentally ascertain the absolute configuration of the alcohol 3.92. 
Up until now, our stereochemical predictions were solely based on the mechanistic 
understanding of the Cram-chelation controlled alkynylation (vide supra) and the 
general structure of the faster reacting diastereomer (3.95, Scheme 3.22 right) in a lipase 
catalyzed kinetic resolution according to Kazlauskas’ rule.271 Our initial attempts to 
form nitrobenzoates from 3.92 for easier crystallization failed, as the isolated products 
were oily liquids, which we were unable to precipitate or crystallize. We therefore 
decided to determine the relative configuration by Mosher ester analysis.272 
Scheme 3.22: Formation of the Mosher esters 3.93 and 3.94. a) S-(+)-MTPACl, pyridine, 
DCM, r.t. 15 h, 95%; b) R-(–)-MTPACl, pyridine, DCM, r.t. 15 h, 98%. General structure 
(3.95, right) of the faster reacting enantiomer in a lipase catalyzed kinetic resolution 
according to Kazlauskas rule. 
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The syntheses of the Mosher esters 3.93 and 3.94 were achieved by acylation with R- or 
S-MTPACl in the presence of pyridine in DCM in almost quantitative yield (Scheme 
3.22). We then compared the 1H-ΔδSR values of the two Mosher esters 3.93 and 3.94 
(Figure 3.11). It should be noted that (R)-MTPACl does give the (S)-Mosher ester, since 
the Cahn-Ingold-Prelog priority273 changes when the chlorine is substituted by oxygen. 
Figure 3.11: ΔδSR values of the Mosher esters 3.93 and 3.94. 
The results show a negative ΔδSR for most of the proton signals, which clearly indicates 
the desired (R)-configured propargylic alcohol 3.92 as the major product of the 
chelation-controlled alkynylation. This finding is also in line with the assumption that 
the faster acylated alcohol in the kinetic resolution should be (R)-configured.271 
Scheme 3.23: Hydrostannylation of the propargylic alcohol 3.92. a) Pd(PPh3)2Cl2, 
HSnBu3, THF, 0 °C, 30 min, 58%, E/Z = 10:1. 
The final step to complete the synthesis of fragment 3.27 was to introduce the vinyl 
stannane (Scheme 3.23). We initially observed decent yield and E/Z selectivities for this 
reaction under standard conditions with a catalytic amount bis(triphenylphosphine) 
palladium(II) chloride and tributyltin hydride (1.5 eq.).274 The product expectedly 
proved to be relatively labile; flash chromatography had to be conducted with an eluent 
containing 0.5 % triethylamine to suppress protodestannylation.275 The compound also 
decomposed within two weeks when stored at 5 °C under argon to several unidentified 
compounds. Stannane 3.27 was therefore prepared immediately before Stille coupling 
experiments, and the majority of the material was stored as the stable, diastereomerically 
pure alcohol 3.92. 
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In summary, stannane fragment 3.27 was expediently synthesized in six steps in an 
overall yield of 42% starting from R-mandelic acid (3.82) with four chromatographic 
purifications on a multigram scale. 
3.7.3 Synthesis of the Dipeptide Fragment 
Scheme 3.24: Synthesis of the protected α-amino acid 3.100. a) Boc2O, NaHCO3, NaCl, 
CHCl3, H2O, reflux, 2 h, 96%; b) AIBN, NBS, hν, CCl4, reflux, 2 h; c) P(OMe)3, DCM, 
reflux, 18 h, 60% over two steps; d) DBU, 3-methoxy-4-[(triisopropylsilyl)oxy]-
benzaldehyde, DCM, 0 °C to r.t., 1 h, 69%, E/Z>30:1; e) H2, Pd/C, MeOH, r.t., 18 h, 
40%; f) H2, (R,R)-Et-Duphos-Rh (I) triflate, EtOAc, r.t., 3–5 d, 98%, 98:2 e.r. 
The last challenge to be addressed was the synthesis of the dipeptide fragment 3.26. 
Initially, the phosphonate 3.97 was prepared in a three-step sequence according to a 
literature procedure (Scheme 3.24).276 Commercially available methyl glycinate 
hydrochloride (3.96) was protected with Boc-anhydride in the presence of sodium 
bicarbonate in a biphasic reaction to give the product in 96% yield after aqueous 
workup. The Boc-protected product was then subjected to radical bromination (AIBN, 
NBS, hν, CCl4), and the obtained labile bromide directly underwent an Arbuzov 
reaction with trimethyl phosphite to give the phosphonate 3.97 in 60% yield over two 
steps. We then commenced screening for optimal HWE conditions to form the Z-
enamide 3.98, as summarized in Table 3.6. 
  
                                                
 
276 J. Fischer, H. Ritter, Beilstein J. Org. Chem. 2013, 9, 2803; T. Nakajima, K. Nakayama, I. Shimizu, J. 
Label. Compd. Radiopharm. 2007, 50, 622. 
NH3Cl
3.96
NHBoc
3.97
PO(OMe)2
BocHN
3.98
a-c d OMe
OTIPS
O
MeO MeO
O
MeO
O
e or f
BocHN
3.99
OMe
OTIPS
MeO
O
BocHN
3.100
OMe
OTIPS
MeO
O
or
Synthetic Studies towards Aetheramide B 
87 
Table 3.6: Screening of HWE reaction conditions to give enamide 3.98.  
Entry 3.1.02 (eq.) 3.1.06 (eq.) Base (eq.) Solvent Time Yield 
1 1.00 1.10 TMG (1.10) DCM 2 h 25% 
2 1.00 1.10 TMG (1.10) THF 2 h 25% 
3 1.00 1.10 DBU (1.10) DCM 1 h 26% 
4 1.00 1.10 DBU (1.10) THF 1 h 24% 
5 1.50 1.00 DBU (1.50) DCM 1 h 40% 
6 1.50 1.00 DBU (1.10) DCM 1 h 45% 
7 1.00 2.00 DBU (1.05) DCM 1 h 65% 
TMG: tetramethyl guanidine; DBU: 1,8-Diazabicyclo[5.4.0]undec-7-ene. 
This type of HWE reaction has been carried out on very similar substrates to give 
aromatic Z-enamides for subsequent enantioselective hydrogenation. The reported 
conditions usually utilize DBU or TMG as the base in THF or DCM and are often very 
high yielding (≥90%).277 Therefore, it was unexpected when initial experiments 
applying these standard conditions (entries 1 to 4) gave low yields of about 25%. We 
also observed considerable side-product formation and could identify TIPS-deprotection 
as the main cause of the erosion in yield. Although reportedly being one of the most 
stable silyl ether protecting groups for phenols,278 we found one literature example of a 
HWE reaction with a TIPS-protected phenol also with lower yields (71%).279 While 
shortening the reaction time (entries 5 and 6) already proved to be beneficial, the final 
conditions involved careful reaction monitoring of the reaction by TLC in order to 
immediately observe excessive side product formation (usually after 1 hour) and 
employing an excess of the aldehyde 3.101 and a minimal excess of DBU (entry 7). 
These conditions gave the desired Z-enamide 3.98 in an acceptable yield of 65%.  
                                                
 
277 S. P. Roche, S. Faure, Angew. Chem. Int. Ed. 2008, 47, 6840; H. Chen, J.-P. Luzy, N. Gresh, C. 
Garbay, Eur. J. Org. Chem. 2006, 2329; J. M. Travins, F. A. Etzkorn, J. Org. Chem. 1997, 62, 8387. 
278  N. Shimizu, N. Takesue, S. Yasuhara, T. Inazu, Chem. Lett. 1993, 1807. 
279 S. P. Roche, S. Faure, D. J. Aitken, Angew. Chem. Int. Ed. 2008, 47, 6840. 
NHBoc
3.97
PO(OMe)2
BocHN
3.98
conditions OMe
OTIPS
MeO
O
MeO
O
3.101
OMe
OTIPS
O
H
+
Chapter 3 
 88 
We then prepared the racemic reference compound 3.1.04 by hydrogenation with 
palladium on activated charcoal and commenced screening of asymmetric 
hydrogenation conditions to form amide 3.100 (Table 3.7). 
Table 3.7: Screening of asymmetric hydrogenation conditions of enamide 3.98.  
Entry Temperature Solvent Conversion Yield e.r. 
1 r.t. MeOH 80% – – 
2 r.t. MeOH/DCM quant. 95% 99:1 
3 r.t. EtOAc quant. 95% 98:2 
4 38 °C MeOH quant. 85% 96:4 
5 38 °C MeOH/DCM quant. 95% 98:2 
6 38 °C EtOAc quant. 97% 98:2 
General conditions: H2 (7.5 bar), (R,R)-Et-Duphos-Rh(I) triflate (0.5 mol%), 0.3 M. 
All reactions were conducted in the presence of the catalyst (R,R)-Et-Duphos-Rh(I) 
triflate (0.5 mol%).280 This catalyst is one of the pinnacles of many years of evolution of 
chiral (bidentate-) phosphine ligands originally developed by Nobel laureate William 
Standish Knowles, and its usefulness was impressively demonstrated in the Monsanto L-
Dopa process.281 Duphos-type ligands have found wide application in the preparation of 
chiral unnatural amino in total synthesis.282 An initial solvent screening at 7.5 bar of H2 
pressure revealed pure methanol (entry 1) to be inferior to a mixture of methanol and 
DCM or pure ethyl acetate (entries 2 and 3). In order to increase the reaction rate and 
assure complete conversion, we performed the same reactions at elevated temperatures 
and also observed excellent yields and enantiomeric ratios (entries 4 to 6).  
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Figure 3.12: Comparison of the chiral HPLC trace of enantiopure compound 3.100 (left) 
and the racemic compound 3.99 (right). 
Although entry 6 reports an inferior e.r. of 98:2 compared to entry 2 (99:1), this 
difference probably lies well within the standard deviation at the detection limit. The 
chiral HPLC traces of 3.99 and 3.100 are shown in Figure 3.12.  
We then continued the synthesis of the dipeptide fragment 3.26 as outlined in Scheme 
3.25. The initial methylation of the chiral carbamate 3.100 with methyl iodide is well 
documented in the literature for similar substrates to give enantiopure products.282 
Unfortunately, complete racemization occurred under these basic conditions, but we 
were not able to identify this issue until a later stage. The resulting complications are 
reported in the following sections. 
Scheme 3.25: Synthesis of the diastereomeric dipeptides 3.103 and 3.104. a) NaH, MeI, 
DMF, r.t., 2 h, 93%; b) NaOH, THF/MeOH/water, r.t., 2 h, 78%; HBTU, HOBT, DIPEA, 
DCM, 0 °C to r.t., 18 h, 81%; d) TFA, DCM, r.t., 30 min, quant., 3.103/3.104 1:1. 
The methylation in DMF gave 91% yield and a 5:4 mixture of rotamers was observed. 
Again formation of byproducts was observed, presumably due to TIPS-deprotection. 
The saponification of the methyl ester 3.1.10 to give the free acid 3.1.11 was then 
thoroughly investigated (Table 3.8). 
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Table 3.8: Screening of saponification conditions of ester 3.105.  
Entry Base (eq.) Time Yielda 
1 LiOH (2.0) 16 h 22% 
2 KOH (2.0) 30 min 45% 
3 KOH (1.0) 30 min 44% 
4 NaOH (2.0) 16 h 46% 
5 NaOH (2.0) 1 h 65% 
6 NaOH (1.5) 2 h 78% 
General conditions: THF/MeOH/H2O 3:1:1, 0.2 M, r.t. a) after chromatographic purification. 
Initial experiments employing standard conditions gave very low yields (entry 1). We 
also observed TIPS-deprotected side product. When stronger bases were used, the yield 
increased but so did side product formation (entries 2 and 3). However, shorter reaction 
times clearly proved to be beneficial (entries 5 and 6). We then settled for sodium 
hydroxide at a slight excess of 1.5 equivalents and two hours reaction time, giving the 
acid in 78% yield after column chromatography (entry 6). This was later further 
improved for the enantiopure amino ester 3.111. Chromatographic purification also 
proved to be mandatory, as the formed byproducts greatly decreased the yield of the 
following peptide coupling reaction. 
The results of the investigation of the peptide bond formation of acid 1.106 are 
summarized in Table 3.9. Initially, the suitability of phosphonium-, carbodiimide- and 
uronium based coupling reagents was investigated (entries 1-3). HBTU (entry 1) and 
PyBOP (entry 3) both gave satisfactory yields. Next, the influence of the solvent was 
investigated. A slight decrease in yield when the solvent was changed to THF (entry 4), 
however this could be overcome by starting the reaction at 0 °C and gradually warming 
to room temperature (entry 5). 
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Table 3.9: Screening of peptide coupling conditions to form dipeptide 3.107.  
Entry Solvent Temp. Reagent (eq.) Yield 
1 DMF r.t. HBTU (1.1) 67% 
2 DMF r.t. EDC (1.2), HOBt (1.2) 20% 
3 DMF r.t. PyBOP (1.2) 64% 
4 THF r.t. HBTU (1.1) 57% 
5 THF 0 °C to r.t. HBTU (1.1) 65% 
6 DCM r.t. HBTU (1.1) 34% 
7 DCM 0 °C to r.t. HBTU (1.1), HOBt (1.1) 81% 
General conditions: methyl valinate hydrochloride (1.0 eq.), DIPEA (2.2 eq.), 0.3 M. 
DCM initially proved to be a poor solvent (entry 6), but addition of HOBt and 
increasing temperature gave a good yield of 81% (entry 7). 
This was also the first stage where we observed some irregularities in the 1H NMR 
spectrum, e.g. two sets of signals for some peaks in a 1:1 ratio. We suspected a 
combination of peptide- and carbamate rotamers to be responsible for this observation. 
We tried to prove this by measuring high temperature NMR spectra to confirm the 
expected coalescence of the signals (Figure 3.13). 
Figure 3.13: 1H NMR spectra of compound 3.107 at 298 K (lower spectrum) and 338 K 
(upper spectrum) in DMSO.  
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From these experiments, we found signal of the valine proton with two vicinal methyl 
groups at 2.05 ppm clearly to coalescence to a much sharper signal. The same effect was 
observed for the valine α-proton at 4.7 ppm, although a rather broad signal was still 
observed. The N-methyl group at 2.7 ppm still showed a distinct set of two signals, even 
though the peaks were much sharper than at the lower temperature, indicating some 
coalescence. These ambiguous findings did not clarify whether the compound only was 
in an equilibrium of rotamers, or if it was indeed a diastereomeric mixture. We therefore 
continued with the Boc deprotection with TFA in DCM, which gave the partially 
separable diastereomeric dipeptides 3.103 and 3.104 as a 1:1 mixture in quantitative 
yield (Scheme 3.25).  
Table 3.10: Screening of Boc deprotection conditions of 3.107.  
Entry Conditions Temperature Time 3.103:3.104a 
1 DCM/TFA 3:2 r.t. 1 h 1:1 
2 HCl (1M in Et2O) r.t. 14 h No Conversion 
3 DCM/TFA 4:1 r.t. 1 h 1:1 
4 HCl (4M in dioxane) 85 °C 1 h 1:1 
5 H3PO4/DCM 1:1 r.t. 72 h 1:1 
6 TFA/DCM 1:1 0 °C 1 h 1:1 
7 HCl (1M in Et2O) 40 °C 4 h 1:1 
8 BiCl3, DCM r.t. 14 h 1:1 
9 CAN, MeCN r.t. to 60 °C 72 h No Conversion 
a) determined by TLC and 1H NMR of the crude product. 
We then had to investigate in which step of the sequence (methylation, hydrolysis, 
peptide coupling or Boc-deprotection) racemization had occurred. Racemization 
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processes for methylation, coupling and Boc-deprotection reactions are known,283 and 
since we had already synthesized a considerable amount of diastereomerically impure 
dipeptide 3.108, we continued to screen for alternative Boc-deprotection procedures 
(Table 3.10). All attempts to cleave the Boc group using acidic conditions gave a 
diastereomeric mixture of compounds (entries 1–7). The attempts to cleave the Boc 
group under Lewis acidic conditions (entry 8)284 or oxidative conditions (entry 9)285 also 
proved to be futile. 
Scheme 3.26: Synthesis of the Cbz protected amide 3.109. a) TFA, DCM, r.t. 30 min, 
quant; b) CbzCl, Na2CO3, Et2O/H2O, r.t., 14 h, 96%; c) NaH, MeI, DMF, r.t., 2hh, 83%; 
d) NaOH, THF/MeOH/H2O, r.t., 2 h; e) HBTU, HOBT, DIPEA, DCM, 0 °C to r.t., 18 h,  
54% over two steps; f) H2, Pd/C, MeOH, r.t., 30 min, quant., 3.103:3.104 1:1. 
We therefore decided to replace the Boc group by Cbz in order to clarify the issue 
(Scheme 3.26). The synthesis of 3.109 proceeded in a similar fashion as with the Boc 
protected derivative. Upon removal of the Cbz group by hydrogenation, a 1:1 mixture of 
the diastereomeric dipeptides 3.103 and 3.104 were obtained. We then decided to 
reinvestigate the sequence for indications of racemization from the beginning, starting 
with the methylation reaction.  
                                                
 
283 S. Balakrishnan, C. Zhao, N. J. Zondlo, J. Org. Chem. 2007, 72, 9834; Y. Jiang, Z. Zhang, R. S. Di 
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2010, 75, 6793. 
284 R. S. Navath, K. B. Pabbisetty, L. Hu, Tetrahedron Lett. 2006, 47, 389. 
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Scheme 3.27: Synthesis of the racemate 3.110. a) H2, Pd/C, MeOH, r.t., 30 min; b) NaH, 
MeI, DMF, r.t., 2 h, 35% over two steps. 
We prepared the racemic compound 3.110 (Scheme 3.27) and developed chiral HPLC 
conditions to separate the enantiomers and compared it with the methylated product 
3.105 synthesized from enantiopure carbamate 3.100. Both chiral HPLC traces indicated 
that racemization had occurred (Figure 3.14). Thus, we had now found the cause of 
racemization as the carbamate methylation using sodium hydride. 
Figure 3.14: Chiral HPLC traces of the methylated product 3.1.10 (left, obtained from 
enantiopure hydrogenation product 3.1.05) and the racemate 3.1.14 (right). 
We then changed our methylation procedure to obtain diastereo- and enantiomerically 
pure material as outlined in Scheme 3.28. Methylation with methyl iodide in the 
presence of an excess of silver(I) oxide is another widely applied procedure for the 
methylation of Boc protected amines.286 When applied to our substrate 3.100, we were 
delighted to obtain the methylated carbamate 3.111 with an enantiomeric ratio of 98:2 
(Figure 3.15), therefore successfully resolving the issue of racemization. 
Scheme 3.28: Synthesis of optically pure dipeptide salt 3.112. a) MeI, Ag2O, DMF, r.t., 
18 h, 97% b) NaOH, THF/MeOH/H2O, r.t., 2 h; e) HBTU, HOBT, DIPEA, DCM, 0 °C to 
r.t., 18 h, 78% over two steps; d) HCl in dioxane (4M), r.t., 40 min, quant.  
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It should be noted that the silver(I) oxide must be freshly prepared prior to reaction, as 
an older reagent bottle gave low conversion (20%) under identical conditions. Other 
silver sources (e.g. silver(I) triflate, silver(I) trifluoroacetate) were also investigated, but 
did not yield any product. Continuing the synthesis according to our optimized route, we 
obtained the diastereomerically pure dipeptide fragment 3.112.  
In summary, the dipeptide fragment 3.112 was synthesized from commercially available 
methyl glycinate hydrochloride 3.96 in 9 steps and 29% overall yield with an 
enantiomeric ratio of 98:2 on a multigram scale. The main challenge was to identify the 
cause of racemization, which was found to be the methylation with sodium hydride and 
methyl iodide. This was then circumvented by methylation with methyl iodide and 
freshly prepared silver(I) oxide. The phenolic TIPS group also proved to be rather labile, 
especially under basic conditions. 
Figure 3.15: Chiral HPLC traces of the racemate 3.110 (left) and enantiopure compound 
3.111 (right). 
This reactivity was also observed later in the synthesis. With all the fragments 3.112, 
3.27 and 3.79 in hand, we proceeded with the final assembly of the macrocycle as 
discussed in the next section. 
3.7.4 Synthesis of the Macrocyle 
3.7.4.1 Evaluation of Synthetic Routes 
We now want to the recapitulate the possible routes for assembly of the macrocycle. 
Scheme 3.29 outlines the main connection points and the corresponding applicable 
reactions. First, the inherent reactivities of the fragments are summarized.  
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Scheme 3.29: Major connections in the assembly of the macrocycle. A) esterification; B) 
Stille coupling; C) amide coupling. 
The vinyl bromide 3.79 proved to be stable under very basic conditions (aldol addition) 
and should also be stable under reasonably acidic conditions. In any case, the free 
hydroxyl group could still be protected if needed. The Boc-protected dipeptide 3.113 
proved to be stable under very acidic conditions (Boc deprotection), but the TIPS group 
was labile under basic conditions (i.e.: ester hydrolysis, methylation with NaH). 
However, the lability in basic media could be harnessed by careful reaction optimization 
and monitoring. The vinyl stannane 3.27 was the most labile of the three fragments, as it 
decomposed readily at 5 °C. It would certainly degrade to some extent under acidic 
(MOM cleavage and protodestannylation) or basic conditions. The general reaction 
pathways A-C were hypothesized to consist of the following steps: A) ester hydrolysis 
(basic conditions), esterification (basic conditions); B) Stille coupling (neutral to basic 
conditions) and C) Boc deprotection (acidic conditions), ester hydrolysis (basic 
conditions) and peptide coupling (basic conditions). With this general framework 
established, we now considered all possible reaction sequences and evaluated their 
likeliness to cause decomposition or side reactions based on the known properties of the 
compounds described before. Table 3.11 illustrates that three sequences A-B-C, A-C-B 
and B-A-C could be immediately ruled out. They all contained the Boc deprotection in 
presence of the MOM ether or the vinyl stannane. These functional groups would most 
likely decompose under these harsh conditions.  
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Table 3.11: Evaluation of reaction sequences. 
Sequence Considerations 
A-B-C  Boc deprotection in presence of MOM 
A-C-B  Boc deprotection in presence of MOM and stannane 
B-C-A  Chemoselectivity between –NH and –OH groups in peptide coupling and 
esterification 
B-A-C  Boc deprotection in presence of MOM and allylic alcohol  
C-A-B  Positional selectivity between two –OH group in esterification 
C-B-A  Positional selectivity between two –OH group in esterification 
 
The anticipated problems for the sequences B-C-A, C-A-B and C-B-A mainly consisted 
of possible chemoselectivity issues for the differentiation between a secondary amine 
and a hydroxy group in the peptide coupling reaction (sequence B-C-A) or positional 
selectivity issues between two hydroxy groups in the esterification (sequences C-A-B 
and C-B-A). For the last two sequences, these positional selectivity issues, should they 
be observed, could be solved with a simple protection of the allylic alcohol. We then 
chose to investigate the sequences C-A-B and C-B-A. 
3.7.4.2 Assembly of the Fragments 
Scheme 3.30: Hydrolysis of ester 3.114: a) NaOH, THF/MeOH/H2O, r.t., 2 h, quant. 
We first investigated the peptide coupling reaction between the acid 3.115 and 
secondary amine 3.112 as the initial step. First, the chromatographically separated anti-
configured ester 3.114 was hydrolyzed with sodium hydroxide in a mixture of 
THF/MeOH/H2O in quantitative yield (Scheme 3.30). The crude acid was then directly 
subjected to the peptide coupling conditions, and our screening efforts for this reaction 
are summarized in Table 3.12.  
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Table 3.12: Screening of peptide coupling conditions to give peptide 3.116.  
Entry Reagent (eq.) 3.112 (eq.) 3.115 (eq.) Yield 
1 HBTU (1.4), HOBt (2.0) 2.0 1.0 0% 
2 PyBroP (1.1) 1.8 1.0 0% 
3 DMTMM-Chloride (1.5) 1.5 1.0 0% 
4 DMTMM-BF4 (1.5) 1.2 1.0 0% 
5 T3P (1.5) 1.2 1.0 0% 
6 EDC (2.0) 1.2 1.0 0% 
General conditions: NEt3 (3.0 eq.), DCM, 0.15 M, 0 °C to r.t.. T3P: 1-Propanephosphonic anhydride 
solution. 
We anticipated the peptide coupling to be challenging, since both the acid 3.115 and the 
secondary amine 3.112 are sterically very hindered. Several very reactive coupling 
reagents for difficult peptide bond formations have been developed in recent years,287 
and we focused on the reportedly most efficient reagents. We started our screening with 
an excess of amine in order to push the reaction to completion (entry 1 to 3), but since 
we did not observe any conversion, we lowered the amount of amine to 1.2 equivalents 
for the following reactions. We first used our previously described procedure involving 
uronium-based reagent HBTU and HOBt (entry 1), but without success. We then tried to 
apply phosphonium based reagent PyBroP,288 which also did not give the desired 
                                                
 
287 Reviews: C. A. G. N. Montalbetti, V. Falque, Tetrahedron 2005, 61, 10827; M. Joullié, K. M. Lassen, 
ARKIVOC 2010, 8, 189.	
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product (entry 2). Triazinylammonium salts289 (entries 3 and 4), the phosphonic 
anhydride based reagent T3P290 (entry 5) and EDC (entry 6) also yielded no product. It 
should be noted that for all these reactions, we were able to reisolate considerable 
amount of the free amine of 3.112, indicating that the amine indeed was not very 
nucleophilic or that no active ester was formed in the first place. We also did not 
observe any homocoupling of the acid with the allylic alcohol, which might also be due 
to insufficient amounts of active ester formed, or the sterically hindred acid 3.115. In 
analogy to the synthesis reported by Ghosh and co-workers,221 we then synthesized the 
TBS-protected acid 3.117 (Scheme 3.31). 
Scheme 3.31: Synthesis of acid 3.117: a) TBSOTf, 2,6-lutidine, 0 °C to r.t., 20 min, 80%; 
b) KOH, THF/MeOH/H2O, 80 °C, microwave, 18 h, quant. 
The TBS-group on the anti-diastereomer 3.114 was introduced with TBS triflate in 
presence of 2,6-lutidine in good yield. Initial experiments under our standard methyl 
ester hydrolysis conditions (NaOH, THF/MeOH/H2O, r.t.) showed low conversion 
(10%) after 18 hours reaction time for the subsequent hydrolysis. We suspected the 
increased steric bulk introduced by the TBS-group to be responsible for this. Thus, we 
applied more forcing conditions with potassium hydroxide as a base in a biphasic 
mixture with THF and water at 80 °C for 18h hours in a microwave reactor. This 
furnished free acid 3.117 in quantitative yield and no epimerization was observed. We 
then continued with the screening of peptide coupling conditions as presented in Table 
3.13. The observed results were very similar to those reported in Table 3.12, and none of 
the peptide coupling reagents gave a trace of product (entries 1 to 6). In the case of EDC 
in the presence of HOBt, we were even able to isolate the HOBt ester formed with acid 
3.117 by flash chromatography (entry 3). This result underlined the weak nucleophilic 
character of the secondary amine, but also the great steric hindrance induced by the TBS 
group, which was in line with the observation of the preceding hydrolysis reaction.   
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Table 3.13: Screening of peptide coupling conditions to form peptide 3.118.  
Entry Reagent (eq.) 3.112 (eq.) 3.117 (eq.) Yield 
1 HBTU (1.4), HOBt (2.0) 1.0 1.0 0% 
2 T3P (1.5) 1.0 1.0 0% 
3 EDC (2.0), HOBt (2.0) 1.0 1.0 0% 
4 PyBroP (2.0) 1.0 1.0 0% 
5 DMTMM-Chloride (2.0) 1.0 1.0 0% 
6 DMTMM-BF4 (2.0) 1.0 1.0 0% 
7 (ClCO)2 (20), DMAP (0.1) 1.0 1.2 51% 
General conditions: NEt3 (3.0 eq.), DCM, 0.15 M, 0 °C to r.t. 
Our last resort was the formation of an acyl halide as a very electrophilic species and 
trapping it with the amine 3.112 to afford the desired product 3.118 in 51 % yield. This 
was accompanied by complete epimerization at the α-position of the acid, giving an 
inseparable mixture 1:1 syn:anti mixture of diastereomers. We also suspected the 
hydrochloric acid already present in the oxalyl chloride and inevitably formed during the 
reaction lowered the yield by cleaving the TBS group as a side reaction. We tried to 
selectively remove the TBS group with one equivalent of TBAF and then oxidize to the 
enone, but instead we selectively removed the phenolic TIPS group (Scheme 3.32), 
although the TBS group was expected to be cleaved first.  
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Scheme 3.32: Selective TIPS deprotection of 3.118. a) TBAF, THF, r.t., 1 h, 78%. 
However, there have been reports on selective TBSOR (R = aliphatic) deprotections in 
presence of TBSOAr and vice versa.291 Nevertheless, with the two fragments finally 
coupled, we continued with the investigation of the Stille reaction (Table 3.14). 
Table 3.14: Screening of Stille coupling conditions to form diene 3.120.  
Entry Reagents (eq.) Observations Yield 
1 Pd(MeCN)2Cl2 (1.0) No conversion 0% 
2 Pd(PtBu3)2 (1.0) Only 3.27 consumed 0% 
3 Pd(PPh3)4 (1.0) Only 3.27 consumed 0% 
4 NBu4Ph2PO2 (4.0), CuTC (2.0) Only 3.27 consumed 0% 
5 Pd(PPh3)4 (1.0), NBu4Ph2PO2 (4.0), 
CuTC (2.0) 
3.118 and 3.27 consumed 33% 
6 Pd(PPh3)4 (1.0), NBu4Ph2PO2 (4.0), 
CuTC (3.5) 
3.118 and 3.27 consumed 63% 
General conditions: 3.27 (1.2 eq.), 3.1.22 (1.0 eq.) DMF (degassed), 0.1 M, 70 °C, 18 h.  
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Standard conditions292 employing bis(acetonitrile)palladium(II) chloride as the pre-
catalyst proved to be ineffective for this reaction, as no conversion was observed (entry 
1). When different palladium(0) catalysts were used, consumption of the stannane 3.27 
was observed, but the bromide 3.118 remained untouched (entries 2 and 3). This 
observation might indicate a faster stannane homocoupling than the oxidative reaction of 
the bromide, which remains unchanged. Bromides similar to 3.118 bearing a vicinal 
methyl group have been shown to be a rather difficult substrate in Stille reactions, and 
often the vinyl iodide is preferred.293 We therefore applied the conditions developed by 
Fürstner’s group for “exigent Stille-Migita reactions”,294 where CuTc is added for a 
proposed transmetalation of the stannane295 and Hedeke’s salt (NBu4Ph2PO2) acts as a 
tin scavenger.296 The presence of a large excess (3.5 eq.) of the copper compound is 
absolutely required, as comparison of entries 4 to 6 indicates. For entries 5 and 6, the 
stannane 3.27 was no longer observed in TLC within 30 minutes, but the reaction had to 
be stirred at 70 °C for at least 12 hours for complete consumption of the bromide 3.118. 
Scheme 3.33: Hydrolysis of methyl ester 3.120. a) KOH, THF/MeOH/H2O, r.t., 30 min, 
quant. 
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Surprisingly, we obtained the TIPS-deprotected product 3.120 under optimized 
conditions in 63 % yield, once more underlining the unexpected lability of this phenolic 
silyl group. We were able to partially separate the diastereomers of the β-hydroxy amide 
at this stage and obtained a more easily interpretable 1H NMR spectrum. 
Although selective protections of phenolic hydroxyl groups in presence of aliphatic 
hydroxyl groups have been reported,297 we decided to directly investigate the 
macrolactonization with compound 3.120 bearing the free phenolic hydroxyl group 
(Table 3.15). The hydrolysis of ester 3.120 proceeded under standard conditions in 
quantitative yield (Scheme 3.33). 
Table 3.15: Screening of macrolactonization conditions of seco acid 3.121.  
Entry Conditions (eq.) Observations 
1 EDC (1.0), DCM Traces of 3.122 
2 TCBC (1.0), DMAP (0.1), toluene No conversion 
3 cyanuric chloride (1.0), DCM No conversion 
4 HBTU (1.0), DCM No conversion 
5 T3P (1.0), DCM No conversion 
6 DMTMM-BF4 (1.0), DCM Traces of 3.122 
7 2-chloro-4,6-dimethoxy-1,3,5-triazine (1.0), 
MeCN 
Traces of 3.122 
8 DCC (1.0), DMAP (0.1), MeCN No conversion 
a) KOH, THF/MeOH/H2O, r.t., 30 min, quant; General macrolactonization conditions: DIPEA (1.0 eq.), 1 
mM, r.t., 3 d.  
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Macrolactonizations have been employed in many total syntheses, and a myriad of 
reagents are available.298 Indeed, many of the reagents have shown to be suitable for 
ester as well as amide bond formation, as both reactions usually involve the activation of 
a carboxylic acid. We expanded upon our array of previously applied peptide coupling 
reagents (entries 1, 4, 5 and 6) by using more specific macrolactonization reagents 
(entries 2, 3, 7 and 8). Yamaguchi-299 and Steglich300 conditions (entries 7 and 8) did not 
lead to formation of product, and neither did HBTU, T3P and DMTMM (entries 3 to 5). 
However, in the crude products of the triazine based reagents (entries 6 and 7) and EDC 
(entry 1), we were able to identify the desired product 3.122 by ESI-MS. TLC also 
indicated that the largest quantity of product was formed for entry 6. 
Scheme 3.34: Macrolactonization to form macrocycle 3.122 and 3.123. a) DMTMM-BF4, 
DIPEA, DCM, 0.3 mM, r.t., 4–6 d, 15%. 
We performed the reaction on a larger scale (Scheme 3.34). An initial experiment with 
50 mg of the acid gave 15% yield of the lactone 3.122. In spite of a very low yield, we 
were encouraged by this result, as outcome of macrolactonizations are often highly 
substrate dependent due to macrocyclic stereocontrol.301 A similar substrate had also 
been shown to be reluctant to undergo macrolactonization, as a discussion with Prof. 
Markus Kalesse revealed to us. Unfortunately, when the reaction was repeated on the 
same scale, we isolated exclusively compound 3.123 in 14% yield, resulting from an 
attack of the phenolic hydroxyl group on the coupling reagent. This problem might be 
solved by using a lower amount of DMTMM-BF4 than the applied 5.0 equivalents and 
by performing the reaction under less basic conditions. We also noted that our ESI 
sample of compound 3.122 (M+Na+ = 901.9) in acetonitrile decomposed almost 
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completely to an unknown compound with m/z = 889.9 over night. We were 
nevertheless able to measure an HRMS-ESI spectrum and could confirm the identity of 
macrolactone 3.122. 
Scheme 3.35: Failed MOM protection of macrolactone 3.122. a) MOMCl, DIPEA, DCM, 
0 °C to r.t., 30 min, quant. 
With the presumably labile lactone 3.122 in hand, we had no choice but to quickly 
continue the synthesis. The next step we addressed was the oxidation of the β-hydroxy 
amide function. We first tried to protect the free phenolic hydroxy group, as such ortho-
methoxy phenols easily undergo ortho-quinone formation and other side reactions under 
oxidative conditions.302 We decided to introduce another MOM group to allow for a 
later global deprotection in a later step (Scheme 3.35). When macrolactone 3.122 was 
treated with MOMCl in the presence of DIPEA in DCM, the starting material was 
completely consumed, but two new products were formed. Since the quantities obtained 
were too low to measure a 1H NMR spectrum, we had to rely on ESI-MS to identify the 
products. The desired product had a mass of 804.4 Da, but the two compounds we had 
isolated had their major m/z signals at m/z = 1027.9 and m/z = 939.9/999.0 respectively. 
The overly MOM protected compound 3.124 has a similar mass of m/z = 1028.6 and 
was suspected to be the first of our isolated compounds. However, we were not able to 
identify a reasonable structural formula to account for the peaks with m/z = 939.9 and 
m/z = 999.0. Nevertheless, we tried to TBS-deprotect the mixture of the two unknown 
compounds. We knew from the work of Ghosh’s group that the deprotection of the TBS 
group would require rather forcing conditions,221 but not even when using TBAF (1M in 
THF) as the solvent at 40 °C in the presence of acetic acid did we observe any 
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conversion in TLC. Stirring in THF with HF-pyridine also gave no conversion after 2 
hours, and the reaction with BF3 etherate only resulted in slow degradation of the 
compounds to give a complex mixture. In hindsight, the macrolactone 3.122 had 
probably already been degraded, as indicated by ESI and discussed above, and the 
subsequent reactions therefore showed unexpected reactivities. Since we had now used 
all our available advanced intermediates, this disclosed our efforts towards the synthesis 
of aetheramide B. 
In summary, we were able to successfully assemble the core structure of Aetheramide A 
and B (3.07 and 3.08). The peptide coupling of acid 3.117 and amine 3.112 was 
accomplished under very harsh conditions in 51% yield by forming the acid chloride. 
The Stille coupling was achieved using Fürstner’s “last resort” conditions294 in a good 
yield of 63%, but with concomitant cleavage of the TIPS group. For the 
macrolactonization, we identified DMTMM-BF4 as the best coupling reagent, but still 
only 15% yield were observed. The formed macrolactone 3.122 also appeared to be 
rather labile, which ultimately brought our endeavor to a halt. 
3.6 Conclusions and Outlook 
We have successfully assembled the macrocyclic core structure 3.122 of aetheramide B 
(3.108). The dipeptide fragment 3.26 was accessed by enantioselective reduction of an 
enamide with an excellent e.r. of 98:2. The syn-diol fragment 3.27 was prepared from 
(R)-mandelic acid (3.82) via a Cram chelation-controlled alkynylation, followed by 
kinetic resolution and hydrostannylation. The key steps in the preparation of the eastern 
fragment 3.79 were a Grignard addition, CBS reduction and aldol addition to give the 
advanced intermediate 3.79 in 98:2 e.r. For the coupling of the fragments 3.26 and 3.79, 
harsh conditions involving the formation of the acid chloride had to be applied, as 
milder coupling reagents were not able to couple the sterically very hindered substrates. 
The subsequent Stille coupling proceeded in good yield applying Fürstner’s conditions. 
Macrolactonization with DMTMM gave the labile macrocycle 3.122 in low yield. 
Further synthetic transformations towards the target were unsuccessful due to the labile 
nature of the intermediate 3.122. 
Looking forward, it would be worthwhile to attempt the synthesis by a different 
fragment assembly sequence, e.g. to form the ester bond first between dipeptide 3.26 
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and diol 3.27, then to perform the peptide coupling reaction and finally establish the 
core structure via a Stille macrocyclization. It should also be noted that the alkyne 3.92 
might be transformed to a vinyl boronic acid or ester for Suzuki-Miyaura coupling, 
giving a more stable intermediate than the stannane 3.27. The phenolic hydroxy group of 
the dipeptide fragment 3.26 should not be protected with TIPS, as the group proved to 
be labile at several stages during the synthesis and eventually was cleaved completely 
during the Stille reaction. Our robust and well-optimized syntheses of the fragments 
should be easily modified and would readily give access to the required new 
compounds.
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4  Conclusion 
In this thesis entitled “Total Synthesis of (–)-Pyridovericin and Synthetic Studies 
towards Aetheramide B” the unique ability of synthetic organic chemistry to achieve 
desired molecular targets with biological activity was demonstrated. 
The second chapter documented the synthesis of the neuritogenic pyridone alkaloid (–)-
pyridovericin (2.46). The biochemical and biological background of pyridone fungal 
metabolites were highlighted and previous synthetic efforts summarized. Our synthesis 
was based on our previously reported syntheses of pyridopolyene natural products. It 
relied on the coupling of an arylphosphonate to the aldehyde side chain. The 
enantioselective synthesis of the side chain was achieved by asymmetric hydrogenation 
in collaboration with the Pfaltz group. (–)-Pyridovericin (2.46) was therefore 
synthesized in 13 linear steps and 22% overall yield. Our modular approach allowed for 
the generation of structural analogs and we successfully conducted an SAR study in the 
PC-12 assay to identify highly neuritogenic truncated natural product analogs. We were 
then able to incorporate the truncated analog in a neuritogenic biocompatible surface 
material. The work demonstrated the great potential released by synergy of synthetic 
organic chemistry, biology and material science. 
The third chapter described our synthetic efforts towards the HIV-inhibitory 
depsipeptide Aetheramide B (3.08). The development of high yielding and 
stereospecific routes to three building blocks was reported. The synthesis of the 
dipeptide fragment 3.26 relied on asymmetric hydrogenation for the introduction of the 
stereocenter. The synthesis of this fragment was initially accompanied by racemization, 
but we eventually identified the cause of racemization and developed an alternative 
route. A chiral pool approach allowed for diastereoselective chelation-controlled 
alkynylation in the synthesis of the diol fragment 3.27. The obtained diastereomers were 
rendered separable by kinetic resolution, and hydrostannylation gave the labile stannane-
diol fragment 3.27. The synthesis of the eastern fragment 3.79 was achieved by a 
Grignard addition and sequential enantioselective reduction of an enone. The fragments 
were then successfully coupled to form the macrocylic core 3.122, but steric hindrance 
caused all the involving reactions to proceed in low yield. Furthermore, the obtained 
macrocyle 3.122 proved to be labile and decomposed within hours to a mixture of 
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unknown byproducts. Nevertheless, with the synthetic knowledge gained and the 
developed expedient and high yielding routes to the fragments, further pursuit of the 
target seems to be worthwhile. Our convergent synthetic approach would allow for a 
streamlined synthesis of structural analogs for SAR studies. 
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5 Experimental Part 
5.1 List of Abbreviations, Acronyms and Symbols 
A activation domain 
Aβ amyloid beta protein 
Ac acetyl 
AChE acetylcholine esterase 
AcOH  acetic acid 
AD Alzheimer disease 
AIBN Azobisisobutyronitrile 
AIDS acquired immunodeficiency syndrome 
6-APA 6-aminopenicillanic acid 
7-ACA 7-aminocephalosporanic acid 
ATP adenosine triphosphate 
aq.  Aqueous 
B. b. Beauveria bassiana 
Bn  benzyl 
brsm based on recovered starting material 
°C degree Celsius 
c  concentration 
CAN cerium (IV) ammonium nitrate 
Cbz  carboxybenzyl 
CBS Corey-Bakshi-Shibata 
CH2Cl2  dichloromethane 
CHCl3  chloroform 
CllP Endopeptidase Clp 
COD  1,5-cyclooctadiene 
Cy cyclisation domain 
δ  chemical shift 
Chapter 5 
 112
d  doublet 
D  deuterium 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DBU  1,8-diazabicyclo[5.4.0]undec-7-en 
DCC N,N'-Dicyclohexylcarbodiimide 
DCM dichloromethane 
DEAD  diethyl azodicarboxylate 
DIA N,N-diisopropyl amine 
DIBAL-H diisobutylaluminium hydride 
DIPEA  N,N-diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DME  dimethoxyethane 
DMEM  Dulbecco’s modified Eagle’s medium 
DMF  dimethylformamide 
DMP  Dess-Martin periodinane 
DMSO  dimethyl sulfoxide 
DMTMM 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium 
DNA deoxyribonucleic acid 
DOS diversity-oriented synthesis 
 L-DOPA  3,4-dihydroxyphenylalanine 
dr  diastereomeric ratio 
DMS  dimethyl sulfide 
E epimerization domain 
e.e  enantiomeric excess 
ESI  electrospray ionization 
Et  ethyl 
Et3N  triethylamine 
Et2O  diethyl ether 
EtOAc  ethyl acetate 
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EtOH  ethanol 
eq.  equivalent 
e.r. enantiomeric ratio 
F formylation domain 
FTIR  Fourier transform infrared spectroscopy 
FOS function-oriented synthesis 
HAT histone acetyltransferase 
HAART highly active anti retroviral therapy 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate 
HD Huntington’s disease 
HDAC histone deacetylase 
HIV human immunodeficiency virus 
HMPA Hexamethylphosphoramide 
HOBt  1-hydroxybenzotriazol 
HPLC  high-performance liquid chromatography 
HRMS  high-resolution mass spectrometry 
HWE Horner-Wadswort-Emmons 
IBX  2-iodoxybenzoic acid 
Im  imidazole 
J  coupling constant 
LDA  lithium diisopropylamide 
LHMDS  lithium bis(trimethylsilyl)amide 
m  multiplet 
m-CPBA  meta-chloroperoxybenzoic acid 
M.p.  melting point 
Me  methyl 
MeOH  methanol 
MEM  minimal essential medium 
Min minutes 
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MOM  methoxymethyl 
MRSA Methicillin-resistant Staphylococcus aureus 
MTPCl α-Methoxy-α-(trifluoromethyl)phenylacetyl chloride 
mRNA messenger ribonucleic acid 
NBS  N-bromosuccinimide 
NGF  nerve growth factor 
NMR  nuclear magnetic resonance spectroscopy 
NMP  N-methyl-2-pyrrolidon 
NMT N-methyl transfer domain 
NOE  nuclear Overhauser effect 
NRP non-ribosomal peptide 
NRPS non-ribosomoal peptide synthetase 
PCC  pyridinium chlorochromate 
PCP peptide carrier protein 
PD Parkinson’s disease 
PDC  pyridinium dichromate 
Ph  phenyl 
PKS polyketide synthase 
PPh3  triphenylphosphine 
PMB  para-methoxybenzyl 
ppm  parts per million 
pTsOH  para-toluenesulfonic acid 
PyBOP (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate 
PyBroP Bromotripyrrolidinophosphonium 
hexafluorophosphate 
q  quartet 
Rf  retention factor 
RNA ribonucleic acid 
(R,R)-Et-DUPHOS (–)-1,2-Bis((2R,5R)-2,5-
diethylphospholano)benzene 
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EDC  1-(3-dimetylaminopropyl)-3-ethylcarbodiimid 
r.t.  room temperature 
s  singlet 
sat.  saturated 
SEM  2-(trimethylsilyl)ethoxymethyl 
SIV simian immunodeficiency virus 
t  triplet 
T3P Propylphosphonic anhydride 
TBAF  tetrabutylammonium fluoride 
TBS  tert-butyldimethylsilyl 
TBDPS tert-butyldiphenylsilyl 
TE thioesterase domain 
Tf triflate 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
THP tetrahydropyran 
TIPS  triisopropylsilyl 
TLC  thin layer chromatography 
TMG tetramethyl guanidine 
TPAP  tetrapropylammonium perruthenate 
tR retention time 
UPLC  ultra high-performance liquid chromatography 
UV  ultraviolet 
VMA vinylogous Mukayama-aldol 
ν  wavenumber (cm-1) 
 
5.2 General Methods and Materials 
Reactions involving air or moisture sensitive reagents or intermediates were performed 
under argon in flame-dried glassware. Concentration under reduced pressure or in vacuo 
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was performed by rotary evaporation at 40 °C (unless otherwise specified). Yields refer 
to purified, dried and spectroscopically pure compounds (>95%) unless stated otherwise.  
 
Reagents were purchased from Sigma-Aldrich, Fluorochem, Acros or Alfa and used 
without further purification unless stated otherwise. 
 
Solvents for work-up and chromatography were distilled from technical grade. Solvents 
used for chemical transformations were either puriss. quality or dried by filtration 
through activated aluminium oxide under argon or nitrogen (H2O content <10 ppm, 
Karl-Fischer titration) in a PureSolve MD 5 solvent purification system and stored over 
3 Å molecular sieves (20% v/v). 
 
Thin layer chromatography (TLC) was performed on Merck silica gel 60 F254 plates 
(0.25 mm thickness) precoated with fluorescent indicator. The developed plates were 
examined under UV light and stained with potassium permanganate followed by 
heating.  
 
Flash chromatography was performed using silica gel 60 (230-240 mesh) from Fluka 
at 0.3–0.5 bar pressure.  
 
1H and 13C NMR spectra were recorded either using Bruker Avance 400 MHz, Bruker 
Avance DRX 5500 MHz, or Bruker DRX 600 MHz spectrometers at room temperature. 
Chemical shifts (δ-values) are reported in ppm and spectra were calibrated related to the 
solvent residual proton chemical shift and the solvent residual carbon chemical shift.303 
Multiplicity is reported as follows: s = singlet, br. s = broad singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet or unresolved. Coupling constants J are reported in Hz. 
Optical rotations [α]D were measured at the sodium D line using a 1 mL cell with 1 dm 
path length on a Jasco P-2000 digital polarimeter at 25 °C. The concentration c is given 
in g/100 mL in the indicated solvent. 
                                                
 
303 G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman, B. M. Stoltz, J. E. Bercaw, 
K. I. Goldberg,  Organometallics 2010, 29, 2176. 
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Melting points (M.p.) were determined using a Büchi B-545 apparatus in open 
capillaries and are uncorrected.  
IR spectra were recorded using a Varian 800 FT-IR ATR Spectrometer. The 
absorptions are reported in cm–1.  
ESI-HRMS were recorded on a bruker maXis 4G with ESI-UHR-TOF.  
ESI-MS direct injection measurments were performed on a bruker daltonics esquire 
3000 plus mass spectrometer. 
Reversed-phase UPLC-MS analysis was performed on an Agilent 1290 Infinity LC 
system with an Eclipse plus C18 (1.8 µm, 50 x 2.1 mm) column and an Agilent 
Technologies 6130 Quadrupol mass spectrometer using ESI-API. The solvents used 
were MeCN containing 0.1% trifluoroacetic acid (solvent A) and water containing 
MeCN 1% and 0.1% trifluoroacetic acid (solvent B). The gradient applied was 0.0-0.4 
min 95% B; 0.4 – 3.0 min 95% B -> 95% A; 3.0 – 4.0 min 95% A at a flow rate of 1 
mL/min. 
Chiral HPLC was performed on a Shimadzu UFLC Prominence LC system with a LC-
20 AD pump, a DGU-20A3 degasser, a SIL-20A HT Autosampler, a SPD-M20A 
UV/VIS detector (25 °C) and a CTO-10As oven. The experiments were run with the 
stated solvent gradients and columns. 
Semi Preparative High Performance Liquid Chromatography (SP-HPLC) was 
performed on a Dionex Chromatography System (Interface Chromeleon, ASI 100 
automatic sample injector, PDA 100 (USB) PD detector, pump P680). The flow rate was 
5 mL/min and a Phenomenex Gemini 5 µm C18 110A column (150 x 10 mm) was used.  
 
Lyophilisations were performed with a Christ Freeze Dryer Alpha 1-2 LD plus. 
Microwave reactions were performed in a Biotage Initiator+ microwave synthesizer in 
sealable microwave vials. 
 
Hydrogenation autoclaves of the type HPM-005 by PREMEX Reactor AG (Lengnau, 
Switzerland) were used to conduct hydrogenation experiments at the indicated pressures. 
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5.3 Experimental Procedures 
(S)-methyl 2-(((tert -butyldiphenylsilyl)oxy)methyl)butanoate (2.70): A high pressure 
steel autoclave (Permex Reactor AG; Lengnau, Switzerland; Model 
HPM-005) with a dry glass insert and a magnetic stir bar was charged 
with (E)-methyl 2-(((tert-butyldimethylsilyl)oxy)methyl)but-2-enoate 
(5) (184 mg, 500 µmol, 1.0 eq.) and dry DCM (2.5 mL) before the catalyst 
[Ir(L)(cod)]BArF (1 mol%) was added. The autoclave was closed and attached to a high-
pressure hydrogen line and purged with H2. The autoclave was sealed under 50 bar of H2 
pressure and the mixture was stirred at 900 rpm for 16 hours at room temperature. After 
release of H2 the solution was concentrated in a stream of nitrogen, diluted with 1 mL of 
hexane/MTBE (4:1), and passed through a short plug of silica gel in a Pasteur pipette. 
The filtrate was concentrated in a stream of nitrogen to give the pure title compound 6 
(184 mg, 500 µmol, quant.) with 93:7 e.r. All analytical data were in full agreement with 
previously reported values304, except for inverted optical rotation of [α]D = +102 (c 
= 0.89 CHCl3). e.r.: 93:7 determined by HPLC (Chiralcel OD-H column, hexane/i-PrOH 
99:1, flow rate 0.5 mL/min, UV 230 nm) tR 8.11 (minor), 9.10 (major). 
(S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)butanal (S1): To a -70 °C cold solution of 
ester 2.70 (370 mg, 1.04 mmol, 1.0 eq.) in dry DCM (4 mL) was added 
DIBAL-H (1.15 mL, 1.15 mmol, 1.10 eq., 1.0 M in DCM) portion wise 
(100 µL every 5 min) in a fashion that the solution was precooled by 
running down the wall of the flask. This mixture was then stirred at -70 °C for 1 h and 
then quenched by slow addition of a mixture of MeOH/DCM (1:1 v/v, 2 mL) in a 
fashion that the solution was precooled by running down the wall of the flask. The 
mixture was diluted with Et2O (20 mL) and then quickly poured onto a saturated 
aqueous solution of  Seignette’s salt (20 mL). The resulting gray slurry was stirred 
vigorously until two clear layers were observed (~1 h), which then were separated. The 
aqueous layer was extracted with Et2O (2 x 20 mL) and the combined organic layers 
were dried over sodium sulfate, filtered, and the solvents removed in vacuo. Flash 
chromatography (SiO2, pentane/Et2O 15:1) gave the title aldehyde (289 mg, 849 µmol, 
82%) as a colorless oil. All analytical data were in full agreement with previously 
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reported values,304 except for the inverted optical rotation of [α]D = +16.7 (c = 0.83 
CHCl3). 
(R,E)-ethyl-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylhex-2-enoate (2.71): 
To a solution of aldehyde S1 (257 mg, 753 µmol, 1.0 eq.) in dry 
DCM (3 mL) was added ethyl 2-
(triphenylphosphoranylidene)propanoate (409 mg, 1.13 mmol, 
1.50 eq.) in one portion. The resulting yellow solution was heated to reflux and the 
consumption of the aldehyde was followed by 1H NMR. After 24 h another portion of 
the phosphorane (136 mg, 376 µmol, 0.50 eq.) was added and after complete 
consumption of the aldehyde (48 h) the solvent was removed in vacuo and the crude 
slurry was directly subjected to flash chromatography (SiO2, pentane/Et2O 25:1) to 
afford the title compound (304 mg, 715 µmol, 95%, E/Z >30:1, 91:9 e.r.) as a colorless 
oil. [α]D = +6.27 (c = 0.93 CHCl3). e.r.: 91:9 determined by HPLC (Chiralpak IC 
column, hexane/i-PrOH 99:1, flow rate 0.5 mL/min, UV 206 nm) tR 11.1 (minor), 11.5 
(major). Rf  = 0.33 (pentane/Et2O 15:1). FTIR (neat): 2962, 2933, 2859, 1710, 1463, 
1388, 1229, 1107, 741, 702 cm-1. 1H NMR (500 MHz, CDCl3): δ = 7.66 – 7.63 (m, 
4H,), 7.45 – 7.35 (m, 6H), 6.59 (dq, J = 10.3, 1.3 Hz, 1H), 4.28 – 4.14 (m, 2H), 3.63 – 
3.53 (m, 2H), 2.60 – 2.50 (m, 1H), 1.81 (d, J = 1.4 Hz, 3H), 1.72 – 1.63 (m, 1H), 1.35 – 
1.25 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.03 (s, 9H), 0.84 (t, J = 7.5 Hz, 3H). 13C NMR 
(126 MHz, CDCl3): δ = 168.4, 143.9, 135.8, 133.8, 129.8, 129.2, 127.8, 66.4, 60.6, 43.5, 
26.9, 24.2, 19.4, 14.5, 13.1, 11.9. HRMS ESI: m/z calc. for C26H36O3NaSi [M+Na]+: 
447.2326, found: 447.2319. 
 
(R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylhex-2-en-1-ol (S2): To a -70 
°C cold solution of the ester 2.71 (300 mg, 706 µmol, 1.0 eq.) in dry 
THF (3 mL) was added drop wise DIBAL-H (2.12 mL, 2.12 mmol, 
3.0 eq., 1.0 M in hexane). The solution was then stirred 20 min at  -70 
°C, then 30 min at 0 °C and finally 1 h at r.t., after which TLC indicated complete 
consumption of the starting material. The reaction was quenched by drop wise addition 
of MeOH (2 mL), diluted with Et2O (20 mL) and then quickly poured onto a saturated 
aqueous solution of Seignette’s salt (20 mL). The resulting gray slurry was stirred 
vigorously until two clear layers were observed (ca. 2 h), which then were separated. 
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The aqueous layer was extracted with Et2O (2 x 20 mL) and the combined organic layers 
were dried over sodium sulfate, filtered, and the solvents removed in vacuo. Flash 
chromatography (SiO2, pentane/Et2O 4:1) gave the title compound (249 mg, 621 µmol, 
88%, E/Z >30:1, 89:11 e.r.) as a colorless oil. [α]D = -24.6 (c = 1.1 CHCl3). e.r.: 89:11 
determined by HPLC (Chiralcel AD-H column, hexane/i-PrOH 99:1, flow rate 0.6 
mL/min, UV 206 nm) tR 15.3 (major), 17.3 (minor). Rf  = 0.30 (pentane/Et2O 4:1). 
FTIR (neat): 3324 (br), 2958, 2930, 2857, 1389, 1427, 1111, 1007, 702 cm-1. 1H NMR 
(400 MHz, CDCl3): δ = 7.69 – 7.64 (m, 4H), 7.45 – 7.35 (m, 6H), 5.13 (dq, J = 9.8, 1.1 
Hz, 1H), 3.98 (d, J = 5.9 Hz, 2H), 3.60 – 3.50 (m, 2H), 2.48 – 2.37 (m, 1H), 1.71 – 1.58 
(m, 1H), 1.62 (d, J = 1.1 Hz, 3H), 1.27 – 1.15 (m, 2H), 1.05 (s, 9H), 0.84 (t, J = 7.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3): δ = 136.4, 135.8, 134.2, 129.7, 128.0, 127.7, 69.1, 
67.2, 42.3, 27.0, 24.7, 19.4, 14.3, 11.8. HRMS ESI: m/z calc. for C24H35O2Si [M+H]+: 
383.2401, found: 383.2401. 
(R,E)-4-(hydroxymethyl)-2-methylhex-2-enal (S3): To a solution of alcohol S2 (160 
mg, 397 µmol, 1.0 eq.) in dry DCM (3 mL) was added powdered 
molecular sieves (50 mg, 4 Å, oven-dried at 120 °C) and N-
methylmorpholine N-oxide (70.0 mg, 596 µmol, 1.50 eq.). To this 
slurry, tetrapropylammonium perruthenate (3.50 mg, 10.0 µmol, 2.5 mol%) was added 
and the resulting black suspension was stirred for 1 h at r.t. after which TLC indicated 
complete consumption of the starting material. The crude mixture was filtered over a 
plug of silica, which was further washed with DCM (70 mL). The solvents were 
removed in vacuo to give the protected aldehyde S4 as a yellow oil (155 mg, 397 µmol, 
99%), which was used without further purification in the next step. Rf = 0.45 
(pentane/Et2O 10:1) 1H NMR (500 MHz, CDCl3) δ = 9.37 (s, 1H), 7.64 – 7.60 (m, 4H), 
7.46 – 7.35 (m, 6H), 6.27 (dq, J = 10.2, 1.3 Hz, 1H), 3.70 (dd, J = 10.0, 5.3 Hz, 1H), 
3.62 (dd, J = 10.0, 6.6 Hz, 1H), 2.73 (dddt, J = 10.2, 9.0, 6.4, 5.2 Hz, 1H), 1.72 (d, J = 
1.3 Hz, 3H), 1.71 – 1.62 (m, 1H), 1.41 – 1.31 (m, 1H), 1.03 (s, 9H), 0.84 (t, J = 7.5 Hz, 
3H). 13C NMR (126 MHz, CDCl3): δ = 195.5, 156.7, 135.6, 135.5, 129.8, 127.7, 66.1, 
43.7, 26.8, 24.0, 11.7, 9.7.  
To a solution of the crude aldehyde S4 (179 mg, 447 µmol, 1.0 eq.) in dry THF (3 mL) 
was added TBAF (450 µL, 450 µmol, 1.0 eq., 1.0 M in THF) and the resulting dark 
yellow solution was stirred at r.t. After 2 h, UPLC-MS indicated complete consumption 
of the starting material and the reaction was poured on saturated aqueous NH4Cl (10 
OH
CH3
CH3
O
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mL) and extracted with Et2O (5 x 10 mL). The combined organic layers were dried over 
sodium sulfate, filtered, and the solvents removed in vacuo. Flash chromatography 
(SiO2, pentane/Et2O 1:10) gave the deprotected aldehyde S3 (60.3 mg, 424 µmol, 95%, 
E/Z >30:1) as a colorless oil. [α]D = -26.6 (c = 0.90 CHCl3). Rf = 0.45 (pentane/Et2O 
1:10). FTIR (neat): 3363 (br), 2962, 2931, 2876, 2361, 2335, 1685, 1042, 766 cm-1. 1H 
NMR (400 MHz, CDCl3): δ = 9.45 (s, 1H), 6.32 (dq, J = 10.1, 1.3 Hz, 1H), 3.75 – 3.60 
(m, 2H), 2.84 – 2.71 (m, 1H), 1.80 (d, J = 1.4 Hz, 3H), 1.72 – 1.62 (m, 1H), 1.46 – 1.34 
(m, 1H), 0.91 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3): δ = 195.3, 155.5, 141.4, 
65.6, 43.9, 24.1, 11.8, 10.0. HRMS ESI: m/z calc. for C8H15O2 [M+H]+: 143.1067, 
found: 143.1066. 
3-((R,2E,4E)-6-(hydroxymethyl)-4-methylocta-2,4-dienoyl)-4-methoxy-5-(4-((4-
methoxybenzyl)oxy)phenyl)pyridin-2(1H)-one (S5): To a suspension of the aldehyde 
S3 (36.0 mg, 253 µmol, 1.20 eq.) and the 
phosphonate 2.57 (103 mg, 211 µmol, 1.0 eq.) in 
THF/H2O (1 mL, 4:1 v/v) was added LiOH•H2O 
(17.7 mg, 422 µmol, 2.0 eq.). A yellow solution formed immediately, which was stirred 
under exclusion of light at r.t. and monitored by UPLC-MS. After 6 days, the dark 
orange reaction mixture was poured on saturated aqueous NH4Cl (10 mL) and extracted 
with EtOAc (4 x 10 mL). The combined organic layers were dried over sodium sulfate, 
filtered, and the solvents removed in vacuo. Flash chromatography (SiO2, DCM/MeOH 
20:1) gave the pyridopolyene S5 (82.0 mg, 162 µmol, 77%, E/Z >30:1) as a yellow oil. 
Rf = 0.30 (DCM/MeOH 20:1). FTIR (neat): 3400 (br), 2934, 2358, 1634, 1611, 1512, 
1237, 1033, 830, 733 cm-1. 1H NMR (500 MHz, CDCl3): δ = 12.91 (s (br), 1H), 7.40 – 
7.35 (m, 3H), 7.32 – 7.27 (m, 2H), 7.22 (d, J = 15.8 Hz, 1H), 7.01 – 6.97 (m, 2H), 6.95 – 
6.91 (m, 2H), 6.50 (d, J = 15.8 Hz, 1H), 5.74 (d, J = 10.1 Hz, 1H), 5.01 (s, 2H), 3.82 (s, 
3H), 3.64 – 3.59 (m, 1H), 3.61 (s, 3H), 3.52 – 3.46 (m, 1H), 2.68 – 2.58 (m, 1H), 1.89 
(d, J = 1.0 Hz, 3H), 1.59 – 1.52 (m, 1H), 1.32 – 1.22 (m, 1H), 0.86 (t, J = 7.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ = 194.2, 168.4, 165.6, 164.4, 159.7, 158.7, 150.6, 
145.4, 145.2, 136.0, 135.2, 130.0, 129.4, 129.3, 126.9, 126.4, 114.8, 113.9, 69.8, 68.8, 
60.7, 55.2, 43.9, 24.2, 13.0, 11.6. HRMS ESI: m/z calc. for C30H34O6N [M+H]+: 
504.2381, found: 504.2377. 
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(–)-Pyridovericin (2.46): A suspension of the pyridopolyene S5 (74.0 mg, 147 µmol, 
1.0 eq.), LiI•3H2O (111 mg, 589 µmol mol, 4.0 
eq.) and pyridine hydrochloride (102 mg, 883 
µmol, 6.0 eq.) in degassed (freeze/thaw) THF (4 
mL) was heated to 60 °C for 4 h in a microwave 
reactor. The yellow suspension was poured on brine (5 mL) and then extracted with 
DCM (3 x 7 mL). The combined organic layers were dried over sodium sulfate, filtered, 
and the solvents removed in vacuo. Flash chromatography (SiO2, DCM/MeOH 20:1) 
gave the crude demethylated pyridone S6 (51.0 mg, 104 µmol, 71%, E/Z > 5:1) as a 
yellow oil. 1H NMR data is given for the E isomer. Rf = 0.40 (DCM/MeOH 15:1). 1H 
NMR (400 MHz, CDCl3): δ = 11.59 (s, 1H), 7.98 (d, J = 15.4 Hz, 1H), 7.62 (d, J = 15.4 
Hz, 1H), 7.44 – 7.33 (m, 5H), 7.07 – 6.98 (m, 2H), 6.98 – 6.89 (m, 2H), 5.82 (d, J = 10.0 
Hz, 1H), 5.01 (s, 2H), 3.82 (s, 3H), 3.71 – 3.60 (m, 1H), 3.56 – 3.45 (m, 1H), 2.75 – 
2.60 (m, 1H), 1.94 (s, 3H), 1.63 – 1.53 (m, 1H), 1.34 – 1.24 (m, 1H), 0.88 (t, J = 7.4 Hz, 
3H). 
The crude pyridone S6 (16.0 mg, 33.0 µmol, 1.0 eq.) was suspended in DCM (2 mL) 
and trifluoroacetic acid (100 µL, 5% v/v in DCM) was added drop wise. The formed 
yellow solution was stirred at r.t. for 30 min, after which TLC indicated complete 
consumption of the starting material. The crude solution was poured on saturated 
aqueous NaHCO3 (5 mL) and extracted with a mixture of DCM/MeOH/EtOAc (6:1:1 
v/v, 5 x 10 mL), after which the aqueous layer was colorless. The combined yellow 
organic layers were dried over sodium sulfate, filtered, and the solvents removed in 
vacuo. Flash chromatography (SiO2, DCM/MeOH 20:1) gave (-)-Pyridovericin (2.46) 
(10 mg, 27 µmol, 83%, E/Z>6:1) as a yellow oil. Fractional crystallization was achieved 
by dissolving the crude material in MeOH/DCM (1:9 v/v, 300 µL) and drop wise 
addition of pentane (1.20 mL) while swirling vigorously. The yellow suspension was 
stored at 5 °C for 10 min, centrifuged and the supernatant removed carefully with a 
syringe. After 5 repetitions of the process, this gave an analytical sample (3 mg) of 1 as 
an amorphous yellow solid with e.r. 93:7 and an E/Z ratio >30:1. [α]D = -10.8 (c = 0.16 
MeOH). e.r.: 93:7 determined by HPLC (Chiralcel IC column, hexane/i-PrOH 70:30, 
flow rate 1.0 mL/min, UV 206 nm) tR 8.3 (minor), 9.2 (major). Rf = 0.17 (DCM/MeOH 
15:1). FTIR (neat): 3287 (br), 2960, 2929, 2360, 2341, 1648, 1610, 1518, 1460, 1263, 
1215, 1037, 985, 835, 769 cm-1. 1H NMR (600 MHz, DMSO): δ = 17.56 (s, 1H), 11.62 
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(s, 1H), 9.48 (s, 1H), 7.99 (d, J = 14.9 Hz, 1H), 7.55 (s, 1H), 7.51 (d, J = 15.6 Hz, 1H), 
7.30 – 7.24 (m, 2H), 6.81 – 6.75 (m, 2H), 5.94 (d, J = 9.6 Hz, 1H), 4.59 (t, J = 5.4 Hz, 
1H), 3.41 – 3.30 (m, 2H), 2.57 – 2.49 (m, 1H), 1.85 (s, 3H), 1.65 – 1.54 (m, 1H), 1.28 – 
1.17 (m, 1H), 0.82 (t, J = 7.5 Hz, 3H). 13C NMR (151 MHz, DMSO): δ = 193.7, 176.9, 
161.8, 156.7, 149.4, 147.5, 140.7, 134.5, 130.1, 123.5, 123.1, 115.0, 112.8, 106.0, 64.0, 
43.6, 24.0, 12.8, 11.7.  HRMS ESI: m/z calc. for C21H24O5N [M+H]+: 370.1649, found: 
370.1647. λmax (MeCN/H2O 60:40): 206, 249, 338 nm. 
Dimethyl ((2Z,4E,6E)-1-(4-methoxy-5-(4-((4-methoxybenzyl)oxy)phenyl)-2-oxo-1,2-
dihydropyridin-3-yl)-6,8-dimethyl-1-oxodeca-2,4,6-trien-2-yl)phosphonate (2.74): 
The phosphonate 2.57 (9.50 mg, 20.0 
µmol, 1.0 eq.) and aldehyde 2.72 (5.70 
mg, 19.5 µmol, 1.0 eq.) were suspended 
in dry THF (300 mL) and one drop of 
DBU was added. The suspension was stirred for 24 h at r.t. under exclusion of light, 
poured on saturated aqueous NH4Cl (2 mL), extracted with DCM (5 x 3 mL), dried over 
sodium sulfate and evaporated. The crude yellow oil was purified by flash 
chromatography (SiO2, DCM/MeOH 20:1) to give the HWE product (4.0 mg, 7.8 µmol, 
40%) and the crude Knoevenagel product. This was further purified by semi preparative 
HPLC (5 – 100% MeCN in H2O in 25 min) to give the Knoevenagel product 2.74 (4.0 
mg, 6.4 µmol, 30%) as a mixture of 4 E/Z isomers. NMR data is given for the major all-
E isomer. Most proton shifts were assigned from 2D-NMR spectra. The signal of the 
carbon atom at the C(3) position of the pyridone could not be detected. Rf = 0.15 
(DCM/MeOH 20:1). FTIR (neat): 2957, 2853, 2361, 1589, 1643, 1513, 1462, 1387, 
1292, 1243, 1177, 1030, 791, 649 cm-1. 1H NMR (600 MHz, CDCl3): δ = 12.62 (s (br), 
1H), 7.62 (dd, J = 14.7, 11.6 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.9 Hz, 2H), 
7.27 (s, 1H), 7.27 (dd, J = 33.0, 11.6 Hz, 1H), 6.99 (d, J = 8.6 Hz, 2H), 6.77 (d, J = 14.7 
Hz, 1H), 6.39 (d, J = 8.5 Hz, 2H), 5.67 (d, J = 9.7 Hz, 1H), 5.01 (s, 2H), 3.83 (d. J = 2.8 
Hz, 6H), 3.74 (s, 3H), 3.58 (s, 3H), 2.50 – 2.39 (m, 1H), 1.87 (s, 3H), 1.44 – 1.35 (m, 
1H), 1.33 – 1.22 (m, 1H), 0.96 (d, J = 6.4 Hz, 3H), 0.82 (t, J = 7.40 Hz, 3H). 13C NMR 
(151 MHz, CDCl3): δ = 193.0, 168.2, 165.0, 163.6, 162.2, 160.7, 159.5, 158.5, 154.8, 
149.7, 134.9, 133.7,  130.0, 129.2, 128.9, 123.2, 117.0, 114.9, 114.0, 69.8, 60.4, 54.3, 
52.8, 35.0, 29.8, 20.1, 12.7, 11.9. 31P NMR (243 MHz, CDCl3): δ = 17.1. HRMS ESI: 
m/z calc. for C34H41O8NP [M+H]+: 622.2564, found: 622.2565.  
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(E)-ethyl 2-methyl-7-oxohept-2-enoate (3.31):305 A commercial solution of glutaric 
aldehyde 3.30 (20 mL, 50% v/v in water) was diluted with 
Et2O (100 mL), extracted with brine (3 x 30 mL) and dried 
over sodium sulfate, which gave after filtration and 
evaporation of solvent spectroscopically (1H NMR) pure glutaric aldehyde. 
To a solution of glutaric aldehyde 3.30 (6.60 g, 65.9 mmol, 5.0 eq.) in Dichloromethane 
(15 mL) was added (Carbethoxyethylidene)triphenylphosphorane (4.78 g, 13.2 mmol, 
1.0 eq.) and the resulting yellow solution heated to reflux for 18 h. Removal of  the 
solvent gave a yellow oil which was directly purified by flash chromatography (SiO2, 
pentane/Et2O 7:2) to give the pure E-isomer of the ester 3.31 as a yellow oil (1.53 g, 
8.30 mmol, 63%). All analytical data were in full agreement with the literature. Rf = 
0.28 (SiO2, pentane/Et2O, 7:2). 1H NMR (400 MHz, CDCl3) δ = 9.78 (t, J = 1.5 Hz, 
1H), 6.71 (d, J = 7.5 Hz, 1H), 6.68 (d, J = 1.4 Hz, 1H), 4.18 (q, J = 7.1 Hz, 3H), 2.47 
(td, J = 7.3, 1.5 Hz, 2H), 2.22 (q, J = 7.4 Hz, 3H), 1.82 (d, J = 1.3 Hz, 3H), 1.81 – 1.77 
(m, 2H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 201.97, 168.15, 
140.55, 129.08, 60.66, 43.34, 27.92, 21.12, 14.41, 12.55. sf266 
 
(E)-ethyl 7-hydroxy-2-methyl-9-(trimethylsilyl)non-2-en-8-ynoate (S7): To a -70 °C 
cold solution of Trimethylsilyl acetylene (960 mg, 9.77 
mmol, 1.20 eq.) in THF (15 mL) was added drop wise a 
solution of n-BuLi (5.40 mL, 8.60 mmol, 1.10 eq., 1.6 M 
in hexane) and then stirred for 10 min. The solution was 
then warmed to 0 °C for 10 min before being cooled to -70 °C and cannulated to a -70 
°C cold solution of the aldehyde 3.31 (1.53 g, 8.14 mmol, 1.0 eq.) in THF (16 mL). The 
mixture was stirred for 10 min, after which the cooling bath was removed and the 
yellow solution was stirred at r.t. for 4 h, after which 1H NMR indicated complete 
consumption of the aldehyde. The reaction was quenched by slow addition of saturated 
aqueous NH4Cl (20 mL), and the aqueous layer was extracted with Et2O (3 x 20 mL). 
The unified organic layers were dried over sodium sulfate, filtered, the solvents removed 
and the obtained crude yellow oil was purified by flash chromatography (SiO2, 
pentane/Et2O 4:1) to give the pure E-isomer of the alcohol S7 as a colorless oil (2.22 g, 
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7.39 mmol, 91%). Rf = 0.41 (SiO2, pentane/Et2O, 4:1). FTIR (neat): 3419 (br), 2957, 
1709, 1249, 1093, 841, 630 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.73 (td, J = 7.4, 1.3 
Hz, 1H), 4.35 (t, J = 6.4 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 2.27 – 2.12 (m, 3H), 1.81 (d, 
J = 0.7 Hz, 3H), 1.76 – 1.67 (m, 2H), 1.66 – 1.57 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 0.15 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ = 168.34, 141.71, 128.31, 106.70, 89.62, 62.60, 
60.57, 37.26, 28.31, 24.27, 14.37, 12.48, -0.04. HRMS ESI calc. for C15H27O3Si+ 
[M+H]+: 283.1724, found 283.1723. sf268 
 
(E)-ethyl 7-methoxy-2-methyl-9-(trimethylsilyl)non-2-en-8-ynoate (3.32): To a -70 
°C cold solution of the alcohol S7 (190 mg, 654 mmol, 
1.0 eq.) in THF (3.0 mL) was added drop wise a solution 
of n-BuLi (500 mL, 780 mmol, 1.10 eq., 1.6 M in 
Hexane). The resulting yellow solution was stirred for 20 
min, after which methyl iodide (370 mL, 5.90 mmol, 9.0 eq.) was added drop wise. 
After 20 min of stirring, the temperature was raised to -30 °C and DMSO (190 mL, 2.60 
mmol, 4.0 eq.) was added in one portion upon which a colorless precipitate formed. The 
stirred suspension was allowed to warm to r.t. overnight, after which TLC indicated 
complete consumption of the alcohol. The reaction was quenched by slow addition of 
saturated aqueous NH4Cl (10 mL), and the aqueous layer was extracted with Et2O (5 x 
15 mL). The unified organic layers were dried over sodium sulfate, the solvents 
removed and the obtained crude oil was purified by flash chromatography (SiO2, 
pentane/Et2O 15:1) to give the alcohol 3.32 as a colorless oil (153 mg, 516 mmol, 79%, 
E/Z > 9:1). Rf = 0.25 (SiO2, pentane/Et2O, 15:1). FTIR (neat): 2955, 2171, 1709, 1250, 
1106, 841, 760, 666 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.74 (t, J = 7.4 Hz, 1H), 4.17 
(q, J = 7.1 Hz, 2H), 3.92 (t, J = 6.3 Hz, 1H), 3.38 (s, 3H), 2.20 (q, J = 7.3 Hz, 2H), 1.82 
(s, 3H), 1.77 – 1.66 (m, 2H), 1.64 – 1.51 (m, 2H), 1.31 – 1.26 (t, J = 7.3 Hz, 3H), 0.17 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ = 168.34, 141.76, 128.30, 104.34, 90.94, 71.46, 
60.54, 56.50, 35.20, 28.42, 24.39, 14.42, 12.51, 0.06. HRMS ESI calc. for C16H29O3Si+ 
[M+H]+:  297.1880, found 297.1880. sf212 
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(E)-methyl 9-methoxy-2,4-dimethyl-3-oxo-11-(trimethylsilyl)undec-4-en-10-ynoate 
(S8): To a 0 °C cold solution of diisopropyl amine (81.0 mg, 801 mmol, 2.50 eq.) in 
THF (1.0 mL) was added drop wise a solution of n-
BuLi (500 mL, 800 mmol, 2.50 eq., 1.6 M in hexane) 
and the resulting solution was stirred for 20 min before 
being cooled to -70 °C. A Solution of methyl 
propionate (70.6 mg, 801 mmol, 2.5 eq.) in THF (1.0 mL) was added drop wise and 
after 1 h of stirring, a solution of the ester S7 (100 mg, 320 mmol, 1.0 eq.) in THF (1.0 
mL) was added drop wise. TLC indicated complete consumption of the starting material 
after 2 h of stirring. The reaction was quenched by slow addition of saturated aqueous 
NH4Cl (10 mL), and the aqueous layer was extracted with Et2O (5x10 mL). The unified 
organic layers were dried over sodium sulfate, the solvents removed and the obtained 
crude oil was purified by flash chromatography (SiO2, pentane/Et2O 4:1) to give the b-
keto ester S8 as a colorless oil (63.0 mg, 182 mmol, 57%, E/Z >30:1). Rf = 0.35 (SiO2, 
pentane/Et2O, 4:1). FTIR (neat): 2953, 1741, 1669, 1453, 1249, 1107, 842, 760, 666 
cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.66 (td, J = 7.2, 1.1 Hz, 1H), 4.16 (q, J = 7.1 Hz, 
1H), 3.94 (t, J = 6.2 Hz, 1H), 3.68 (s, 3H), 3.39 (s, 3H), 2.29 (dt, J = 13.2, 6.8 Hz, 2H), 
1.80 (s, 3H), 1.76 – 1.69 (m, 2H), 1.67 – 1.59 (m, 2H), 1.36 (d, J = 7.1 Hz, 3H), 0.18 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ = 197.35, 171.91, 143.83, 136.85, 104.17, 91.11, 
71.36, 71.34, 56.57, 52.49, 46.74, 35.17, 28.98, 24.34, 24.33, 14.34, 11.81, 0.06. HRMS 
ESI calc. for C18H30NaO4Si+ [M+Na]+:: 361.1806, found 361.1806. sf296 
 
(E)-tert-butyl 9-methoxy-2,4-dimethyl-3-oxo-11-(trimethylsilyl)undec-4-en-10-
ynoate (S9): To a 0 °C cold solution of diisopropyl 
amine (46.0 mg, 450 mmol, 3.0 eq.) in THF (0.5 
mL) was added drop wise a solution of n-BuLi (280 
mL, 450 mmol, 3.0 eq., 1.6 M in hexane) and the 
resulting solution was stirred for 20 min before being cooled to -70 °C. A Solution of 
tert-butyl propionate (59.0 mg, 450 mmol, 3.0 eq.) in THF (0.5 mL) was added drop 
wise and after 1 h of stirring, a solution of the ester S7 (47 mg, 0.15 mmol, 1.0 eq.) in 
THF (0.5 mL) was added drop wise. The reaction was allowed to warm to r.t. overnight, 
and the reaction was quenched by slow addition of saturated aqueous NH4Cl (5 mL) and 
the aqueous layer was extracted with Et2O (5 x 5 mL). The unified organic layers were 
dried over sodium sulfate, the solvents removed and the obtained crude oil was purified 
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by flash chromatography (SiO2, pentane/Et2O 10:1) to give the β-keto ester S9 as a 
colorless oil (39.1 mg, 100 mmol, 68%, E/Z >15:1). Rf = 0.15 (SiO2, pentane/Et2O 
10:1). FTIR (neat):  2938, 2363, 1731, 1672, 1368, 1249, 1151, 1108, 842, 760 cm
-1. 1H 
NMR (400 MHz, CDCl3) δ = 6.64 (td, J = 7.2, 1.2 Hz, 1H), 4.0 (q, J = 7.0 Hz, 1H), 3.94 
(t, J = 6.2 Hz, 1H), 3.39 (s, 3H), 2.29 (q, J = 7.2 Hz, 2H), 1.80 (d, J = 0.8 Hz, 2H), 1.77 
– 1.69 (m, 2H), 1.68 – 1.58 (m, 2H), 1.41 (s, 9H), 1.31 (d, J = 7.0 Hz, 3H), 0.18 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ = 197.69, 170.74, 142.87, 137.05, 104.20, 91.07, 81.40, 
71.38, 56.56, 48.16, 35.25, 28.97, 28.02, 24.43, 14.04, 11.91, 0.08. HRMS ESI calc. for 
C21H37O4Si+ [M+H]+:  381.2456, found 381.2450. sf272 
 
6-Ethyl-2,2,5-trimethyl-4H-1,3-dioxin-4-one (3.40):306 To a 500 mL round bottom 
flask charged with flame dried potassium carbonate (114 g, 882 mmol, 
4.0 eq.) and THF (250 mL) was added methyl 3-oxovalerate (26.5 mL, 
206 mmol, 1.0 eq.). The mixture was stirred vigorously for 10 min after 
which methyl iodide (14.1 mL, 226 mmol, 1.10 eq.) was added slowly and the mixture 
was heated to reflux for 15 h, after which 1H NMR indicated complete consumption of 
the starting material (additional methyl iodide was added and refluxing was continued in 
case of incomplete transformation). The mixture was allowed to warm to r.t., filtered 
over a plug of diatomaceous earth and washed with Et2O (150 mL) to give after removal 
of solvent methyl 2-methyl-3-oxopentanoate (22.1 g, 206 mmol, quant.), which was 
used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ = 3.72 
(s, 3H), 3.53 (q, J = 7.2 Hz, 1H), 2.69 – 2.42 (m, 2H), 1.33 (d, J = 7.2 Hz, 3H), 1.06 (t, J 
= 7.2 Hz, 3H). sf318 
To a 0 °C cold solution of methyl 2-methyl-3-oxopentanoate (2.50 g, 16.5 mmol, 1.0 
eq.) in MeOH/H2O (16.5 mL, 1:1 v/v) was added KOH (1.09 g, 16.5 mmol, 1.0 eq.) in 
one portion. After stirring for 1 h at r.t. TLC indicated complete consumption of the 
starting material, the reaction was adjusted to pH 7–8 with saturated aqueous NH4Cl (20 
mL) and then to pH 1 by careful addition of aqueous HCl (1 M) – excess HCl causes 
decarboxylation! The aqueous layer was extracted with Et2O (5 x 20 mL), dried over 
sodium sulfate and filtered. The solvent was removed carefully on the rotavap (20 °C 
water bath temperature) to give the product 2-methyl-3-oxopentanoic acid (2.19 g, 16.8 
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mmol, quant.) as a colorless oil, which was used without further purification in the next 
step. Care must be taken to remove all methanol and water from the crude material, as 
the subsequent dioxinone formation reaction is sensitive to residual solvent. However, 
prolonged drying on the rotavap under vacuum causes decarboxylation. 1H NMR (400 
MHz, CDCl3) δ = 12.52 (s, 1H), 3.56 (q, J = 7.2 Hz, 1H), 2.74 – 2.51 (m, 2H), 1.37 (dd, 
J = 6.4, 0.8 Hz, 3H), 1.09 (t, J = 7.2 Hz, 3H). sf319 
To a 0 °C cold solution of 2-methyl-3-oxopentanoic acid (15.0 g, 116 mmol, 1.0 eq.) in 
dry acetone (39 mL) was added acetic anhydride (21.6 mL, 231 mmol, 2.0 eq., freshly 
filtered over basic aluminum oxide) and sulfuric acid (1.54 mL, 28.8 mmol, 0.25 eq.) 
after 30 min, the yellow solution was allowed to warm to r.t. and stirred overnight, after 
which TLC indicated complete consumption of the starting material. The formed dark 
red suspension was poured carefully on saturated aqueous bicarbonate (200 mL) and 
extracted with Et2O (200 mL). The organic layer was extracted with saturated aqueous 
bicarbonate (200 mL), and the combined aqueous layers were extracted with Et2O (2 x 
200 mL). Drying over sodium sulfate and filtration gave a crude yellow oil, which was 
distilled to afford the title compound 3.40 (12.7 g, 74.8 mmol, 65%) as a colorless oil. 
Distillation can be reapplied if required. All analytical data were in full agreement with 
the reported literature values. B.p. 54 °C (0.01 mbar). 1H NMR (400 MHz, CDCl3) δ = 
2.29 (q, J = 7.6 Hz, 2H), 1.82 (s, 3H), 1.64 (s, 6H), 1.11 (t, J = 7.6 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 166.91, 163.13, 104.77, 99.64, 25.19, 24.42, 10.43, 9.99. sf323 
 
Diethyl (1-(2,2,5-trimethyl-4-oxo-4H-1,3-dioxin-6-yl)ethyl)phosphonate (3.44): The 
compound was prepared in analogy to a literature procedure.307 
To a -70 °C cold solution of LDA (840 mL, 1.67 mmol, 1.50 eq., 
2.0 M in THF) was cannulated a -70 °C solution of dioxinone 3.40 
(200 mg, 1.12 mmol, 1.0 eq.) in THF (1.1 mL) and the resulting orange mixture was 
stirred for 20 min at -25 °C before being cooled to -70 °C. Diethyl chlorophosphite (340 
mL, 2.20 mmol, 2.0 eq.) was added drop wise and after 20 min of stirring, the yellow 
solution was stirred at r.t. for 20 min, upon which a suspension had formed. DCM (3.5 
mL) and hydrogen peroxide (4.0 mL, 30% aqueous solution) were added subsequently 
and the biphasic mixture was stirred vigorously for 30 min. The mixture was poured on 
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brine (10 mL) and the aqueous layer was extracted with DCM (3 x 10 mL). Drying over 
sodium sulfate, filtration and removal of solvent gave a crude yellow oil, which was 
purified by flash chromatography (SiO2, EtOAc) to give the phosphonate 3.44 as a 
colorless oil (107 mg, 349 mmol, 31%). Rf = 0.35 (SiO2, EtOAc). FTIR (neat): 3479 
(br), 2985, 2927, 1721, 1640, 1357, 1240, 1155, 1019, 920, 666 cm-1. 1H NMR (400 
MHz, CDCl3) δ = 4.22 – 4.07 (m, 4H), 3.19 (dq, J = 22.9, 7.2 Hz, 1H), 1.86 (d, J = 3.4 
Hz, 3H), 1.66 (d, J = 5.5 Hz, 6H), 1.40 (dd, J = 18.2, 7.2 Hz, 3H), 1.32 (td, J = 7.1, 0.5 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 162.55 (d, J = 2.3 Hz), 161.01 (d, J = 10.6 
Hz), 105.25 (s), 102.55 (d, J = 9.5 Hz), 62.55 (d, J = 7.1 Hz), 62.44 (d, J = 6.9 Hz), 
35.42 (s), 34.04 (s), 25.68 (s), 24.23 (s), 16.48 (d, J = 5.9 Hz), 11.16 (d, J = 5.8 Hz), 
10.35 (d, J = 1.5 Hz). HRMS ESI calc. for C13H24OP+ [M+H]+: 307.1305, found 
307.1306. sf332 
 
2,2,5-Trimethyl-5-propionyl-1,3-dioxane-4,6-dione (S10): The compound was 
prepared in analogy to a literature procedure.308 To a -70 °C cold solution 
of methyl Meldrum’s acid (330 mg, 2.09 mmol, 1.0 eq.) in DCM (4.0 mL) 
was added pyridine (340 mL, 4.20 mmol, 2.0 eq.) and drop wise 
propionyl chloride (220 mL, 2.20 mmol, 2.0 eq.). After 10 min, the 
solution was warmed to r.t. and stirred for 2 h, upon which 1H NMR indicated complete 
consumption of the starting material. The orange suspension was diluted with DCM (5 
mL), poured on aqueous HCl (10 mL, 2 M) and the aqueous layer was extracted with 
DCM (2 x 10 mL). The unified organic layers were dried over sodium sulfate, filtered 
and the solvents removed in vacuo. The obtained crude yellow oil was purified by flash 
chromatography (SiO2, pentane/Et2O 1:1) to give the title compound S10 as a colorless 
crystalline solid (346 mg, 1.62 mmol, 77%). Rf = 0.45 (SiO2, pentane/Et2O 1:1). FTIR 
(neat): 2948, 1748, 1736, 1717, 1380, 1298, 1204, 1101, 1071, 972, 883 cm-1. 1H NMR 
(400 MHz, CDCl3) δ = 2.71 (q, J = 7.1 Hz, 1H), 1.87 (s, 1H), 1.75 (d, J = 4.9 Hz, 2H), 
1.18 (t, J = 7.4 Hz, 1H), 1.10 (t, J = 7.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 
199.58, 165.23, 106.30, 100.14, 31.84, 29.44, 28.38, 20.61, 8.0. HRMS ESI calc. for 
C10H14NaO5+ [M+Na]+: 237.0733, found 237.0732. sf303  
                                                
 
308 E. Bourcet, F. Fache, O. Piva, Tetrahedron 2010, 66, 1319. 
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N-methoxy-N-methylmethacrylamide (S11): The compound was prepared according 
to a literature procedure.309 To a -20 °C cold solution of N,O-
dimethylhydroxylamine hydrochloride (1.94 g, 20.0 mmol, 1.0 eq.) in 
dry DCM (40 mL) was slowly added pyridine (4.0 mL, 50.0 mmol, 2.50 
eq.) and the mixture was stirred for 20 min. Methacryloyl chloride (2.10 mL, 20.0 
mmol, 1.0 eq.) was then added drop wise to the suspension and the reaction was allowed 
to warm to r.t.. After 2 h of stirring, 1H NMR indicated complete consumption of the 
starting material. The solvent was removed and the residue dissolved in Et2O/DCM (30 
mL, 1:1 v/v), washed with HCl (2 x 20 mL, 1 M) and saturated aqueous sodium 
carbonate solution (2 x 20 mL) and the organic layer was dried over sodium sulfate and 
filtered. Removal of solvents and drying under high vacuum gave the Weinreb amide 
S11 as a colorless oil (2.38 g, 18.4 mmol, 93%), which was used without further 
purification. All analytical data were in full agreement with the reported literature 
values. 1H NMR (400 MHz, CDCl3) δ = 5.30 (dd, J = 3.1, 2.0 Hz, 1H), 5.25 – 5.21 (m, 
1H), 3.65 (s, 3H), 3.23 (s, 3H), 1.98 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 171.69, 
140.34, 117.50, 61.35, 33.45, 20.04. sf347  
 
2-Methyl-1-morpholinoprop-2-en-1-one (S12): To a -20 °C cold solution of 
morpholine (6.10 mL, 70.0 mmol, 3.50 eq.) in dry DCM (40 mL) was 
slowly added methacryloyl chloride (2.10 mL, 20.0 mmol, 1.0 eq.) and 
the reaction was allowed to warm to r.t. After 1 h of stirring, 1H NMR 
indicated complete consumption of the starting material. The solvent was removed and 
the residue dissolved in Et2O/DCM (30 mL, 1:1 v/v), washed with aqueous HCl (2 x 20 
mL, 1 M) and saturated aqueous sodium carbonate solution (2 x 20 mL, and the organics 
dried over sodium sulfate and filtered. Removal of solvents and drying under high 
vacuum gave the Weinreb amide S12 as a colorless oil (2.83 g, 19.9 mmol, 96%), which 
was used without further purification. FTIR (neat): 2854, 1619, 1431, 1267, 1194, 1113, 
1035, 916, 630 cm-1.1H NMR (400 MHz, CDCl3) δ =5.23-5.20 (m, 1H), 5.05-5.02 (m, 
1H), 3.76-3.50 (m, 8H), 1.98-1.93 (m, 3H). 13C NMR (101 MHz, CDCl3) δ = 171.34, 
140.15, 115.93, 67.07, 20.59. HRMS ESI calc. for C8H13NaO2+ [M+Na]+: 178.0838, 
found 178.0839. sf348  
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(E)-3-bromo-N-methoxy-N,2-dimethylacrylamide (3.58): To a 0 °C cold solution of 
Weinreb amide S11 (2.36 g, 18.3 mmol, 1.0 eq.) in DCM (5 mL) was 
added drop wise a solution of bromine (950 mL, 18.0 mmol, 1.0 eq.) 
in DCM (5 mL) and the resulting orange solution was stirred at r.t. 
for 4 h, after which 1H NMR indicated complete consumption of the starting material. 
The mixture was cooled to 0 °C and DBU (4.10 mL, 27.0 mmol, 1.50 eq.) was added 
drop wise and the resulting dark solution was stirred at r.t. for 15 h, after which TLC 
indicated complete consumption of the intermediate dibromo species. The dark brown 
mixture was poured on saturated aqueous sodium thiosulfate solution (10 mL), the 
organic layer was washed with aqueous HCl (30 mL, 1 M), and the aqueous layers were 
extracted with DCM (30 mL). Drying over sodium sulfate and removal of solvents gave 
a brown oil, which appeared pure in 1H NMR, but not in TLC. It was therefore purified 
by flash chromatography (SiO2, pentane/Et2O 1:4) to give the title compound 3.58 as a 
colorless oil (2.20 g, 10.6 mmol, 58%). Rf = 0.35 (SiO2, pentane/Et2O 1:4). FTIR (neat): 
2936, 1643, 1370, 1278, 1160, 1027, 821, 715, 684 cm-1. 1H NMR (400 MHz, CDCl3) δ 
= 6.71 (q, J = 1.3 Hz, 1H), 3.63 (s, 3H), 3.23 (s, 3H), 2.02 (d, J = 1.4 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 168.91, 137.10, 113.01, 61.51, 33.45, 17.69. HRMS ESI calc. 
for C6H11BrNO2+ [M+H]+: 207.9968, found 207.9968. sf349 
 
(E)-3-bromo-2-methyl-1-morpholinoprop-2-en-1-one (3.59): To a 0 °C cold solution 
of morpholineamide S12 (2.36 g, 18.3 mmol, 1.0 eq.) in DCM (5 
mL) was added drop wise a solution of bromine (950 mL, 18.0 
mmol, 1.0 eq.) in DCM (5 mL) and the resulting orange solution 
was stirred at r.t. for 4h, after which 1H NMR indicated complete consumption of the 
starting material. The mixture was cooled to 0 °C and DBU (4.1 mL, 27 mmol, 1.5 eq.) 
was added drop wise and the resulting dark solution was stirred at r.t. for 15 h, after 
which TLC indicated complete consumption of the intermediate dibromo species. The 
dark brown mixture was washed with aqueous HCl (30 mL, 1 M), and the aqueous layer 
was extracted with DCM (20 mL). Drying over sodium sulfate and removal of solvents 
gave a brown oil, which was purified by flash chromatography (SiO2, Et2O) to give the 
title compound 3.59 as a colorless oil (1.21 g, 5.17 mmol, 28%). Rf = 0.40 (SiO2, Et2O). 
FTIR (neat): 2855, 1629, 1428, 1288, 1240, 1113, 1031, 843, 686, 632 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ = 6.37 (q, J = 1.5 Hz, 1H), 3.71 – 3.62 (m, 5H), 3.60 – 3.43 (m, 
4H), 1.99 (d, J = 3.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ =168.68, 137.30, 110.12, 
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66.93, 18.12. HRMS ESI calc. for C8H13BrNO2+ [M+H]+: 234.0125, found 234.0124. 
sf350 
 
tert-Butyl 3-hydroxy-2,4-dimethylpent-4-enoate (S13): The compound was prepared 
in analogy to a literature procedure.310 To a 0 °C cold solution of 
diisopropyl amine (5.09 mL, 36.0 mmol, 1.20 eq.) in THF (20 mL) 
was added drop wise a solution of n-BuLi (21.1  mL, 36.0 mmol, 
1.20 eq., 1.6 M in hexane) and the resulting solution was stirred at 0 °C for 30 min, after 
which the solution was cooled to -70 °C. A solution of tert-butyl propionate (4.62 mL, 
30.0 mmol, 1.0 eq.) in THF (30 mL) was added via a dropping funnel within 10 min and 
the resulting solution was stirred for 50 min, after which neat acrolein (3.72 mL, 45.0 
mmol, 1.50 eq.) was added drop wise. The resulting solution was stirred for 20 min, 
quenched by addition of saturated aqueous NH4Cl (80 mL) and separated between water 
(40 mL) and Et2O (100 mL). The aqueous layer was extracted with Et2O (3 x 120 mL) 
and the combined organic layers were dried over sodium sulfate, filtered and the 
solvents removed. Flash chromatography (SiO2, pentane/Et2O 8:1) afforded the title 
compound S13 as a colorless oil (5.2 g, 25 mol, 82%) in a 1:1 mixture of 
diastereoisomers. Analytical data were in full agreement with the literature values. Rf = 
0.30 (SiO2, pentane/Et2O 8:1).  1H NMR (400 MHz, CDCl3) δ = 4.96 (dddd, J = 19.2, 
11.6, 6.0, 4.6 Hz, 1H), 4.34 (d, J = 4.1 Hz, 0.5H), 4.08 (d, J = 7.6 Hz, 0.5H), 2.86 (br s, 
0.5H), 2.70 (gr s, 0.5H), 2.63 – 2.50 (m, 1H), 1.75 – 1.69 (m, 3H), 1.49 – 1.44 (m, 9H), 
1.10 (dd, J = 7.2, 1.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 175.49, 144.76, 113.63, 
43.74, 28.22, 19.08, 17.43, 14.71, 10.71. sf358 
 
2,2,5-trimethyl-6-(prop-1-en-2-yl)-4H-1,3-dioxin-4-one (3.52):310 To a solution of 
allylic alcohol S13 (5.08 g, 24.1 mmol, 1.0 eq.) in DMSO (40 mL) was 
added IBX (8.50 g, 31.3 mmol,, 1.30 eq.) and the resulting suspension 
was stirred at r.t. overnight, after which TLC indicated complete 
consumption of the starting material. The residue was filtered off and the filtrate was 
diluted with Et2O (400 mL) and washed with water (4x100 mL). The organic layer was 
dried over sodium sulfate, filtered and removal of solvent gave tert-butyl 2,4-dimethyl-
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3-oxopent-4-enoate (4.69 g, 23.7 mmol, 98%) as a colorless oil, which was used without 
further purification in the next step. All analytical data were in full agreement with the 
literature values. Rf = 0.45 (SiO2, pentane/Et2O 8:1). 1H NMR (400 MHz, CDCl3) δ = 
5.98 (s, 1H), 5.82 (q, J = 1.3 Hz, 1H), 4.0 (q, J = 7.0 Hz, 1H), 1.90 (d, J = 0.7 Hz, 3H), 
1.41 (s, 9H), 1.33 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 197.74, 170.46, 
144.16, 125.18, 81.62, 77.48, 77.36, 77.16, 76.84, 48.64, 27.96, 18.08, 13.71. sf368  
To a 0 °C cold solution of the ester 3.56 (1.0 g, 4.8 mmol, 1.0 eq.) in dry Acetone (1.8 
mL, 24 mmol, 5.0 eq.) was added trifluoroacetic anhydride (3.3 mL, 24 mmol, 5.0 eq.) 
and after 15 min of stirring trifluoroacetic acid (1.8 mL, 24 mmol, 5.0 eq.) was added. 
The solution was stirred at r.t. for 2 h after which TLC indicated incomplete 
transformation. Argon was bubbled through the reaction mixture for 20 min, which 
pushed the reaction to completion. The orange reaction mixture was diluted with Et2O 
(70 mL) and washed with saturated aqueous bicarbonate solution (3 x 30 mL). The 
organic layer was dried over sodium sulfate, filtered and the solvents removed in vacuo 
to give the title compound 3.52 (959 mg, 4.79 mmol, 98%, 91% pure in Et2O) as an 
orange oil which was used without further purification. Rf = 0.30 (SiO2, pentane/Et2O 
4:1). FTIR (neat):  2998, 2942, 1724, 1630, 1358, 1284, 1205, 1148, 968, 919, 633 cm
-
1. 1H NMR (400 MHz, CDCl3) δ = 5.44 (dd, J = 3.0, 1.5 Hz, 1H), 5.28 (d, J = 0.9 Hz, 
1H), 1.91 (s, 3H), 1.90 – 1.89 (m, 3H), 1.67 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 
=163.55, 162.47, 136.91, 121.64, 104.91, 100.98, 25.0, 19.96, 11.71. HRMS ESI calc. 
for C10H15O3+ [M+H]+: 183.1016, found 183.1018. sf370 
 
(E)-1-bromo-2-methylocta-1,7-dien-3-one (3.60): To a suspension of flame dried 
magnesium turnings (43 mg, 1.8 mmol, 3.7 eq.) in dry THF (1 
mL) was added a solution of 5-Bromo-1-pentene (200 mL, 1.7 
mmol, 3.5 eq.) in dry THF (1.5 mL). The solution became warm 
and turbid, and after it had reached r.t. again (ca. 30 min), it was cannulated to a -70 °C 
cold solution of the Weinreb amide 3.58 (100 mg, 184 mmol, 1.0 eq.) in dry THF (0.5 
mL). The solution was stirred for 10 min and then warmed to -30 °C, upon which TLC 
indicated formation of product. The greenish solution was stirred for 1 h and was then 
quenched by addition of saturated aqueous NH4Cl (4 mL). The layers were separated, 
the aqueous layer was extracted with Et2O (3 x 5 mL) and the unified organic layers 
were dried over sodium sulfate, filtered and concentrated in vacuo. Flash 
chromatography (SiO2, pentane/Et2O 50:1) afforded the title compound 3.60 as a 
O
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colorless oil (30.0 mg, 138 mmol, 29%). Rf = 0.40 (SiO2, pentane/Et2O 50:1). FTIR 
(neat):  = 2933, 1677, 1601, 1369, 1290, 1185, 1043, 913, 729, 660 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ = 7.47 (q, J = 1.3 Hz, 1H), 5.77 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 
5.08 – 4.96 (m, 2H), 2.68 – 2.60 (m, 2H), 2.08 (q, J = 7.1 Hz, 3H), 1.73 (p, J = 7.4 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ = 197.86, 143.06, 137.98, 123.53, 115.58, 37.39, 
33.18, 23.46, 15.27. HRMS ESI calc. for C9H13BrNaO+ [M+Na]+: 239.042, found 
239.041. sf376 sf372 
 
(E)-3-bromo-2-methylacrylaldehyde (3.64):311 To a 0 °C cold solution of methyl 
methacrylate (21.3 mL, 200 mmol, 1.0 eq.) in DCM (40 mL, 5M) was 
slowly added a solution of bromine (10.4 mL, 200 mmol, 1.0 eq.) in 
DCM (20 mL, 10 M) via a dropping funnel. After stirring at r.t. for 4 h, 
DBU (54 ml 300 mmol, 1.50 eq.) was added via a dropping funnel, upon which the 
solution turned from brown orange to bright yellow. The mixture was stirred overnight, 
poured on aqueous HCl (200 mL 1 M) and the separated aqueous layer was extracted 
with Et2O (3 x 70 mL) The unified organic layers were dried over sodium sulfate and 
concentrated in vacuo to yield pure (E)-methyl 3-bromo-2-methylacrylate (32.5 g, 198 
mmol, 99%),  which was used without further purification in the next step. All analytical 
data were in full agreement with the literature. 1H NMR (400 MHz, CDCl3) δ =7.52 (q, 
J = 1.4 Hz, 1H), 3.76 (s, 3H), 2.0 (d, J = 1.5 Hz, 3H).  
To a 0 °C cold stirred suspension of LiAlH4 (7.14 g, 198 mmol, 1.0 eq.) in dry Et2O 
(300 mL, 0.6 M) was added drop wise a solution of (E)-methyl 3-bromo-2-
methylacrylate (32.5 g, 198 mmol, 1.0 eq.) in dry Et2O (100 mL, 1.9M) via a dropping 
funnel. The mixture was stirred at r.t. for 1h, after which TLC indicated complete 
consumption of the starting material. MeOH (12 mL) was added drop wise (!) until 
bubbling ceased, then water (8 mL) was added followed by aqueous NaOH (8 mL, 4 M) 
and finally water (25 mL). The mixture was stirred until a white precipitate had formed, 
which was filtered off. Removal of the solvent under rotary evaporation at 500 mbar and 
40 °C gave the (E)-3-bromo-2-methylprop-2-en-1-ol (37.3 g, 160 mmol, 85%) as a 64% 
w/w solution in Et2O, which was used without further purification in the next step. The 
compound was stored preferably at this stage, as the corresponding aldehyde 
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decomposes. All analytical data were in full agreement with the literature. 1H NMR 
(400 MHz, CDCl3) δ = 6.26 – 6.23 (m, 1H), 4.09 (s, 2H), 1.82 (d, J = 0.5 Hz, 3H). 
To a solution of (E)-3-bromo-2-methylprop-2-en-1-ol (2.52 g, 60% w/w in Et2O, 10.0 
mmol, 1.0 eq.) in DCM (30 mL) was added activated MnO2 (9.56 g, 110 mmol, 11.0 eq., 
oven-dried at 120 °C) and the black suspension was stirred at r.t. After 18 h TLC 
indicated incomplete conversion and MnO2 (4.0 eq.) was added. After 36 h TLC 
indicated complete conversion and the suspension was filtered over diatomaceous earth 
and concentrated by rotary evaporation (630 mbar, 40 °C) to give the title compound 
3.64 (7.5 g, 20% w/w in DCM, 10.0 mmol, quant.). The compound partially decomposes 
within 2–3 weeks at 5 °C, and even faster when stored neat. A colorless precipitate and 
browning of the solution is then observed, but a filtration can yield again sufficiently 
pure aldehyde for the Grignard reaction according to 1H NMR. For Grignard reactions, 
the DCM was removed prior to the reaction by rotary evaporation (200 mbar, 40 °C). 
All analytical data were in full agreement with the literature. 1H NMR (400 MHz, 
CDCl3) δ = 9.49 (s, 1H), 7.44 (dd, J = 2.6, 1.3 Hz, 1H), 1.90 (d, J = 1.3 Hz, 3H). 
 
(E)-1-bromo-2-methylocta-1,7-dien-3-ol (S14): To a suspension of flame dried 
magnesium turnings (147 mg, 6.04 mmol, 2.2 eq.) in dry THF 
(4.0 mL) was added a solution of 5-bromo-1-pentene (0.65 mL, 
5.5 mmol, 2.0 eq.) in dry THF (2.0 mL). The solution became 
warm and turbid, and after it had reached r.t. again (ca. 30 min), it was cannulated to a -
70 °C cold solution of the aldehyde 3.64 (409 mg, 2.75 mmol, 1.0 eq.) in dry THF (4.0 
mL). The grey suspension was stirred for 30 min and then stirred at r.t. for 20 min, upon 
which TLC indicated complete consumption of the aldehyde. The greenish solution was 
then quenched by addition of saturated aqueous NH4Cl (10 mL). The layers were 
separated, the aqueous layer was extracted with Et2O (3 x 10 mL) and the unified 
organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. Flash 
chromatography (SiO2, pentane/Et2O 4:1) afforded the title compound S14 as a colorless 
oil (433 mg, 1.98 mmol, 72%). Rf = 0.25 (SiO2, pentane/Et2O 4:1). FTIR (neat): 2862, 
1639, 1290, 996, 911, 632 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.23 (dt, J = 2.1, 1.2 
Hz, 1H), 5.79 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.05 – 4.94 (m, 2H), 4.13 (td, J = 6.5, 
2.8 Hz, 1H), 2.08 (q, J = 7.2 Hz, 2H), 1.78 (d, J = 0.9 Hz, 3H), 1.62 – 1.54 (m, 4H), 1.52 
– 1.42 (m, 1H), 1.41 – 1.30 (m, 1H). 13C NMR (101 MHz, CDCl3) δ = 144.07, 138.48, 
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115.07, 104.75, 76.15, 34.37, 33.60, 24.90, 14.93. HRMS ESI calc. for C9H15BrNaO+ 
[M+Na]+: 241.0198, found 241.0200. sf381 sf384 
 
(E)-1-bromo-3-methoxy-2-methylocta-1,7-diene (3.53): To a 0 °C solution of the 
alcohol S14 (342 mg, 1.48 mmol, 1.0 eq.) in dry THF (5.0 mL) 
was added NaH (297 mg, 7.41 mmol, 5.0 eq., 60% dispersion in 
mineral oil) and after 2 min methyl iodide (0.55 mL, 8.9 mmol, 
6.0 eq.). After 10 min, the solution was stirred at r.t. for 20 min, after which TLC 
indicated complete consumption of the starting material. The reaction was quenched by 
addition of saturated aqueous NH4Cl (9 mL) and was then diluted with water (10 mL) 
and Et2O (20 mL). The layers were separated, the aqueous layer was extracted with Et2O 
(3 x 15 mL) and the unified organic layers were dried over sodium sulfate, filtered and 
concentrated in vacuo. The residual mineral oil was removed by filtration with pentane 
over a silica plug and washing off the title compound 3.53 with pentane/Et2O (4:1) to 
give a colorless oil (350 mg, 1.50 mmol, 100%). The compound could not be ionized by 
our available LCMS ESI or HRMS ESI methods. Rf = 0.20 (SiO2, pentane). FTIR 
(neat): 2942, 1640, 1459, 1285, 1099, 911, 717, 607 cm
-1. 1H NMR (400 MHz, CDCl3) 
δ = 6.15 (dd, J = 1.2, 0.5 Hz, 1H), 5.78 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.04 – 4.93 (m, 
2H), 3.57 – 3.51 (m, 1H), 3.20 (d, J = 3.6 Hz, 3H), 2.05 (q, J = 7.1 Hz, 2H), 1.70 (d, J = 
1.3 Hz, 3H), 1.68 – 1.57 (m, 2H), 1.54 – 1.38 (m, 2H), 1.36 – 1.25 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ = 141.89, 138.59, 114.94, 105.0, 85.44, 77.48, 77.36, 77.16, 76.84, 
56.44, 33.67, 33.13, 25.08, 14.05. sf385 sf387 
 
2-(triphenylphosphoranylidene)propanal (S15):312 A 20 mL microwave vial with a 
stirring bar was charged with triphenyl phosphine (7.8 g, 30 mmol, 1.0 
eq.) and iodoethane (2.4 mL, 30 mmol, 1.0 eq.), sealed and heated to 
150 °C for 4h in a microwave reactor. Precipitation from pentane/Et2O 
(1:1 v/v) gave ethyltriphenylphosphonium iodide (13 g, 30 mmol, 
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OMe
Br
P
O H
Experimental Part 
137 
99%) as a colorless solid. All analytical data were in full agreement with the literature. 
1H NMR (400 MHz, CDCl3) δ =  7.86 – 7.76 (m, 9H), 7.75 – 7.67 (m, 6H), 3.77 (dq, J 
= 12.4, 7.5 Hz, 2H), 1.39 (dt, J = 20.0, 7.5 Hz, 3H).  
To a solution of ethyltriphenylphosphonium iodide (1.0 g, 2.39 mmol, 1.0 eq.) in dry 
THF (7.2 mL 0.3 M) was added n-BuLi (1.64 mL, 2.63 mmol, 1.1 eq., 1.6 M in hexane) 
at r.t. and a dark red solution formed, which was stirred for 30 min before being cooled 
to 0 °C in an ice bath. KOtBu (2.63 mL, 2.63 mmol, 1.1 eq. 1.0 M in THF) and neat 
ethyl formate (0.5 mL, 6.0 mmol, 2.5 eq.) were added in quick succession, and the dark 
brown solution was stirred at 0 °C for 15 min before being diluted with DCM (7 mL) 
and quenched by addition of aqueous HCl (3 mL, 1 M, 1.25 eq.). The pH  was adjusted 
to 7–8 with aqueous NaOH (2 M) when necessary. The biphasic mixture was stirred for 
30 min and the layers were separated. The aqueous layer was extracted with DCM (10 
mL) and the yellow organic layer was dried over sodium sulfate, filtered and the solvent 
removed to give the title compound S15 as an amorphous yellow sticky solid (737 mg, 
2.32 mmol, 97%) of sufficient purity for further reactions which was stored at -20 °C. 
All analytical data were in full agreement with the literature. 1H NMR (400 MHz, 
CDCl3) δ = 7.94 (d, J = 5.0 Hz, 1H), 7.70 – 7.52 (m, 15H), 1.87 (d, J = 13.5 Hz, 3H). 
sf420 sf518 
 
2-(3-bromopropyl)-1,3-dioxolane (3.69):313 To a -70 °C cold solution of ethyl-4-
bromobutyrate 3.68 (3.9 g, 20 mmol, 1.0 eq.) in DCM (40 mL) was 
added a solution of DIBAL-H (4.3 mL, 21 mmol, 1.05 eq., 1.1 M in 
cyclohexane) via transfer cannula. The solution was stirred for 1 h and the poured on ice 
cold aqueous HCl (60 m, 3M) and stirred vigorously for 1 h. The layers were separated 
and the aqueous layer was extracted with DCM (3 x 30 mL), dried over sodium sulfate, 
filtered and concentrated under reduced pressure (630 mbar, 40 °C). The obtained 
colorless oil (10 g) was used directly in the next step without further purification. 
To a solution of crude aldehyde (3.0 g, 20 mmol, 1.0 eq.) in toluene (60 mL) was added 
ethylene glycol (8.39 mL, 150 mmol, 7.50 eq.) and p-toluenesulfonic acid (152 mg, 800 
mmol, 4 mol%). The mixture was heated to reflux with a Dean-Stark trap attached 
overnight, after which 1H NMR indicated complete consumption of the aldehyde. The 
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mixture was quenched with NaHCO3 (800 mg), extracted with saturated aqueous  
NaHCO3 (40 mL), dried over sodium sulfate, filtered and the solvent removed in vacuo. 
The crude colorless oil (4.5 g) was purified by fractional distillation to yield the title 
compound 3.69 (1.93 g, 10.6 mmol, 51% over two steps) as a colorless oil. All 
analytical data were in full agreement with the literature. B.p.: 71 °C, 14 mbar. 1H NMR 
(400 MHz, CDCl3) δ = 4.90 (t, J = 4.5 Hz, 1H), 4.02 – 3.92 (m, 2H), 3.90 – 3.81 (m, 
2H), 3.46 (t, J = 6.8 Hz, 2H), 2.06 – 1.96 (m, 2H), 1.86 – 1.79 (m, 2H). sf411 
 
(E)-2-(6-bromo-4-methoxy-5-methylhex-5-en-1-yl)-1,3-dioxolane (S16): To a 
suspension of freshly ground and oven dried magnesium 
turnings (127 mg, 5.23 mmol, 1.70 eq.) in dry THF (2.5 mL) 
was added a solution of 2-(3-bromopropyl)-1,3-dioxolane 3.69 
(1.0 g, 4.6 mmol, 1.5 eq.) in THF (2.5 mL) in one portion. The mixture began to reflux 
quickly and the resulting grey suspension was stirred for 30 min, after which it was 
transferred via cannula to a 0 °C solution of aldehyde 3.64 (2.30 g of a 20% solution in 
DCM, 3.08 mmol, 1.0 eq.) in THF (3.0 mL). The yellow mixture was stirred for 1 h at 
r.t. before being quenched with saturated aqueous NH4Cl (8 mL), diluted with ether (10 
mL) and the separated aqueous layer was extracted with ether (3 x 10 mL). The unified 
organic layers were dried over sodium sulfate, filtered, and the solvents removed to give 
a colorless oil (950 mg), which was used without further purification in the next step. 
The neat oil decomposed at 5 °C within 12 h. 1H NMR (400 MHz, CDCl3) δ = 6.23 (s, 
1H), 4.85 (t, J = 4.7 Hz, 1H), 4.13 (t, J = 6.5 Hz, 1H), 4.01 – 3.93 (m, 2H), 3.92 – 3.81 
(m, 2H), 1.77 (d, J = 1.0 Hz, 3H), 1.74 – 1.58 (m, 6H). 
The crude alcohol (950 mg, 3.08 mmol, 1.00 eq.) was dissolved in dry THF (9.0 mL, 0.3 
M), cooled to 0 °C, and sodium hydride (370 mg, 9.24 mmol, 3.0 eq., 60% in mineral 
oil) was added. After stirring for 10 min, methyl iodide (0.80 mL, 12.3 mmol, 4.0 eq.) 
was added and stirring was continued for 10 min at 0 °C and 20 min at r.t.. The yellow 
mixture was carefully quenched with saturated aqueous NH4Cl (4 mL), diluted with 
ether (10 mL) and the separated aqueous layer was extracted with ether (3 x 10 mL). 
The unified organic layers were dried over sodium sulfate, filtered, and the solvents 
removed to give a colorless oil (950 mg). The mineral oil was washed off by filtration 
over a silica plug with pentane (50 mL) before the product was eluted with Et2O/pentane 
(1:1 v/v, 50 mL). Removal of solvents gave the methylated alcohol S16 (708 mg, 279 
mmol, 91%) as a colorless oil. Rf = 0.35 (SiO2, pentane/Et2O 4:1). 1H NMR (400 MHz, 
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CDCl3) δ = 6.14 (q, J = 2.4 Hz, 1H), 4.83 (t, J = 4.8 Hz, 1H), 4.03 – 3.90 (m, 2H), 3.90 
– 3.80 (m, 2H), 3.55 – 3.51 (m, 1H), 3.18 (s, 3H), 1.70 (d, J = 1.3 Hz, 3H), 1.65 – 1.33 
(m, 6H). 13C NMR (101 MHz, CDCl3) δ = 141.75, 105.12, 104.52, 85.41, 64.99, 56.44, 
33.75, 29.58, 24.10, 20.42, 14.04. 
 
(2E,8E)-9-bromo-7-methoxy-2,8-dimethylnona-2,8-dienal (S17): A 5 mL microwave 
reactor vial was charged with the dioxolane S16 (200 mg, 
612 mmol, 1.0 eq.) and p-TsOH•H2O (13.0 mg, 61.2 
mmol, 10 mol%) and suspended in a mixture of 
acetone/H2O (2.5 mL, 3:1 v/v). The suspension was heated to 100 °C for 40 min, diluted 
with Et2O (8 mL) and extracted with half saturated aqueous Na2CO3 (2 x 4 mL). Drying 
over sodium sulfate, filtration and evaporation gave the crude aldehyde S18 (180 mg, 
612 mmol, 80% w/w pure, 90%) together with unreacted starting material (20% w/w). 
Prolonged reaction time or higher amount of acid catalyst did not improve the 
conversion. The compounds were inseparable by flash chromatography. The crude 
mixture was used without further purification in the next step. Rf = 0.40 (SiO2, 
pentane/Et2O 4 :1) 1H NMR (400 MHz, CDCl3) δ =  9.76 (t, J = 1.5 Hz, 1H), 6.17 (s, 
1H), 3.55 (t, J = 6.3 Hz, 1H), 3.19 (s, 3H), 2.45 (dt, J = 6.9, 3.5 Hz, 2H), 1.71 (d, J = 1.2 
Hz, 3H), 1.68 – 1.61 (m, 4H). Sf422 
The crude aldehyde S18 (400 mg, 75% pure, 1.28 mmol, 1.00 eq.) was dissolved in a 
dry mixture of toluene/DCM (2:1 v/v, 0.2 M final conc.) and the flask equipped with a 
reflux condenser. Phosphorane S15 (450 mg, 1.28 mmol, 1.00 eq.) was added and the 
mixture was stirred in a sand bath at 65 °C for 24 h, upon which 1H NMR indicated a 
ratio product/starting material of ca. 4:5 in the crude brown mixture. Phosphorane S15 
(450 mg, 1.28 mmol, 1.00 eq.) was added and stirring for another 24 h provided a 
mixture of ca. 2:1 product/starting material as determined by 1H NMR (further addition 
of phosphorane and prolonged stirring does not increase the ratio and byproduct 
formation was observed). The solvents were removed and the crude brown oil was 
purified by flash chromatography (SiO2, pentane/Et2O 4:1) to provide the unsaturated 
aldehyde S17 (252 mg, 70% pure w/w, 640 mmol, 50%, E/Z >20:1) with ca. 30% w/w 
of unreacted dioxolane S16 as an impurity. Rf = 0.30 (SiO2, pentane/Et2O 4:1). FTIR 
(neat): 2932, 2865, 1686, 1450, 1285, 1097, 715 cm-1. 1H NMR (400 MHz, CDCl3) δ = 
9.39 (s, 1H), 6.46 (td, J = 7.4, 1.3 Hz, 1H), 6.17 (d, J = 0.8 Hz, 1H), 3.55 (dd, J = 7.2, 
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5.6 Hz, 1H), 3.19 (s, 3H), 2.36 (q, J = 7.2 Hz, 2H), 1.74 (d, J = 0.9 Hz, 3H), 1.71 (t, J = 
1.6 Hz, 4H), 1.68 – 1.42 (m, 4H). 13C NMR (101 MHz, CDCl3) δ = 195.35, 154.07, 
141.61, 139.81, 105.30, 85.20, 56.48, 33.40, 28.87, 24.76, 14.09, 9.38. HRMS ESI calc. 
for C12H19BrNaO2+ [M+Na]+: 297.0461, found 297.0459. sf423 sf426  
 
(4E,10E)-methyl 11-bromo-3-hydroxy-9-methoxy-2,4,10-trimethylundeca-4,10-
dienoate 3.71: To a 0 °C cold solution of diisopropyl amine (120 mg, 1.19 mmol, 1.80 
eq.) in THF (1.0 mL) was added drop wise a 
solution of n-BuLi (703 mL, 1.12 mmol, 1.70 eq., 
1.6 M in hexanes) and the mixture was stirred for 20 
min before being cooled to -70 °C. A solution of methyl propionate (87 mg, 99 mmol, 
1.5 eq.) in THF (1.0 mL) was added to the LDA solution via transfer cannula, and  the 
mixture was stirred for 30 min at -70 °C before a solution of the aldehyde S17 (260 mg, 
661 mmol, 1.00 eq., 70% w/w pure) in THF (1.0 mL) was added slowly drop wise. The 
yellow mixture was stirred for 40 min before saturated aqueous NH4Cl (3 mL) was 
added, diluted with Et2O (5 mL) and the aqueous layer was extracted with Et2O (2 x 5 
mL). The unified organic layers were dried over sodium sulfate, filtered, and the 
solvents removed to give a yellow oil (330 mg). The crude oil was purified by flash 
chromatography (SiO2, pentane/Et2O 3:2) to provide the b-hydroxy ester 3.71 (180 mg, 
470 mmol, 71%) as a mixture of partially separable diastereomers (ca. 2:1). Analytical 
data is given for the major diastereomer. Rf = 0.20 (SiO2, pentane/Et2O 3:2). FTIR 
(neat): 3459 (br), 2938, 1737, 1454, 1346, 1251, 1163, 1049, 1026, 798, 714 cm
-1. 1H 
NMR (400 MHz, CDCl3) δ = 6.13 (q, J = 1.2 Hz, 1H), 5.40 (t, J = 7.1 Hz, 1H), 4.06 (d, 
J = 9.0 Hz, 1H), 3.70 (s, 3H), 3.52 (t, J = 6.7 Hz, 1H), 3.17 (s, 3H), 2.68 – 2.60 (m, 1H), 
2.03 (q, J = 7.3 Hz, 2H), 1.68 (d, J = 1.2 Hz, 3H), 1.58 (d, J = 0.6 Hz, 3H), 1.50 – 1.35 
(m, 3H), 1.32 – 1.22 (m, 2H), 1.01 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
= 176.50, 141.64, 134.46, 129.27,  104.92, 85.21, 79.93, 56.20, 51.79, 43.06, 33.18, 
27.25, 25.45, 14.32, 13.74. HRMS ESI calc. for C16H27BrNaO4+ [M+Na]+: 385.0985, 
found 385.0985. sf427 sf428  
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(4-bromobutoxy)triethylsilane (3.75):314 A dry 50 mL round bottom flask under an 
argon atmosphere equipped with a reflux condenser was charged 
with triethylsilane (5.34 mL, 33.5 mmol, 1.0 eq.), THF (4.22 
mL, 51.5 mmol, 1.54 eq.) and freshly distilled allyl bromide 
(7.57 mL, 87.0 mmol, 2.60 eq.) in this order. To the stirred mixture was added 
palladium(II) chloride (102 mg, 569 mmol, 1.7 mol%). The palladium(II) chloride must 
(!) be added last or rapid decomposition and boiling of the solution ensues! The solution 
began to reflux and was maintained at 70 °C for 18h, after which the volatiles were 
removed by rotary evaporation. Fractional distillation gave the title compound 3.75 as a 
colorless oil (6.69 g, 25.4 mmol, 76%). In some cases redistillation of some fractions 
had to be conducted. All analytical data were in full agreement with the literature. B.p.: 
79 °C, 1.4 mbar. 1H NMR (400 MHz, CDCl3) δ = 3.64 (t, J = 6.2 Hz, 2H), 3.45 (t, J = 
6.8 Hz, 2H), 1.99 – 1.90 (m, 2H), 1.71 – 1.62 (m, 2H), 0.96 (t, J = 7.9 Hz, 9H), 0.59 (q, 
J = 7.9 Hz, 6H). 
 
(E)-1-bromo-2-methyl-7-((triethylsilyl)oxy)hept-1-en-3-ol (S19): To a suspension of 
freshly ground oven dried magnesium turnings (157 mg, 
6.47 mmol, 1.7 eq.) in dry THF (3.5 mL) in a round 
bottom flask equipped with a small reflux condenser was 
added a solution of alkyl bromide 3.75 (1.60 g, 5.71 mmol, 1.50 eq.) in dry THF (3.5 
mL). The suspension started to reflux and turned greyish-black after 15 min and was 
stirred at r.t. for 40 min total, after which no more dissolving of magnesium and 
warming was observed. This Grignard solution (ca. 1 M) was transferred via cannula to 
a 0 °C cold solution of aldehyde 3.64 (567 mg, 3.81 mmol, 1.00 eq.) in THF (8 mL, 0.5 
M), upon which the mixture turned dark yellow. The mixture was stirred for 2 h at r.t., 
after which 1H NMR indicated complete consumption of the aldehyde. Saturated 
aqueous NH4Cl (8 mL) was added, then the mixture was diluted with Et2O (10 mL) and 
the separated aqueous layer was extracted with Et2O (3 x 10 mL). The unified organic 
layers were dried over sodium sulfate, filtered, and the solvents removed to give a 
yellow-greenish oil. The crude oil was purified by flash chromatography (SiO2, 
pentane/Et2O 4:1) to provide the alcohol S19 (870 mg, 2.56 mmol, 68%) as a slightly 
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yellow oil. The neat alcohol should be used immediately and not be stored longer than 
1–2 weeks at 5°C, as significant decomposition is observed in the 1H NMR. Rf = 0.30 
(SiO2, pentane/Et2O 4:1). FTIR (neat): 3377 (br), 2950, 2876, 1459, 1289, 1096, 1005, 
660 cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.24 – 6.22 (m, 1H), 4.13 (t, J = 6.5 Hz, 1H), 
3.61 (t, J = 6.5 Hz, 2H), 1.78 (d, J = 1.2 Hz, 3H), 1.63 – 1.50 (m, 4H), 1.47 – 1.27 (m, 
2H), 0.95 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 8.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 
144.06, 104.70, 76.23, 62.81, 34.72, 32.60, 22.11, 14.95, 6.93, 4.54. HRMS ESI calc. 
for C14H29BrNaO2Si+ [M+Na]+: 359.1012, found 359.1012. sf433 
 
(E)-7-bromo-5-methoxy-6-methylhept-6-en-1-ol (S20): To a 0 °C cold solution of the  
alcohol S19 (220 mg, 652 mmol, 1.0 eq.) in dry THF (2 mL, 
0.3 M) was added sodium hydride (78 mg, 2.0 mmol, 3.0 eq., 
60% dispersion in mineral oil). After stirring for 10 min, MeI 
(160 mL, 2.61 mmol, 4.0 eq.) was added and the suspension was stirred for 30 min, after 
which TLC indicated complete consumption of the starting material. The mixture was 
cooled to 0 °C and saturated aqueous NH4Cl (4 mL) was added, then the mixture was 
diluted with Et2O (10 mL) and water (4 mL), and the separated aqueous layer was 
extracted with Et2O (3 x 10 mL). The unified organic layers were dried over sodium 
sulfate, filtered, and the solvents removed to give a colorless oil (230 mg, 622 mmol , 
95%) which was used without further purification in the next step. Rf = 0.85 (SiO2, 
pentane/Et2O 4:1). 1H NMR (400 MHz, CDCl3) δ = 6.14 (s, 1H), 3.59 (t, J = 6.7 Hz, 
2H), 3.54 (t, J = 6.8 Hz, 1H), 3.19 (s, 3H), 1.70 (s, 3H), 1.65 – 1.46 (m, 4H), 1.38 – 1.19 
(m, 2H), 0.95 (t, J = 8.0 Hz, 9H), 0.59 (q, J = 7.9 Hz, 6H). sf442 
The crude alcohol (230 mg, 622 mmol, 1.0 eq.) was dissolved in dry THF (1 mL) and 
TBAF (690 mL, 690 mmol, 1.05 eq., 1.0 M solution in THF) was added. After 1h TLC 
indicated complete consumption of the starting material and saturated aqueous NH4Cl (4 
mL) was added, then the mixture was diluted with Et2O (5 mL) and the separated 
aqueous layer was extracted with Et2O (2 x 5 mL). The unified organic layers were dried 
over sodium sulfate, filtered, and the solvents removed to give a colorless oil. The crude 
oil was purified by flash chromatography (SiO2, pentane/Et2O 1:1) to provide the 
alcohol S20 (115 mg, 475 mmol, 73%) as a colorless oil. Rf = 0.20 (SiO2, pentane/Et2O 
1:1). FTIR (neat): 3380, 2934, 1631, 1450, 1286, 1087, 905, 79, 714 cm
-1. 1H NMR 
(400 MHz, CDCl3) δ = 6.15 (s, 1H), 3.64 (t, J = 6.5 Hz, 2H), 3.55 (dd, J = 7.0, 6.3 Hz, 
1H), 3.19 (s, 3H), 1.71 (d, J = 1.3 Hz, 3H), 1.68 – 1.27 (m, 8H).13C NMR (101 MHz, 
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CDCl3) δ = 141.66, 104.97, 85.36, 62.77, 56.31, 33.32, 32.50, 21.95, 13.91. HRMS ESI 
calc. for C9H17BrNaO2+ [M+Na]+: 259.0304, found 259.0302. sf443 
 
(E)-7-bromo-5-methoxy-6-methylhept-6-enal (3.70): To a solution of the alcohol S20 
(100 mg, 422 mmol, 1.0 eq.) in DMSO (1 mL) was added IBX 
(177 mg, 633 mmol, 1.5 eq.). After 2 h a white suspension had 
formed and TLC/1H NMR indicated complete consumption of the 
starting material. The mixture was diluted with Et2O (10 mL) and extracted with water 
(5 mL) and saturated aqueous Na2CO3 (2 x 5 mL), where the colorless precipitate stays 
mainly in the organic layer. The organic layer was dried, filtered and evaporated, 
dissolved in Et2O and filtered over cotton in a Pasteur pipette to remove the colorless 
precipitate. The product 3.70 was obtained as a colorless oil (90 mg, 0.38 mmol, 90%) 
after evaporation. Rf = 0.50 (SiO2, pentane/Et2O 1:1). FTIR (neat): 2932, 1708, 1631, 
1286, 1101, 941, 794, 715. cm-1. 1H NMR (400 MHz, CDCl3) δ = 9.76 (t, J = 1.6 Hz, 
1H), 6.17 (qd, J = 1.4, 0.6 Hz, 1H), 3.58 – 3.52 (m, 1H), 3.19 (s, 3H), 2.49 – 2.42 (m, 
2H), 1.71 (d, J = 1.3 Hz, 3H), 1.68 – 1.48 (m, 6H).13C NMR (101 MHz, CDCl3) δ = 
202.25, 141.54, 105.39, 85.16, 56.46, 43.72, 33.15, 18.50, 14.11. HRMS ESI calc. for 
C10H19BrNaO3+ [M+Na]+: 289.0410, found 289.0408. sf444 
 
(E)-1-bromo-2-methyl-7-((triethylsilyl)oxy)hept-1-en-3-one (S21): The racemic 
allylic alcohol S19 (1.28 g, 3.63 mmol, 1.0 eq.) was 
dissolved in dry DCM (12 mL) and NMO (638 mg, 5.54 
mmol, 1.5 eq.) and powdered molecular sieves (4 Å, 800 
mg) were added. The stirring suspension was cooled to 0 °C and TPAP (63.8 mg, 182 
mmol, 5 mol%) was added. The reaction was monitored by TLC (pentane/Et2O 4:1) and 
was found to have stalled after 30 min (addition of more catalyst can drive the reaction 
to quantitative conversion, but none was available. Chromatography can then be 
replaced by filtration over a silica plug with DCM). The dark green-black reaction 
mixture was therefore concentrated and the crude slurry was purified by flash 
chromatography (SiO2, pentane/Et2O 4:1) to give the product S21 (867 mg, 2.59 mmol, 
71%, 91% brsm) and starting material S19 (247 mg, 732 mmol, 20%). The alcohol was 
directly used in the next step, as it decomposes overnight at 5 °C. All attempts to 
measure an ESI-HRMS had failed, as the sample had already decomposed before 
measurement. Rf = 0.70 (SiO2, pentane/Et2O 4:1). FTIR (neat):  = 2926, 2360, 1680, ν~
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1375, 1236, 1071 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.48 (dd, J = 2.6, 1.2 Hz, 1H), 
3.62 (t, J = 6.3 Hz, 2H), 2.70 – 2.65 (m, 2H), 1.96 (d, J = 1.3 Hz, 3H), 1.73 – 1.64 (m, 
2H), 1.59 – 1.49 (m, 2H), 0.95 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 7.9 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ = 198.0, 143.0, 123.55, 62.61, 38.09, 32.35, 29.86, 21.17, 15.26, 
6.93, 6.73, 5.95, 4.55. sf477 
 
(R,E)-7-bromo-5-methoxy-6-methylhept-6-en-1-ol (S22): The labile bromo-enone 
S21 (860 mg, 2.56 mmol, 2.0 eq.) was dissolved in dry 
toluene (13 mL) and (S)-CBS catalyst (213 mg, 768 mmol, 
0.3 eq.) was added. The stirring reaction was cooled to -70 °C 
and borane dimethyl sulfide complex (2.56 mL, 5.12 mmol, 2.0 eq., 2 M in THF) was 
added slowly. The reaction was stirred for 15 min, warmed to -35 °C, stirred for 30 min 
and then stirred at 0 °C. After 2h TLC indicated complete consumption of the starting 
material, and MeOH (5 mL) was added carefully to the reaction mixture. The colorless 
solution was diluted with Et2O (40 mL), washed with water (3 x 10 mL) and dried over 
sodium sulfate. Upon filtration and removal of solvent a crude colorless oil (950 mg, 
2.81 mmol, 104%) was obtained. All analytical data were in full agreement with the 
racemic compound S19. The crude labile (!) allylic alcohol was directly used in the next 
step. e.r. = 98:2 (determined with chiral HPLC; Chiralpak OD-H, heptane/isopropanol 
99:1, 1.0 mL/min, injection vol.: 1 µL, 25 °C, tR (S): 7.98 min, tR  (R): 8.59 min. sf473 
sf478 sf523 
The crude alcohol (860 mg, 2.55 mmol, 1.0 eq.) was dissolved in dry THF (9.0 mL, 0.3 
M), cooled to 0 °C and sodium hydride (306 mg, 7.65 mmol, 3.0 eq., 60% dispersion in 
mineral oil) was added. After stirring for 10 min, methyl iodide (0.64 mL, 10.2 mmol, 
4.0 eq.) was added and stirring was continued for 10 min at 0 °C and 1 h at r.t., upon 
which TLC indicated complete consumption of the starting material. The yellow mixture 
was quenched carefully by drop wise addition of MeOH (2 mL), diluted with ether (20 
mL) and the separated aqueous layer was extracted with ether (2 x 10 mL). The unified 
organic layers were dried over sodium sulfate, filtered and the solvents removed to give 
a crude yellow oil. The mineral oil was removed by filtration over a silica plug, first 
washing with  50 mL pentane and then the product was eluted with Et2O/pentane (50 
mL 1:1 v/v). Removal of the solvents gave the methylated alcohol S22 (783 mg, 2.23 
mmol, 87% over two steps) as a colorless oil. All analytical Data were identical with the 
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racemic compound. An analytical sample for optical rotation measurement was obtained 
by flash chromatography (SiO2, pentane/Et2O 20:1). [α]D = +23.5 (c = 0.34 CHCl3). Rf 
= 0.45 (SiO2, pentane/Et2O, 20:1). 1H NMR (400 MHz, CDCl3) δ = 6.15 – 6.13 (m, 1H), 
3.59 (t, J = 6.6 Hz, 2H), 3.54 (t, J = 6.8 Hz, 1H), 3.19 (s, 3H), 1.70 (d, J = 1.3 Hz, 3H), 
1.66 – 1.47 (m, 2H), 1.39 – 1.25 (m, 2H), 0.95 (t, J = 7.9 Hz, 9H), 0.59 (q, J = 7.8 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ = 141.85, 105.02, 85.53, 62.83, 56.43, 33.46, 
32.81, 22.14, 14.0, 6.93, 4.56. sf479 
The crude methyl ether (759 mg, 2.16 mmol, 1.0 eq.) was dissolved in dry THF (8 mL, 
0.27 M) and cooled to 0 °C, upon which TBAF (2.37 ml, 2.37 mmol, 1.1 eq., 1.0 M in 
THF) was added. The reaction was warmed to r.t. and stirred for 30 min, upon which 
TLC indicated complete consumption of the starting material. The solution was diluted 
with Et2O (20 mL) and washed with water (10 mL), dried over sodium sulfate, filtered 
and the solvents removed. Flash chromatography (SiO2, pentane/Et2O 3.5:1.5) gave the 
title compound S22 (480 mg, 2.02 mmol, 94%) as a colorless oil. All analytical data 
were in full agreement with the racemic compound S20. [α]D = +9.6 (c = 1.05 CHCl3). 
sf480 
 
(R,E)-7-bromo-5-methoxy-6-methylhept-6-enal (3.78): The compound was prepared 
in analogy to the procedure of the racemic compound 3.70. 
All analytical data were in full agreement. [α]D = + 21 (c = 
0.28 CHCl3). sf484 
 
(R,2E,8E)-9-bromo-7-methoxy-2,8-dimethylnona-2,8-dienal (S23): To a solution of 
the aldehyde 3.78 (3.27 g, 13.2 mmol, 1.0 eq.) in dry 
benzene (32 mL) and DCM (3 mL) was added phosphorane 
S15 (4.87g, 14.5 mmol, 1.1 eq.) and the mixture was heated to 90 °C for 18 h, after 
which 1H NMR indicated a ratio of product/ starting material of 5:4. More phosphorane 
S15 (0.50 eq.) was added and the mixture was heated to 90 °C for 3 h, after which more 
phosphorane S15 (0.50 eq., 2.10 eq. total) was added and the mixture was heated at 90 
°C. After 24 h total heating time 1H NMR indicated complete consumption of the 
starting material. The solvents were removed in vacuo and the remaining brown oil was 
purified by flash chromatography (SiO2, pentane/Et2O 3.5:1.5) to give the title 
compound S23 (3.44 g, 13.2 mmol, 95%) as a slightly yellow oil. All analytical data 
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were in full agreement with the racemic compound S17. [α]D = +13.8 (c = 0.27, CHCl3). 
Sf530 
 
(4E,9R,10E)-methyl 11-bromo-3-hydroxy-9-methoxy-2,4,10-trimethylundeca-4,10-
dienoate (3.79): The compound was prepared in analogy to the procedure of the racemic 
compound 3.71. All analytical data were in full 
agreement. sf532 
 
(4E,9R,10E)-methyl 11-bromo-3-((tert-butyldimethylsilyl)oxy)-9-methoxy-2,4,10-
trimethylundeca-4,10-dienoate (S24): To a 0 °C cold solution of the alcohol 3.71 
(1.50g, 3.92 mmol, 1.0 eq.) in DCM (40 mL) was 
added 2,6-lutidine (1.68 mL, 15.7 mmol, 4.0 eq.) 
and the solution was stirred for 10 min. TBSOTf (1.80 mL, 7.84 mmol, 2.0 eq.) was 
added slowly and the mixture was warmed to r.t. and stirred for 20 min, upon which 
TLC indicated complete consumption of the starting material. Saturated NaHCO3 (15 
mL) was added and the layers were separated. The aqueous layer was extracted with 
DCM (15 mL) and the unified organic layers were dried over sodium sulfate, filtered 
and the solvents removed. Flash chromatography (SiO2, pentane/Et2O 9:1) furnished the 
product (1.54 g, 3.92 mmol, 82%) as a colorless oil. Rf = 0.40 (SiO2, pentane/Et2O, 9:1). 
FTIR (neat): 2930, 2857, 1790, 1461, 1168, 1063, 836, 669, 626 cm-1. 1H NMR (400 
MHz, CDCl3) δ = 6.14 (q, J = 1.4 Hz, 1H), 5.32 (t, J = 7.2 Hz, 1H), 4.06 (d, J = 9.9 Hz, 
1H), 3.66 (s, 3H), 3.55 – 3.51 (m, 1H), 3.19 (d, J = 0.8 Hz, 3H), 2.64 – 2.55 (m, 1H), 
2.07 – 1.97 (m, 2H), 1.69 (d, J = 1.2 Hz, 3H), 1.66 – 1.58 (m, 1H), 1.52 (d, J = 0.8 Hz, 
3H), 1.49 – 1.35 (m, 2H), 1.33 – 1.24 (m, 1H), 0.92 – 0.86 (m, 2H), 0.82 (s, 9H), -0.02 
(s, 3H), -0.06 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 176.47, 141.85, 141.81, 135.14, 
135.12, 129.22, 129.21, 105.03, 105.02, 85.43, 81.84, 56.45, 51.60, 44.89, 33.41, 33.37, 
27.42, 25.76, 25.57, 25.53, 18.10, 14.36, 14.02, 14.0, 10.39, -4.50, -4.52, -5.34. . ESI-
HRMS calc. for C22H41BrNaO4Si+ [M+Na]+: 499.1850, found 499.1851. sf545 
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(9R,12S)-methyl 5-((R,2E,8E)-9-bromo-7-methoxy-8-methylnona-2,8-dien-2-yl)-12-
isopropyl-9-(3-methoxy-4-((triisopropylsilyl)oxy)benzyl)-2,2,3,3,6,8-hexamethyl-
7,10-dioxo-4-oxa-8,11-diaza-3-silatridecan-13-oate (3.118): A biphasic solution of the 
methyl ester S24 (1.54 g, 3.06 
mmol, 1.0 eq.) in THF/MeOH/KOH 
(20 mL, 3:1:1 v/v/v, 10 M KOH  in 
H2O) in a 20 mL microwave vial 
was heated to 80 °C for 4 h, after 
which no signal of the methyl ester function was observed in the 1H NMR spectrum of 
an aliquot (TLC is misleading when monitoring this hydrolysis, as a byproduct with the 
same Rf as the starting material is observed). The solution was acidified to pH 1 with 
HCl (40 mL, 1 M), upon which a white emulsion formed. The layers were separated, the 
aqueous phase extracted with Et2O (3 x 30 mL), dried over sodium sulfate, filtered and 
the solvents removed. The obtained crude oil appeared to still contain some water (small 
droplets and turbid oil) and was therefore dissolved in ether (20 mL), dried over sodium 
sulfate, filtered and the solvents removed in vacuo to give the crude acid 3.117 (1.49 g, 
3.06 mmol, 99%), which was directly used in the next step without further purification. 
The flask containing the crude acid 3.117 (1.49 g, 3.06 mmol, 1.20 eq.) was purged with 
argon three times and the acid dissolved in dry DCM (5 mL, 0.6 M). DMF (2 drops) was 
added and the solution was cooled to 0 °C, after which oxalyl chloride (4.36 mL, 50.8 
mmol, 20.0 eq.) was added slowly. The mixture was stirred at 0 °C for 10 min and at r.t. 
for 30 min, after which the solvents and excess reagent were removed carefully under 
high vacuum with an additional cooling trap until a yellow sticky oil remained and 
bubbling had ceased. This oil was dissolved in dry DCM (5 mL, 0.6 M) and cooled to 0 
°C. A suspension of the hydrochloride salt 3.112 (1.42 g, 2.54 mmol, 1.0 eq.), NEt3 
(2.86 mL, 20.3 mmol, 8.0 eq.) and DMAP (31 mg,  0.25 mmol, 0.10 eq.) in dry DCM (5 
mL) was added to the 0 °C cool solution of the acid chloride and the resulting brown 
suspension was allowed to warm to r.t. and stirred for 1 h. The mixture was then diluted 
with Et2O (50 mL) and washed with aqueous HCl (30 mL, 1 M), water (40 mL) and 
saturated aqueous NaHCO3 (30 mL), dried over sodium sulfate, filtered and the solvents 
removed in vacuo. The obtained brown crude oil was subjected to flash chromatography 
(SiO2, pentane/Et2O 2:3) to furnish the product 3.118 (1.20 g, 2.54 mmol, 50%) as a 
colorless oil and a mixture of inseparable diastereomers (6:4), as the α-position of the 
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acid had epimerized. Rf = 0.40 (SiO2, pentane/Et2O, 2:3). 1H NMR (500 MHz, CDCl3) 
δ = 8.13 (d, J = 2.0 Hz, 1H), 6.78 – 6.61 (m, 3H), 6.14 (dd, J = 5.1, 1.1 Hz, 1H), 5.40 – 
5.34 (m, 2H), 4.45 (dd, J = 8.2, 5.1 Hz, 1H), 4.14 (d, J = 9.5 Hz, 1H), 3.88 – 3.80 (m, 
1H), 3.76 (s, 3H), 3.70 (s, 3H), 3.65 -3.60 (m, 1H), 3.55 – 3.51 (m, 1H), 3.19 (s, 3H), 
3.05 (s, 3H), 2.94-2.71 (m, 2H), 2.08 – 1.95 (m, 3H), 1.70 (d, J = 1.3 Hz, 3H), 1.56 (s, 
1H), 1.49 – 1.38 (m, 2H), 1.07 (d, J = 3.2 Hz, 18H), 0.86 (s, 9H), 0.84 – 0.77 (m, 6H), 
0.05 (s, 3H), – 0.03 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 177.25, 171.57, 169.89, 
155.76, 144.16, 141.71, 129.50, 129.73, 119.16, 121.57, 120.11, 113.64, 104.83, 85.26, 
81.69, 57.14, 57.12, 56.15, 55.40, 51.87, 40.57, 34.84, 33.19, 31.25, 31.0, 27.18, 25.77, 
25.66, 25.31, 19.12, 18.86, 18.02, 17.81, 13.78, 12.75, 10.36, -4.56, -5.12. ESI-HRMS 
calc. for C47H83BrN2O8Si2+ [M+Na]+: 939.4944, found 939.4943. sf548 
 
(5R,6R,7E,9E,11R,15E,21R,24S)-methyl 17-((tert-butyldimethylsilyl)oxy)-6-
hydroxy-21-(4-hydroxy-3-methoxybenzyl)-24-isopropyl-11-methoxy-10,16,18,20-
tetramethyl-19,22-dioxo-5-phenyl-2,4-dioxa-20,23-diazapentacosa-7,9,15-trien-25-
oate (3.120): In a round bottom flask tetrabutylammonium diphenylphosphinate (54 mg, 
117 mmol, 4.5 eq.) was 
dried under high 
vacuum (heat gun at 
low setting, ca. 150 
°C), whereupon the 
solid first melted and ceased bubbling after ca. 4 min. The flask was then purged with 
argon and cooled to r.t. 
In a separate flask, stannane 3.27 (16 mg, 31 mmol, 1.2 eq.) and vinyl bromide 3.118 
(26 mg, 26 mmol, 1.0 eq.) were dissolved in dry DMF (1 mL) and degassed by bubbling 
argon through the solution for 20 min, after which it was transferred to the flask 
containing the dried phosphinate. Copper(I) thiophene-2-carboxylate (17 mg, 91 mmol, 
3.50 eq.) and Pd(PPh3)4 (13 mg, 26 mmol, 1.0 eq., yellow crystalline flakes) were added 
and the mixture turned from bright yellow to dark brown within 10 minutes. After 30 
min TLC indicated complete consumption of the stannane, but bromide was still present, 
and the reaction was therefore sealed with a Teflon fitted glass stopper and stirred 
overnight at 70 °C. TLC then also indicated complete consumption of the bromide, and 
the black reaction mixture was diluted with Et2O (7 mL), washed with water (3 x 3 mL), 
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dried over sodium sulfate, filtered and dried in vacuo. The purple crude oil was purified 
by flash chromatography (SiO2, Et2O) to give the product 3.120 (15 mg, 26 mmol, 63%) 
as a yellow oil and a mixture of partially separable diastereomers (6:4). Rf = 0.35 (SiO2, 
Et2O). FTIR (neat): 3355, 2931, 2360, 1743, 1517, 1271, 1207, 1151, 1100, 1034, 912, 
837, 701 cm-1. 1H NMR (500 MHz, CDCl3) δ = 7.36 – 7.27 (m, 5H), 6.78 – 6.71 (m, 
3H), 6.44 (ddd, J = 15.3, 11.0, 1.4 Hz, 1H), 5.86 (d, J = 11.0 Hz, 1H), 5.63 (s, 1H), 5.45 
(dd, J = 15.2, 5.6 Hz, 1H), 5.40 – 5.32 (m, 2H), 4.63 – 4.57 (m, 2H), 4.45 (d, J = 7.5 Hz, 
1H), 4.28 (dd, J = 8.4, 4.8 Hz, 1H), 4.24 (d, J = 9.4 Hz, 1H), 3.84 (s, 3H), 3.66 (s, 3H), 
3.38 (s, 3H), 3.53-3.39 (m, 2H) 3.12 (s, 3H), 3.07 (s, 3H), 3.04-3.02 (m, 1H), 2.99 – 2.92 
(m, 1H), 2.59 (dd, J = 12.9, 2.8 Hz, 1H), 2.09 – 1.97 (m, 3H), 1.58 (d, J = 0.9 Hz, 3H), 
1.56 (s, 3H), 1.53 – 1.34 (m, 4H), 0.87 (d, J = 7.5 Hz, 2H), 0.86 (s, 9H), 0.80 (d, J = 6.9 
Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H), 0.04 (s, 3H), -0.03 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 177.49, 172.0, 170.59, 144.28, 146.34, 134.85, 133.85, 133.81, 133.59, 
131.67, 130.10, 129.24, 128.23, 127.40, 126.57, 114.05, 123.54, 122.20, 112.14, 111.86, 
94.28, 86.72, 82.03, 81.85, 75.25, 57.17, 57.16, 57.14, 56.98, 54.01, 49.97, 40.19, 33.37, 
33.08, 33.08, 30.75, 29.86, 29.84, 27.11, 25.96, 18.57, 17.93, 13.80, 10.52, 10.52, -4.52, 
-5.02. ESI-HRMS calc. for C50H78N2NaO11Si+ [M+Na]+: 933.5267, found 933.5259. 
sf556 sf557 
 
Methyl (tert-butoxycarbonyl)glycinate (S25):315 To a solution of methyl glycinate  
hydrochloride (3.96) (10.0 g, 80.0 mmol, 1.0 eq.) in CHCl3 (70 mL) 
a solution of sodium bicarbonate (6.72 g, 80.0 mmol, 1.0 eq.) in water (120 mL) was 
added, then a solution of di-tert-butyl dicarbonate (17.4 g, 80.0 mmol, 1.0 eq.) in CHCl3 
(15 mL) was added and finally sodium chloride (15.0 g) was added. The mixture was 
stirred at reflux for 2 h before the layers were separated. The aqueous layer was 
extracted with CHCl3 (2 x 60 mL) and the unified organic fractions were dried over 
MgSO4, filtered, the solvent was removed under reduced pressure and the title 
compound S25 (14.6 g, 77.0 mmol, 96%) was obtained as colorless oil. Rf = 0.72 (SiO2, 
DCM/MeOH, 9:1). 1H NMR (400 MHz, CDCl3) δ = 5.0 (br. s, 1H), 3.92 (d, J = 5.6 Hz, 
2H), 3.75 (s, 3H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 170.81, 155.66, 80.04, 
52.23, 42.30, 28.31, 27.42.  
                                                
 
315 J. Fischer, H. Ritter, Beilstein J. Org. Chem. 2013, 9, 2803. 
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Methyl 2-((tert-butoxycarbonyl)amino)-2-(dimethoxyphosphoryl)acetate (3.97):316 
To a solution of azobisisobutyronitrile (250 mg, 1.52 mmol, 2 
mol%) in CCl4 (130 mL), methyl(tert-butoxycarbonyl)glycinate 
(S25) (14.4 g, 76.0 mmol, 1.0 eq.) was added and afterwards N-bromosuccinimide (14.7 
g, 83.0 mmol, 1.09 eq.) was added. The flask was irradiated with a mercury lamp (150 
W) and stirred at reflux for 2 h. The suspension was allowed to cool to room 
temperature and was filtered. The residue was extracted with DCM (20 mL). The filtrate 
was concentrated under reduced pressure, resulting in a yellow oil of methyl 2-bromo-2-
[(tert-butoxycarbonyl)amino]acetate S26 (20.4 g, 76.0 mmol, 100%), which was 
immediately used in the next step without further purification. Rf = 0.21 (SiO2, 
DCM/MeOH, 9:1). 1H NMR (400 MHz, CDCl3) δ = 6.29 (d, J = 9.5 Hz, 1H), 6.18 – 
6.01 (m, 1H), 3.78 (s, 3H), 1.40 (s, 9 H). 13C NMR (101 MHz, CDCl3) δ = 177.98, 
166.56, 152.24, 65.69, 53.44, 28.01. 
The following reaction as well as the removal of the trimethyl phosphite on the rotavap 
should be performed in an extremely well ventilated hood. In a 250 mL round bottom 
flask equipped with a reflux condenser the bromide S26 (20.3 g, 76.0 mmol, 1.0 eq.) 
was dissolved in DCM (150 mL) under vigorous stirring. Trimethyl phosphite (9.43 mL, 
80.0 mmol, 1.05 eq.) was added upon which the solution began to reflux and the mixture 
was heated to reflux overnight. The reaction mixture was cooled to room temperature 
and the solvent was removed under reduced pressure (very smelly). Subsequent flash 
chromatography (SiO2, EtOAc/Et2O 3:1) furnished the phosphonate 3.97 (13.6 g, 45.7 
mmol, 60%) as a yellow oil which became solid after being stored at -20 °C overnight. 
Rf = 0.41 (SiO2, EtOAc/Et2O 3:1). FTIR (neat): 3251, 3061, 2961, 2857, 1757, 1708, 
1542, 1436, 1300, 1246, 1157, 1050, 1025, 917, 879, 830 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 5.35 (d, J = 9.5 Hz, 1H), 4.86 (ddd, J = 21.9, 10.2, 2.8 Hz, 1H), 3.84 – 3.79 
(m, 9H), 1.45 – 1.42 (m, 9H). 13C NMR (101 MHz, CDCl3) δ = 167.50, 154.89, 80.94, 
54.03 (t, J = 6.0 Hz ), 53.26, 50.92, 28.18. 31P NMR(162 MHz, CDCl3) δ = 18.87. ESI–
HRMS calc. for C10H21NO7P+ [M+H]+: 298.1056, found 298.1050. 
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3-Methoxy-4-[(triisopropylsilyl)oxy]benzaldehyde (3.101):317 An oven-dried 250 mL 
two necked round bottom flask equipped with a dropping funnel 
was charged with imidazole (21.8 g, 320 mmol, 4.0 eq.), 4-
hydroxy-3-methoxybenzaldehyde (12.2 g, 80.0 mmol, 1.0 eq.) and 
DMF (50 mL). At 0 °C neat chlorotriisopropylsilane (17.0 ml, 80.0 mmol, 1.0 eq.) was 
added drop wise via the dropping funnel to the clear solution, giving a colorless 
suspension. After stirring for further 10 min at 0 °C, the reaction was allowed to warm 
to room temperature. TLC indicated full consumption of the starting material after 1 h. 
The suspension was diluted with Et2O (200 mL), washed with H2O (6 x 100 mL), brine 
(100 mL) and dried over magnesium sulfate. After removal of the solvent the aldehyde 
3.101 (23.4 g, 72.4 mmol, 91%) was obtained as a colorless viscous oil. NMR indicated 
minor impurities of ~4% of TIPSOH. All analytical data were in full agreement with the 
literature. Rf = 0.82 (SiO2, pentane/Et2O, 9:1). 1H NMR (400 MHz, CDCl3) δ = 9.84 (s, 
1H), 7.39 (d, J = 1.9 Hz, 1H), 7.35 (dd, J = 8.0, 1.9 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 
3.87 (s, 3H), 1.34 – 1.20 (m, 3H), 1.10 (d, J = 7.4 Hz, 18H). 13C NMR (101 MHz, 
CDCl3) δ = 190.98, 151.83, 151.59, 130.60, 126.21, 120.14, 110.04, 65.85, 55.44, 17.82, 
12.94. 
Methyl (Z)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl}acrylate (3.98): To a 0°C cold solution of the phosphonate 3.97 (8.99 g, 
30.3 mmol, 1.0 eq.) in DCM (100 mL) was added drop 
wise DBU (5.07 g, 33.3 mmol, 1.1 eq.), upon which the 
reaction mixture turned yellow. After further stirring at 0 
°C for 15 min, a solution of the aldehyde 3.101 (18.6 g, 60.5 mmol, 2.0 eq.) in DCM (20 
mL) was added drop wise. The reaction was allowed to warm to room temperature and 
stirring was continued for 1 h (Longer reaction time leads to an increase of byproducts). 
The organic layer was extracted with aqueous citric acid (10%, 2 x 100 ml,) and H2O 
(100 mL), dried over sodium sulfate, filtered and the solvents were removed. Flash 
chromatography (SiO2, pentane/Et2O, 3:2) gave the title compound 3.98 (14.5 g, 21.0 
mmol, 69%) as a colorless solid. M.p.: 100 – 102 °C. Rf = 0.21 (SiO2, pentane/Et2O, 
3:2). FTIR (neat): 3220, 3112, 2944, 2667, 1705, 1594, 1507, 1361, 1279, 1165, 1132, 
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1027, 898, 676 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.25 (s, 1H), 7.15 (d, J = 2.1 Hz, 
1H), 7.05 (dd, J = 8.3, 2.1 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 6.02 (s, 1H), 3.84 (s, 3H), 
3.80 (s, 3H), 1.46 – 1.35 (m, 9H), 1.32 – 1.19 (m, 3H), 1.09 (d, J = 7.3 Hz, 18H). 13C 
NMR (101 MHz, CDCl3) δ = 166.32, 150.65, 147.05, 131.82, 127.34, 123.80, 120.28, 
113.34, 80.78, 55.34, 52.44, 28.16, 17.87, 12.91. ESI-HRMS calc. for C25H41NNaO6 Si+ 
[M+Na]+: 502.2601, found 502.2595. 
Methyl-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(triisopropyl-silyl)oxy]-
phenyl}propanoate (3.99): A 20 mL round bottom flask was charged with alkene 3.98 
(176 mg, 0.36 mmol, 1.0 eq.) and Pd/C (18 mg, 0.16 
mmol, 0.44 eq., 10% Pd) and then purged three times with 
argon. MeOH (3 mL) was added and stirring was started. A 
balloon with H2 (2 L) was attached and after bubbling H2 through the suspension for 10 
min, the reaction was stirred overnight under hydrogen atmosphere. After 16 h TLC 
indicated complete consumption of the starting material and the mixture was filtered 
repeatedly through a pad of diatomaceous earth until no more grey dust was observed in 
the filtrate. The solvent was removed under reduced pressure and the title compound 
3.99 was obtained as a colorless powder (70.1 mg, 0.14 mmol, 40%). M.p. 101 – 104°C. 
Rf = 0.20 (SiO2, pentane/Et2O, 3:2). FTIR (neat): = 3373, 2941, 2866, 1740, 1704, 
1506, 1368, 1292, 1223, 1169, 1150, 906, 881 cm-1. 1H NMR (400 MHz, CDCl3) δ = 
6.78 (d, J = 8.0 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 6.54 (dd, J = 8.0, 2.1 Hz, 1H), 4.94 (d, 
J = 8.3 Hz, 1H), 4.53 (q, J = 6.7 Hz, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 3.01 – 2.98 (m, 2H), 
1.42 (s, 9 H), 1.27 – 1.20 (m, 3 H), 1.07 (d, J = 7.5 Hz, 18H). 13C NMR (101 MHz, 
CDCl3) δ = 172.51, 155.07, 150.79, 144.54, 128.96, 121.34, 120.38, 113.04, 79.85, 
55.40, 54.54, 52.12, 38.06, 28.32, 17.89, 12.84. ESI-HRMS calc. for C25H43NNaO6 Si+: 
504.2741, found 504.2752. 
Methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl} propanoate (3.100): To a solution of the alkene 3.98 (1.50 g, 3.13 mmol, 
1.0 eq.) in EtOAc (10 mL, degassed by bubbling argon for 
20 min) in a flame-dried vial was added  the catalyst 1,2-
bis[(2R,5R)-2,5-diethylphospholano]benzene(1,5-
cyclooctadiene)-rhodium(I) trifluoromethanesulfonate (11.5 mg, 0.01 mmol, 0.50 
mol%) and the vial was put into a hydrogenation autoclave. The autoclave was set under 
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H2 atmosphere (7.5 bar) and stirred for 3 d at room temperature. The reaction mixture 
was filtered through a pad of silica and extracted with a pentane/ether mixture (1:1, 50 
mL) before the solvent was removed at reduced pressure. The title compound 3.100 was 
obtained as a colorless powder (1.48 g, 3.07 mmol, 98%). [α]D = –8.3 (c = 0.38 
acetone). e.r. = 98:2 (determined with chiral HPLC; Chiralpak IA, 95:5 
heptane/isopropanol, 0.5 mL/min, injection vol.: 1 µL, 25°C, tR (R): 14.5 min, tR (S): 
19.5 min.). Rf = 0.20 (SiO2, pentane/Et2O, 3:2). FTIR (neat): 3373, 2941, 2866, 1740, 
1704, 1506, 1368, 1292, 1223, 1169, 1150, 906, 881 cm-1. 1H NMR (400 MHz, CDCl3) 
δ = 6.78 (d, J = 8.0 Hz, 1H), 6.59 (d, J = 2.1 Hz, 1H), 6.54 (dd, J = 8.1, 2.1 Hz, 1H), 
4.94 (d, J = 8.3 Hz, 1H), 4.53 (d, J = 7.4 Hz, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 2.99 (d, J = 
6.1 Hz, 2H), 1.42 (s, 10H), 1.24 – 1.19 (m, 3H), 1.08 (d, J = 7.3 Hz, 18H). 13C NMR 
(101 MHz, CDCl3) δ = 172.51, 155.07, 150.79, 144.54, 128.96, 121.34, 120.38, 113.04, 
79.85, 55.40, 54.54, 52.12, 38.06, 28.32, 17.89, 12.84. ESI-HRMS calc. for 
C25H43NNaO6Si+ [M+Na]+: 504.2741, found 504.2748. 
 
Methyl-{[tert-butoxycarbonyl](methyl)amino}-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl}propanoate (3.105): To a 0 °C cold solution of the carbamate 3.100 (1.33 
g, 2.78 mmol, 1.0 eq.) in dry DMF (20 mL) was added NaH (167 
mg, 4.16 mmol, 1.5 eq., 60% dispersion in mineral oil), after which 
the mixture turned bright yellow. After stirring for 10 min at 0 °C, 
methyl iodide was added (1.59 g, 11.1 mmol, 4.0 eq.). The reaction 
mixture was allowed to warm to room temperature and stirred for 1.5 h (when the 
reaction is run for longer than 2 h increased byproduct formation is observed by TLC).  
The reaction was quenched by careful addition of saturated aqueous NH4Cl (20 mL) and 
the mixture was extracted with Et2O (3 x 30 mL). The combined organic layers were 
washed with H2O (4 x 70 mL) and dried over sodium sulfate before the solvents were 
removed. The residue was purified by flash chromatography (SiO2, pentane/Et2O, 3:2) 
to furnish the methylated carbamate 3.105 (1.28 g, 2.60 mmol, 93%) as a yellowish oil. 
Racemization occurs under these basic condition as chiral HPLC indicates. Rotamers are 
visible in the NMR (ca. 2:3, CDCl3). Rf = 0.32 (SiO2, pentane/Et2O, 3:1). [α]D = +1.2 (c 
= 0.89 acetone). e.r.: 46:54 (determined with chiral HPLC; Chiralpak IA, 95:5 
heptane/isopropanol, 1 mL/min, injection vol.: 1 µL, 25 °C, tR (minor): 4.12 min, tR  
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(major): 4.43 min). FTIR (neat): 2944, 2867, 2010, 1745, 1696, 1584, 1515, 1464, 
1392, 1366, 1313, 1280, 1233, 1158, 1074, 1039, 997, 917, 884, 814, 771, 679 cm-1. 1H 
NMR (400 MHz, CDCl3) δ = 6.78 (d, J = 7.9 Hz, 1H), 6.72-6.54 (m, 2H), 4.85 (d, J = 
5.1 Hz, 0.5H), 4.31 (d, J = 6.4 Hz, 0.5H), 3.77 (s, 3H), 3.72 (d, J = 3.8 Hz, 3H), 3.21 (s, 
1H), 2.97 (s, 1H), 2.67 (s, 3H), 1.39 (s, 9H), 1.29-1.18 (m, 3H), 1.07 (d, J = 7.2 Hz, 
18H). 13C NMR (101 MHz, CDCl3) δ =172.12, 155.02, 150.76, 144.19, 130.86, 121.07, 
120.36, 113.02, 112.71, 62.46, 59.51, 55.41, 52.05, 33.6, 28.24, 17.85, 12.77. ESI-
HRMS calc. for C26H45NNaO6Si + [M+Na]+: 518.2914, found: 518.2908. 
 
2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl}propanoic acid (3.106): To a solution of the ester 3.105 (300 mg, 600 
µmol, 1.0 eq.) in a mixture of THF/MeOH/H2O (3 mL:1 mL:0.4 
mL) at 0 °C was slowly added aqueous NaOH (0.6 mL, 1.20 
mmol, 2.0 eq.). The mixture was allowed to warm to r.t. and 
stirred for 1 h before acidification with aqueous citric acid (10%, 10 mL) to pH ~3. 
Longer reaction times lead to increased cleavage of the TIPS protecting group. The 
suspension was extracted with Et2O (4 x 20 mL) and the combined organic layers were 
dried over sodium sulfate. The solvents were removed and the crude product was 
purified by flash chromatography (SiO2, pentane/Et2O/acetic acid, 4:1:0.05) to furnish 
the free acid 3.106 (212 mg, 0.44 mmol, 73%) as a colorless oil. Rf = 0.25 (SiO2, 
pentane/Et2O/acetic acid, 4:1:0.05). 1H NMR (400 MHz, CDCl3) δ = 6.79 (d, J = 8.0 
Hz, 1H), 6.64 (t, J = 10.8 Hz, 2H), 4.65 (s, 0.5H), 4.36 (d, J = 6.6 Hz, 0.5H), 3.78 (s, 
3H), 3.33 – 2.93 (m, 2H), 2.66 (d, J = 12.6 Hz, 3H), 1.41 (s, 9H), 1.31 – 1.14 (m, 3H), 
1.07 (d, J = 6.6 Hz, 18H). 13C NMR (101 MHz, MeOD) δ = 173.81, 155.74, 150.69, 
143.93, 131.48, 120.85, 112.798, 63.26, 60.88, 55.64, 35.55, 32.60, 28.37, 21.22, 18.17, 
13.87. ESI-HRMS calc. for C25H43NNaO6Si+ [M+Na]+:  504.2758, found: 504.2752.  
 
Methyl {2-[(tert-butoxycarbonyl)methyl]amino-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl}propanoyl}-S-valinate (3.107): To a solution of the acid 3.106 (248 mg, 
512 mmol, 1.0 eq.) in dry DCM (2 mL) at 0 °C was 
added S-valine methyl ester hydrochloride (88 mg, 0.52 
mmol, 1.02 eq.), HOBt (76.5 mg, 0.56 mmol, 1.20 eq.), O
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HBTU (215 mg, 0.56 mmol, 1.20 eq.) and diisopropylethylamine (145 mg, 1.13 mmol, 
2.20 eq.). The mixture was stirred at r.t. and monitored by UPLC-MS. After 14 h the 
solution was diluted with EtOAc (5 mL), washed with aqueous HCl (10 mL, 1 M), 
saturated aqueous NaHCO3 (10 mL) and brine (10 mL) before drying over sodium 
sulfate, filtration and subsequent removal of the solvent. The residue was purified by 
flash chromatography (SiO2, pentane/Et2O, 3:2) to furnish the dipeptide 3.107 as a 
colorless solid (247 mg, 413 mmol, 81%). Rf = 0.31 (SiO2, pentane/Et2O, 3:2). [α]D = 
+6.3 (c = 0.89 acetone). FTIR (neat): 3342, 2944, 2867, 2582, 1744, 1687, 1584, 1513, 
1465, 1390, 1283, 1235, 1155, 1038, 998, 903, 813, 684, 632 cm-1. 1H NMR (400 MHz, 
MeOD) δ = δ 7.90 – 7.71 (m, 1H), 6.84 (d, J = 1.8 Hz, 1H), 6.80 – 6.63 (m, 2H), 4.92 – 
4.90 (m, 1 H) 4.34 – 4.32 (m, 1H), 3.79 (s, 3H), 3.72 (s, 3H), 3.26 – 3.10 (m, 1H), 3.02 – 
2.84 (m, 1H), 2.25 – 2.05 (m, 1H), 1.42 (d, J = 2.4 Hz, 9H), 1.36 – 1.18 (m, 3H), 1.12 
(d, J = 6.6 Hz, 18H), 0.94 (m, 6H). 13C NMR (101 MHz, MeOD) δ = 171.97, 156.61, 
150.65, 143.94, 130.53, 120.85, 119.87, 112.65, 80.05, 61.08, 57.71, 54.41, 51.10, 
34.03, 30.34, 27.18, 16.96, 12.65. ESI-HRMS calc. for C31H54N2NaO7Si+ [M+Na]+:  
617.3598, found: 617.3592. 
 
(R)-methyl-((tert-butoxycarbonyl)(methyl)amino)-3-{3-methoxy-4-[ 
(triisopropylsilyl)-oxy]phenyl}propanoate (3.111): Silver(I) oxide was prepared from 
silver nitrate.318 A solution of NaOH (3.8 mL, 71 mmol, 
1.1 eq., 50% w/w in water) was added slowly to a boiling 
solution of AgNO3 (11 g, 65 mmol, 1.0 eq.) in water (500 
mL). A brown solid formed immediately. The precipitate was filtered, extracted with 
water, acetone, Et2O and dried in vacuo to give a dark brown amorphous solid (7.1 g, 30 
mmol, 93%). The compound was preferably used within the next 2 days. The 
methylation reaction does not reach complete conversion if old Ag2O is used. 
To a solution of methyl carbamate 3.100 (1.55 g, 3.06 mmol, 1.0 eq.) in DMF (16 mL) 
was added freshly prepared (!) Ag2O (7.1 g, 30 mmol, 10 eq.) and  methyl iodide (9.62 
mL g, 150 mmol, 50 eq.). The flask was wrapped in aluminum foil to exclude light, 
sealed with a glass stopper with a metal clamp and stirred at 40 °C overnight, after 
which a grey-white precipitate had formed. The brown-grey suspension was filtered 
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though a frit and washed with Et2O (120 mL), washed with water (5 x 25 mL) and dried 
over sodium sulfate. Removal of the solvents gave the methylated amine 3.111 (1.47 g, 
2.97 mmol, 97%) as a yellowish oil. All analytical data were in full agreement with the 
racemic compound 3.110. [a]D= +44.6 (c = 0.39 CHCl3). e.r.: 99:1 (determined with 
chiral HPLC; Chiralpak IA, 95:5 heptane/isopropanol, 1 mL/min, injection vol.: 1 µL, 25 
°C, tR (S): 4.12 tR (R): 4.43. sf496 
(S)-methyl 2-((R)-2-((tert-butoxycarbonyl)(methyl)amino)-3-(3-methoxy-4-
((triisopropylsilyl)oxy)phenyl)propanamido)-3-methylbutanoate (S28): The 
compound was prepared in analogy to the procedure 
described for the racemate 3.107. Enantiomerically pure 
amino ester 3.111 (2.20 g, 4.22 mmol) gave in two steps 
(without chromatography of the intermediate crude acid) 
the title compound S28 (2.07 g, 3.30 mmol, 78% over two steps) as a pure 
diastereoisomer with a ratio of rotamers of about 2:1. All analytical data were in full 
agreement with the diastereomeric mixture, except optical rotation, 1H NMR and 13C 
NMR. [α]D = +59.3 (c = 0.75 CHCl3). NMR data is given for the major rotamer: 1H 
NMR (400 MHz, CDCl3) δ = δ 6.83 – 6.56 (m, 3H), 4.94 – 4.86 (m, 1H), 4.45 (dd, J = 
8.7, 4.6 Hz, 1H), 3.76 (s, 3H), 3.70 (s, 3H), 3.25 (dd, J = 14.5, 6.9 Hz, 1H), 2.89 (dd, J = 
14.5, 9.3 Hz, 1H), 2.71 (s, 3H), 2.19 – 2.11 (m, 1H), 1.42 (s, 9H), 1.28 – 1.16 (m, 1H), 
1.06 (d, J = 7.4 Hz, 18H), 0.93 – 0.87 (m, 3H), 0.87 – 0.81 (m, 3H). 13C NMR (101 
MHz, CDCl3) δ = 172.12, 170.95, 159.79, 150.64, 143.89, 130.43, 120.98, 120.12, 
112.50, 80.41, 59.35, 56.92, 55.22, 51.86, 33.11, 30.82, 30.67, 18.83, 17.68, 17.31, 
12.61. sf498 
 
(R)-1-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-3-(3-methoxy-4-
((triisopropylsilyl)oxy)phenyl)-N-methyl-1-oxopropan-2-aminium chloride (3.112): 
The Boc-protected dipeptide S28 (1.26 g, 2.01 mmol, 1.0 
eq.) was dissolved in HCl (6 mL, 4 M in dioxane, 0.3 M) 
and stirred at r.t. until TLC indicated complete 
consumption of the starting material (usually ca. 30 
min). The solvents were removed carefully and the crude beige solid was dried under 
high vacuum to give the hydrochloride salt 3.112 (1.05 g, 2.01 mmol, 98%) as a beige 
amorphous solid. All analytical data were in full agreement with the diastereomeric 
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mixture, except optical rotation, 1H NMR and 13C NMR. Rf = 0.00 (SiO2, pentane/Et2O, 
3:2). [α]D = –36.3° (c = 0.95 CHCl3). 1H NMR (400 MHz, MeOD) δ = 6.73 – 6.70 (m, 
2H), 6.60 (dd, J = 8.1, 2.1 Hz, 1H), 4.11 (d, J = 5.4 Hz, 1H), 4.01 (dd, J = 9.7, 5.6 Hz, 
1H), 3.70 (s, 3H), 3.62 (s, 2H), 3.02 (dd, J = 13.3, 5.5 Hz, 1H), 2.94 (dd, J = 13.3, 9.7 
Hz, 1H), 2.58 (s, 3H), 1.98 – 1.90 (m, 1H), 1.19 – 1.10 (m, 3H), 0.99 (d, J = 7.3 Hz, 
18H), 0.67 (d, J = 6.9 Hz, 3H), 0.64 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 
= 172.72, 168.68, 152.04, 146.10, 127.88, 122.70, 121.49, 114.38, 64.04, 59.69, 55.83, 
52.57, 37.46, 32.40, 30.97, 19.33, 18.34, 18.30, 14.07. 
 
Methyl (Z)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3-methoxyphenyl)-
acrylate (S29): To a solution of the TIPS protected phenol 3.98 (1.0 g, 2.08 mmol, 1.0 
eq.) in dry THF (10 mL) was added TBAF solution (1 M in THF, 2.3 
mL, 2.3 mmol, 1.1 eq.) at -40 °C. The solution turned bright yellow 
and was stirred at -40 °C for 10 min. Then the mixture was allowed 
to warm to room temperature and stirring was continued for 1 h. The 
reaction was quenched with saturated aqueous NH4Cl solution (10 
mL), then extracted with Et2O (4 x 30 mL), dried over sodium sulfate and the solvent 
was removed at reduced pressure. The residue was purified by flash chromatography 
(SiO2, pentane/Et2O 3:1) to furnish the deprotected phenol S29 (618 mg, 1.91 mmol, 
92%) as a colorless oil. Rf = 0.27 (SiO2, pentane/Et2O, 3:1). FTIR (neat): 3763, 3404, 
3209, 3163, 3086, 2983, 2926, 1690, 1598, 1513, 1430, 1357, 1303, 1251, 1211, 1154, 
1028, 994, 953, 908 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.10 (s, 1H), 7.04 (dd, J = 
8.3, 1.9 Hz, 1H), 6.83 (d, J = 8.3 Hz, 1H), 6.01 (s, 1H), 5.74 (s, 1H), 3.82 (s, 3H), 3.77 
(s, 3H), 1.35 (s, 9H). 13C NMR (101 MHz, CDCl3) δ = 166.32, 146.99, 146.29, 131.73, 
126.41, 124.68, 114.45, 111.86, 80.85, 69.82, 55.82, 52.50, 28.17. ESI-HRMS calc. for 
C16H21NNaO6+ [M+Na]+: 346.1267, found: 346.1261. 
 
3-Methoxy-4-[(4-methoxybenzyl)oxy]benzaldehyde (S30):319 To a suspension of 
vanillin (1.00 g, 6.51 mmol, 1.0 eq.), tetrabutylammonium iodide 
(481 mg, 1.30 mmol, 0.20 eq.) and K2CO3 (1.08 g, 7.81 mmol, 
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1.20 eq.) in dry acetone (30 mL) was added 4-methoxybenzyl chloride (1.22 g, 7.81 
mmol, 1.20 eq.) and the resulting mixture was stirred at reflux for 18 h. TLC indicated 
full consumption of starting material and water (30 mL) and DCM (20 mL) were added 
and the layers separated. The aqueous layer was extracted with DCM (3 x 30 mL). The 
combined organic layers were washed with brine (80 mL) and dried over sodium sulfate. 
The solvents were removed and the crude oil was purified by flash chromatography 
(SiO2, pentane/Et2O, 2:3) to give the PMB protected phenol S30 (830 mg, 3.05 mmol, 
47%) as a yellowish solid. All analytical data were in full agreement with the literature. 
Rf = 0.27 (SiO2, pentane/Et2O, 2:3). 1H NMR (400 MHz, CDCl3) δ = 9.84 (s, 1H), 7.46 
– 7.33 (m, 4H), 7.01 (d, J = 8.1 Hz, 1H), 6.95 – 6.87 (m, 2H), 5.17 (s, 2H), 3.93 (s, 3H), 
3.81 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 191.07, 159.78, 153.86, 150.25, 130.36, 
129.18, 128.15, 126.76, 114.28, 112.56, 109.47, 70.87, 56.19, 55.45. 
 
Methyl (Z)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(4-methoxybenzyl)-
oxy]phenyl}acrylate (S31): To a solution 0 °C cold solution of the phosphonate 3.97 
(293 mg, 1.0 mmol, 1.0 eq.) in DCM (3 mL) was added drop wise 
DBU (183 mg, 1.20 mmol, 1.20 eq.), upon which the reaction 
mixture turned yellow. After stirring at 0 °C for 15 min, the 
aldehyde S30 (327 mg, 1.20 mmol, 1.20 eq.) was added in small 
portions and the reaction was allowed to warm to room temperature 
and stirring was continued for 1 h (longer reaction time leads to an increase of 
byproducts). The organic layer was extracted with aqueous citric acid (10%, 10 mL), 
H2O (10 mL), dried over sodium sulfate and the solvents removed. Flash 
chromatography (SiO2, pentane/Et2O, 3:2) gave the title compound S31 as a colorless 
solid (200 mg, 450 mmol, 46%). Rf = 0.27 (SiO2, pentane/Et2O, 3:1). FTIR (neat): 
3227, 3110, 2976, 2874, 1720, 1696, 1595, 1514, 1462, 1435, 1355, 1246, 1151, 1030, 
992, 811, 779, 726, 654 cm-1. 1H NMR (400 MHz, CDCl3) δ= 7.35 (d, J = 8.6 Hz, 2H), 
7.25 (s, 1H), 7.20 (d, J = 1.6 Hz, 1H), 7.08 (d, J = 8.3 Hz, 1H), 6.88 (t, J = 8.6 Hz, 3H), 
5.11 (s, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H), 1.40 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ = 166.40, 159.60, 149.48, 129.13, 128.84, 127.30, 114.16, 113.48, 112.95, 
70.75, 56.0, 55.43, 52.64, 28.30. ESI-HRMS calc. for C24H29NNaO7+ [M+Na]+: 
466.1842, found: 466.1836.  
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Methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(4-methoxy-benzyl)-
oxy]phenyl}propanoate (S32): A flame-dried 5 mL vial with a screw cap was charged 
with the alkene S31 (80.0 mg, 0.18 mmol, 1.0 eq.) and the catalyst 
1,2-bis[(2R,5R)-2,5-diethylphospholano]benzene-(1,5-
cyclooctadiene)rhodium(I) trifluoromethanesulfonate (1.33 mg, 1.80 
µmol, 1 mol%) was added. The two solids were dissolved in a 
DCM/EtOAc mixture (1.5 mL, 1:2 v/v, degassed by argon bubbling 
for 20 min) and the open vial put into a hydrogenation autoclave. The reaction was set 
under H2 atmosphere (7.5 bar) and stirred for 5 d at RT. The mixture was then diluted 
with pentane (2 mL) and filtered through a short pad of silica. After rinsing the pad with 
Et2O (20 mL) the solvents were removed under reduced pressure to obtain the title 
compound S32 (79.0 mg, 0.17 mmol, 98%) as a yellowish solid. Rf = 0.27 (SiO2, 
pentane/Et2O, 3:1). [a]D= –35.2 (c = 0.93 CHCl3). FTIR (neat): 3362, 2939, 2875, 2840, 
2361, 2118, 1740, 1690, 1613, 1588, 1513, 1451, 1367, 1294, 1249, 1226, 1160, 1027, 
998, 867, 802, 752, 618 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.35 (d, J = 8.6 Hz, 2H), 
6.89 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.1 Hz, 2H), 6.68 – 6.56 (m, 2H), 5.03 (d, J = 11.0 
Hz, 2H), 4.95 (d, J = 7.1 Hz, 1H), 4.55 (dd, J = 12.8, 5.0 Hz, 1H), 3.85 (s, 3H), 3.80 (s, 
3H), 3.70 (s, 3H), 3.07 – 2.96 (m, 2H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3) δ = 
129.07, 129.05, 121.39, 114.11, 113.96, 112.89, 77.21, 70.84, 55.88, 55.26, 52.17, 
37.90, 28.26. ESI-HRMS calc. for C24H31NNaO7+[M+Na]+: 468.1999, found: 468.1993. 
 
Methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3-methoxyphenyl)-
propanoate (S33): A suspension of hydrogenation product S32 (20.0 mg, 44.9 mmol, 
1.0 eq.) and Pd/C (10%, 4.78 mg, 4.49 mmol, 0.1 eq.) in MeOH (2 
mL) was purged with H2 for 5 min and then stirred under a hydrogen 
atmosphere overnight. The solvent was removed under reduced 
pressure. The crude product was purified by flash chromatography 
(SiO2, pentane/Et2O, 2:3) to furnish the phenol S33 as a colorless oil 
(10.0 mg, 30.7 mmol, 68%). Rf = 0.32 (SiO2, pentane/Et2O, 2:3). [α]D = –34.0 (c = 0.5 
CHCl3). e.r. = 97:3 determined with chiral HPLC; Chiralpak IA, 80:20 
hexane/isopropanol, 1.0 mL/min, injection vol.: 5 µL, 25 °C, tR (R): 7.4 min, tR (S): 10.6 
min. FTIR (neat): 3370, 3336, 3009, 2979, 2933, 2359, 2117, 2053, 1737, 1687, 1603, 
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1531, 1441, 1393, 1362, 1271, 1224, 1158, 1065, 1028, 980, 895, 862, 816, 775, 712 
cm-1. 1H NMR (400 MHz, CDCl3) δ = 6.82 (d, J = 8.0 Hz, 1H), 6.60 (d, J = 8.1 Hz, 2H), 
5.55 (s, 1H), 4.97 (d, J = 7.4 Hz, 1H), 4.54 (dd, J = 13.6, 6.0 Hz, 1H), 3.86 (s, 3H), 3.71 
(s, 3H), 3.08 – 2.94 (m, 2H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3) δ = 172.59, 
155.23, 146.61, 144.84, 127.87, 122.23, 114.52, 111.77, 80.07, 55.99, 54.70, 52.33, 
38.14, 28.45. ESI-HRMS calc. for C16H23NNaO6+ [M+Na]+: 348.1423, found: 
348.1418. 
 
Methyl (R)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(4-
methoxybenzyl)oxy]phenyl}propanoate (S34): To a solution of the carbamate S33 
(1.14 g, 2.56 mmol, 1.0 eq.) in dry DMF (40 mL) was 
added NaH (154 mg, 3.84 mmol, 1.50 eq., 60% suspension 
in mineral oil) at 0 °C. After stirring for 10 min, MeI (1.45 
g, 10.2 mmol, 4.0 eq.) was added and the solution allowed to warm to r.t. After 4 h the 
reaction mixture was carefully quenched with saturated aqueous NH4Cl solution (50 
mL) and extracted with ether (3 x 30 mL). The combined organic layers were washed 
with water (4 x 50 mL) and dried over sodium sulfate. After removal of the solvent at 
reduced pressure the residue was purified by flash chromatography (SiO2, pentane/Et2O, 
2:3) to furnish the methylated carbamate S34 as a yellowish oil (1.0 g, 2.19 mmol, 
85%). Rotamers are visible in the 1H NMR (ca. 2:3, CDCl3). Rf = 0.27 (SiO2, 
pentane/Et2O, 3:1). [a]D= +13.0 (c = 0.85 CHCl3). FTIR (neat): 2952, 2361, 1742, 1692, 
1612, 1513, 1455, 1391, 1321, 1249, 1139, 1032, 992, 822, 650 cm-1. 1H NMR (400 
MHz, CDCl3) δ = 7.38 – 7.31 (m, 2H), 6.93 – 6.85 (m, 2H), 6.83 – 6.58 (m, 3H), 5.04 (s, 
2H), 4.91 (dd, J = 10.8, 5.2 Hz, 0.5H), 4.43 (dd, J = 10.5, 4.1 Hz, 0.5H), 3.85 (s, 3H), 
3.80 (s, 3H), 3.73 (d, J = 7.6 Hz, 3H), 3.32 – 3.10 (m, 1H), 3.01 – 2.90 (m, 1H), 2.70 (d, 
J = 6.5 Hz, 2H), 1.44 – 1.28 (m, 9H). 13C NMR (126 MHz, CDCl3) δ =165.59, 155.94, 
153.18, 135.23, 129.03, 121.0, 113.94, 112.67, 86.15, 70.90, 67.94, 61.97, 59.34 55.76, 
55.27, 52.12, 34.75, 32.40, 28.20. ESI-HRMS calc. for C25H33NNaO7+ [M+Na]+: 
482.2155, found: 482.2149.  
COOMe
PMBO
OMe
NBoc
H3C
Experimental Part 
161 
Methyl (R)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(4-methoxy-
benzyl)oxy]phenyl}propanoyl-S-valinate (S35): The methyl ester S34 (452 mg, 980 
mmol, 1.0 eq.) was dissolved in a mixture of 
THF/MeOH/H2O (6:2:1 v/v/v, 14 mL). A solution of 
NaOH (1.48 mL, 2.95 mmol, 3.0 eq., 2M in water) 
was then added and the solution was stirred for 30 min 
at r.t. The reaction mixture was extracted with diethylether (3 x 30 mL) to remove 
byproducts and the aqueous phase was then acidified with 1 M HCl to pH ~2, where the 
formation of a white precipitate could be observed. The suspension was extracted with 
Et2O (3 x 40 mL) and the combined organic phases were dried over sodium sulfate 
before removal of the solvent. The crude oil was used directly in the next step without 
further purification. 
The crude acid was dissolved in DCM (4 mL) and cooled to 0 °C. S-valine methyl ester 
hydrochloride (157 mg, 0.94 mmol, 1.02 eq.), HOBt (137 mg, 1.01 mmol, 1.20 eq.), 
HBTU (384 mg, 1.01 mmol, 1.20 eq.) and diisopropylethylamine (262 mg, 2.02 mmol, 
2.20 eq.) were added. The suspension was allowed to warm to r.t. and stirred for 14 h. 
The reaction mixture was then diluted with EtOAc (5 mL), washed with aqueous HCl 
(10 mL, 1 M), saturated aqueous NaHCO3 (10 mL) and brine (10 mL). After drying over 
sodium sulfate, filtration and subsequent removal of the solvent at reduced pressure the 
residue was purified by flash chromatography (SiO2, pentane/Et2O, 2:3) to furnish the 
dipeptide S35 (382 mg, 682 µmol, 70% over 2 steps) as a colorless oil. Rf = 0.31 (SiO2, 
pentane/Et2O, 3:2). [α]D = +21.5 (c = 0.5 CHCl3). FTIR (neat): 3353, 2965, 2876, 2838, 
2336, 2049, 1741, 1683, 1612, 1588, 1512, 1463, 1398, 1320, 1249, 1141, 1033, 957, 
865, 822, 770, 737, 653, 623 cm-1. 1H NMR (400 MHz, MeOD) δ = 7.33 (d, J = 8.6 Hz, 
2H), 6.98 – 6.82 (m, 4H), 6.73 (dd, J = 8.2, 1.7 Hz, 1H), 4.98 (s, 2H), 4.32 (d, J = 6.2 
Hz, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.72 (s, 3H), 2.79 (s, 3H), 2.13 (s, 1H), 1.38 (s, 9H), 
0.89 (s, 6H). 13C NMR (126 MHz, CDCl3) δ =172.0, 159.60, 149.79, 130.50, 129.31, 
121.02, 114.81, 112.85, 72.19, 60.61, 59.17, 56.41, 55.64, 52.47, 35.43, 35.43, 35.39, 
31.49, 31.68, 28.54, 28.49, 19.12, 18.98. ESI-HRMS calc. for C30H42N2NaO8+ 
[M+Na]+:  581.2839, found: 581.2833.  
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Methyl (R)-2-{[(benzyloxy)carbonyl]amino}-3-{3-methoxy-4-[(triisopropyl-silyl)-
oxy]phenyl}propanoate (3.109): To a 0 °C cold solution of the carbamate 3.100 (502 
mg, 1.04 mmol, 1.0 eq.) in dry DCM (2 mL) TFA (2 mL) was 
added slowly. After 30 min, TLC indicated full consumption of the 
starting material and the solvents were removed under reduced 
pressure. After carefully drying under high vacuum, the residue was 
directly used in the next step. 
The crude product was dissolved in a mixture of Et2O (4.5 mL) and H2O (6 mL) and 
Na2CO3 was added (276 mg, 2.60 mmol, 2.50 eq.). After stirring for 10 min, benzyl 
chloroformate (177 mg, 1.04 mmol, 1.0 eq.) was added drop wise. The mixture was then 
stirred at room temperature for 14 h. The suspension was diluted with Et2O (5 mL) and 
the organic phase was washed with brine (2 x 20 mL) and dried over sodium sulfate. 
After removal of the solvent at reduced pressure, the residue was purified by flash 
chromatography (SiO2, pentane/Et2O, 3:1) to obtain the Cbz-protected compound 3.109 
(512 mg, 0.99 mmol, 96% over 2 steps) as a colorless oil. Rf = 0.37 (SiO2, pentane/Et2O 
3:1). [α]D = –33.8 (c = 0.67 CHCl3). FTIR (neat): 3339, 3034, 2945, 2866, 1722, 1585, 
1512, 1462, 1346, 1280, 1236, 1211, 1160, 1128, 1038, 883, 818, 774, 738, 679 cm-1. 
1H NMR (400 MHz, CDCl3) δ = 7.41 – 7.28 (m, 5H), 6.77 (d, J = 8.0 Hz, 1H), 6.65 – 
6.43 (m, 2H), 5.19 (d, J = 8.1 Hz, 1H), 5.09 (q, J = 12.3 Hz, 2H), 4.71 – 4.50 (m, 1H), 
3.72 (s, 3H), 3.68 (s, 3H), 3.08 – 2.96 (m, 2H), 1.31 – 1.16 (m, 3H), 1.07 (d, J = 7.2 Hz, 
18H). 13C NMR (126 MHz, CDCl3) δ = 172.23, 155.72, 150.99, 144.77, 136.39, 128.88, 
128.76, 128.67, 128.54, 128.33, 128.24, 121.49, 120.57, 113.11, 67.07, 55.51, 55.07, 
52.37, 38.16, 18.01, 12.95. ESI-HRMS calc. for C28H41NNaO6Si+ [M+Na]+: 538.2601, 
found: 538.2595. 
 
Methyl (R)-2-{[(benzyloxy)carbonyl](methyl)amino}-3-{3-methoxy-4-[(triisopropyl-
silyl)oxy]phenyl}propanoate (S36): To a solution of the carbamate 3.109 (539 mg, 
1.05 mmol, 1.0 eq.) in dry DMF (8 mL) was added NaH 
(50.0 mg, 1.25 mmol, 1.20 eq., 60% dispersion in mineral 
oil) at 0 °C. After stirring for 20 min, MeI (593 mg, 4.18 
mmol, 4.0 eq.) was added and the reaction mixture was allowed to warm to r.t. After 1.5 
h, the reaction was carefully quenched with saturated aqueous NH4Cl (20 mL) and then 
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extracted with Et2O (3 x 30 mL). The combined organic layers were then washed with 
water (3 x 80 mL) and dried over sodium sulfate. After removal of the solvent, the crude 
product was purified by flash chromatography (SiO2, pentane/Et2O, 3:2) to furnish the 
methylated carbamate S36 (463 mg, 0.87 mmol, 83%) as a slightly yellow oil. Rf = 0.31 
(SiO2, pentane/Et2O, 3:2). [α]D = +9.2 (c = 0.42 CHCl3). FTIR (neat): 2944, 2866, 
2356, 1744, 1703, 1585, 1514, 1460, 1401, 1280, 1234, 1138, 1039, 1005, 884, 618, 
767, 734, 677 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.41 – 7.20 (m, 5H), 6.79 – 6.52 
(m, 3H), 5.18 – 5.0 (m, 2H), 4.98 – 4.61 (m, 1H), 3.71 (d, J = 8.2 Hz, 3H), 3.66 (d, J = 
4.8 Hz, 3H), 3.33 – 3.12 (m, 1H), 3.08 – 2.86 (m, 1H), 2.79 (d, J = 15.5 Hz, 3H), 1.33 – 
1.16 (m, 3H), 1.07 (d, J = 7.2 Hz, 18H). 13C NMR (126 MHz, CDCl3) δ = 171.78, 
156.62, 156.38, 150.97, 144.29, 130.23, 128.59, 128.15, 128.04, 127.72, 121.09, 120.53, 
112.85, 112.68, 109.75, 67.54, 67.34, 61.37, 60.48, 55.51, 52.37, 35.14, 34.71, 32.78, 
31.99, 18.02, 17.84, 12.95. ESI-HRMS calc. for C29H43NNaO6Si+ [M+Na]+: 552.2758, 
found: 552.2752. 
 
Methyl [(R)-2-{[(benzyloxy)carbonyl](methyl)amino}-3-{3-methoxy-4-[(triiso-
propylsilyl)oxy]phenyl}propanoyl}-S-valinate (S37): To a solution of the methyl ester 
S36 (423 mg, 793 µmol, 1.0 eq.) in THF/MeOH/H2O 
(6:2:1 v/v/v, 9 mL) was added aqueous NaOH (0.59 
mL, 1.20 mmol, 1.50 eq., 2 M) and the mixture was 
stirred for 30 min. The reaction mixture was then 
acidified with 1 M HCl to pH ~2, where the formation of a white precipitate could be 
observed. The suspension was extracted with Et2O (3 x 40 mL) and the combined 
organic layers were dried over sodium sulfate before removal of the solvent. The crude 
acid was directly used in the next step. 
The crude acid was dissolved in DCM (3.5 ml) cooled to 0 °C. S-valine methyl ester 
hydrochloride (113 mg, 674 mmol, 1.00 eq.), HOBt (98.6 mg, 0.72 mmol, 1.20 eq.), 
HBTU (277 mg, 723 mmol, 1.20 eq.) and diisopropylethylamine (189 mg, 1.46 mmol, 
2.20 eq.) were added. The suspension was allowed to warm to r.t. and stirred for 14 h. 
The reaction mixture was then diluted with EtOAc (5 mL), washed with aqueous HCl 
(10 mL, 1 M), saturated NaHCO3 (10 mL) and brine (10 mL). After drying over sodium 
sulfate, filtration and subsequent removal of the solvent at reduced pressure, the residue 
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was purified by flash chromatography (SiO2, pentane/Et2O, 1:1) to furnish dipeptide S37 
(274 mg, 0.43 mmol, 54% over 2 steps) as a colorless oil. Rf = 0.28 (SiO2, pentane/Et2O, 
1:1). [a]D20 = + 19.2 (c = 0.47, CHCl3). FTIR (neat): 3382, 2944, 2867, 2358, 1743, 
1675, 1606, 1585, 1513, 1463, 1395, 1282, 1236, 1211, 1154, 1037, 998, 885, 818, 767, 
734, 680, 632 cm-1. 1H NMR (400 MHz, MeOD) δ = 7.30 (m, 5H), 6.93 – 6.55 (m, 3H), 
5.22 – 4.94 (m, 4H), 4.32 (d, J = 6.2 Hz, 2H), 3.89 – 3.65 (m, 6H), 3.19 (s, 2H), 3.01 – 
2.82 (m, 4H), 2.10 (ddd, J = 31.3, 18.7, 4.9 Hz, 1H), 1.32 – 1.16 (m, 3H), 1.09 (d, J = 
7.2 Hz, 18H), 0.95 – 0.85 (m, 6H). 13C NMR (126 MHz, MeOD) δ = 172.01, 171.99, 
157.18, 150.75, 128.11, 128.0, 127.12, 120.86, 119.95, 112.57, 67.08, 66.98, 65.51, 
60.06, 57.91, 57.86, 57.84, 54.34, 51.06, 47.76, 30.21, 17.93, 16.95, 12.65. ESI-HRMS 
calc. for C34H52N2NaO7Si+ [M+Na]+: 651.3442, found: 651.3445.  
  
Methyl {(R)-3-(3-methoxy-4-[(triisopropylsilyl)oxy]phenyl}-2-(methylamino)-
propanoyl}-S-valinate (3.103/3.104): To a solution of Cbz-protected amine S37 (129 
mg, 0.20 mmol,  1.0 eq.) in MeOH (4 mL) was added 
Pd/C (10%, 40.0 mg, 0.32 mmol, 1.10 eq.) and after 
bubbling H2 through the solution for 10 min, the flask 
was closed and kept under a hydrogen atmosphere while 
stirring for 2 h monitored by TLC. The mixture was filtered over a pad of diatomaceous 
earth and washed with DCM (20 mL). After drying over sodium sulfate, filtration and 
removal of the solvent, two the diastereomers 3.103 and 3.104 (91.0 mg, 0.18 mmol, 
90%, ratio: 43:57) could be isolated by flash chromatography (SiO2, EtOAc). Major 
diastereomer: Rf = 0.31 (SiO2, EtOAc). [α]D = +34.8 (c = 1.0 CHCl3). FTIR (neat): 
3302, 3174, 2943, 2866, 2358, 1731, 1664, 1514, 1464, 1382, 1291, 1211, 1159, 1137, 
1040, 1015, 908, 827, 674 cm-1. 1H NMR (400 MHz, MeOD) δ = 6.82 – 6.75 (m, 2H), 
6.69 – 6.63 (m, 1H), 4.22 (d, J = 5.9 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 3.38 (dd, J = 
16.3, 9.4 Hz, 2H), 2.82 (d, J = 7.4 Hz, 2H), 2.34 (s, 3H), 2.0 (td, J = 13.6, 6.9 Hz, 1H), 
1.33 – 1.18 (m, 3H), 1.10 (d, J = 7.1 Hz, 18H), 0.77 (dd, J = 6.9, 1.6 Hz, 6H). 13C NMR 
(101 MHz, MeOD) δ = 176.06, 173.38, 152.0, 145.53, 131.70, 122.48, 121.16, 114.42, 
66.53, 59.14, 55.84, 52.42, 40.02, 34.46, 31.53, 19.43, 18.54, 18.41, 14.16. Minor 
diastereomer: Rf = 0.34 (SiO2, EtOAc). [α]D = –28.6 (c = 1.0 CHCl3). FTIR (neat): 
3341, 2944, 2867, 2352, 1743, 1673, 1605, 1512, 1464, 1280, 1235, 1157, 1037, 1016, 
883, 816, 757, 678 cm-1. 1H NMR (500 MHz, MeOD) δ = 6.79 – 6.72 (m, 2H), 6.63 (dd, 
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J = 8.0, 2.1 Hz, 1H), 4.31 (d, J = 6.2 Hz, 1H), 3.77 (s, 3H), 3.64 (s, 3H), 3.48 – 3.31 (m, 
1H), 2.90 – 2.74 (m, 2H), 2.31 (s, 3H), 2.11 – 2.03 (m, 1H), 1.30 – 1.17 (m, 3H), 1.08 
(d, J = 7.3 Hz, 18H), 0.89 (d, J = 6.8 Hz, 6H). 13C NMR (126 MHz, MeOD) δ = 175.89, 
172.97, 152.05, 131.76, 122.45, 121.24, 114.28, 66.91, 58.90, 55.74, 52.53, 40.13, 
34.74, 31.98, 19.49, 18.47, 18.39, 14.13. ESI-HRMS calc. for C26H46N2NaO5Si+ 
[M+Na]+: 517.3074, found: 517.3068. 
 
 Methyl (Z)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(triisopropyl-
silyl)oxy]phenyl}acrylate (S38): The carbamate 3.98 (311 mg, 0.65 mmol, 1.0 eq.) was 
dissolved in DMF (5 mL) and cooled to 0 °C. NaH (31.0 mg, 0.77 
mmol, 1.20 eq., 60% dispersion in mineral oil) was added and 
stirring was continued for 10 min before MeI (368 mg, 2.59 mmol, 
4.0 eq.) was added drop wise. The reaction mixture was allowed to 
warm to r.t. and after 1.5 h was quenched with saturated aqueous NH4Cl (20 mL). The 
suspension was extracted with Et2O (3 x 20 mL) and the combined organic layers were 
washed with H2O (4 x 50 mL) before drying over sodium sulfate. After removal of the 
solvent, the residue was purified by flash chromatography (SiO2, pentane/Et2O, 3:2) to 
furnish methylated product S38 (273 mg, 0.55 mmol, 86%) as a slightly yellow oil. Rf = 
0.31 (SiO2, pentane/Et2O, 3:2). FTIR (neat): 2945, 2867, 2360, 1715, 1635, 1596, 1512, 
1463, 1434, 1347, 1285, 1228, 1153, 1069, 1037, 1009, 901, 819, 776, 681 cm-1. 1H 
NMR (250 MHz, CDCl3) δ= 7.29 (s, 1H), 7.16 – 7.08 (m, 1H), 7.05 – 6.96 (m, 1H), 
6.91 – 6.82 (m, 1H), 3.82 (s, 3H), 3.79 (s, 3H), 2.96 (s, 3H), 1.35 (s, 9H), 1.29 – 1.17 
(m, 3H), 1.09 (d, J = 6.7 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ = 166.39, 155.10, 
150.89, 147.53, 134.46, 128.91, 126.41, 124.17, 120.39, 112.71, 80.31, 55.15, 52.04, 
34.30, 28.14, 17.69, 12.71. ESI-HRMS calc. for C26H43NNaO6Si+ [M+Na]+: 516.2758, 
found: 516.2752.  
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Methoxymethyl (R)-2-(methoxymethoxy)-2-phenylacetate (S39):320 (R)-(–)-mandelic 
acid (3.82) (2.00 g, 10.0 mmol, 1.0 eq.) was dissolved in dry DCM 
(25 ml). DIPEA (5.43 ml, 30.0 mmol, 3.0 eq.) was added followed 
by chloromethyl methyl ether (2.50 ml, 30 mmol, 3.00 eq.) upon 
which the formation of HCl gas could be observed. The mixture was gently refluxed for 
18 h. The mixture was then washed with water (3 x 50 mL). The organic layer was dried 
over Sodium sulfate and filtered before removal of the solvent. The crude product was 
further purified by flash chromatography (SiO2, pentane/Et2O, 4:1) to obtain compound 
S39 (2.91 g, 0.01 mmol, 93%) as a colorless oil. All analytical data were in full 
agreement with the literature data. 1H NMR (400 MHz, CDCl3) δ = 7.51 – 7.46 (m, 2H), 
7.41 – 7.32 (m, 3H), 5.26 (dd, J = 20.7, 5.9 Hz, 2H), 5.20 (s, 1H), 4.74 (dd, J = 26.2, 6.9 
Hz, 2H), 3.40 (s, 3H), 3.29 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 170.53, 136.13, 
128.97, 128.83, 127.60, 95.18, 91.04, 57.68, 56.16. 
 
(R)-2-(Methoxymethoxy)-2-phenylacetaldehyde (3.83):320 To a -78 °C cold solution of 
ester S39 (1.0 g, 4.18 mmol, 1.0 eq.) in dry DCM (10 ml) was slowly 
added DIBAL-H (4.60 ml, 4.60 mmol, 1.10 eq., 1 M in cyclohexane). 
The solution was stirred at -78 °C for 2 h and then quenched with 
MeOH (10 mL). The mixture was then allowed to warm to r.t. and the viscous 
suspension filtered over a pad of diatomaceous earth. The residue was washed with H2O 
(20 ml) and extracted with DCM (50 ml) and the aqueous phase was extracted with 
DCM (3 x 30 ml). The combined organic layers were dried over sodium sulfate and the 
solvent removed at reduced pressure. The residue was purified by flash chromatography 
(SiO2, pentane/ether, 3:2) to obtain the MOM-protected ester 3.83 (572 mg, 3.17 mmol, 
76%) as a colorless and semi stable oil (5% decomposition after storage for 4 weeks at -
20 °C). All analytical data were in full agreement with the literature data. 1H NMR (400 
MHz, CDCl3) δ = 9.62 (d, J = 1.6 Hz, 1H), 7.50 – 7.32 (m, 5H), 5.04 (s, 1H), 4.85 – 
4.68 (m, 2H), 3.42 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 198.01, 133.67, 129.18, 
129.10, 127.76, 95.36, 83.31, 56.15.  
                                                
 
320 E. J. Corey, F. J. Hannon, N. W. Boaz, Tetrahedron 1989, 45, 545. 
OMOM
O
OMOM
OMOM
O
H
Experimental Part 
167 
(1R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-ol (3.84): The aldehyde 3.83 (1.52 g, 
8.47 mmol, 1.0 eq.) was dissolved in dry THF (15 mL) and cooled to -
78 °C. Then ethynylmagnesium bromide (25.4 mL, 12.7 mmol, 1.5 
eq., 0.5 M solution in THF) was added drop wise and the reaction 
stirred for 1 h while slowly warming to room temperature. The mixture was then 
quenched with saturated aqueous NH4Cl (30 mL) and extracted with Et2O (3 x 30 mL). 
The combined organic layers were dried over sodium sulfate, filtered and after removal 
of the solvent purified by flash chromatography (SiO2, pentane/Et2O, 2:3) to furnish the 
propargylic alcohol 3.84 (1.41 g, 6.82 mmol, 81%, d.r.: 3:2 syn/anti) as a colorless oil. 
Rf = 0.25 (SiO2, pentane/Et2O 2:3). FTIR (neat): 3412, 3288, 3033, 2951, 2983, 2827, 
2681, 2334, 2118, 1605, 1454, 1403, 1262, 1212, 1150, 1073, 1025, 916, 846, 762, 703, 
632 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.47 – 7.30 (m, 5H), 4.79 – 4.60 (m, 3H), 
4.52 (dd, J = 6.5, 1.6 Hz, 1H), 3.44 (d, J = 27.2 Hz, 3H), 2.93 (d, J = 13.3 Hz, 1H), 2.43 
(dd, J = 29.9, 2.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 137.0, 136.91, 128.74, 
128.55, 128.45, 128.10, 127.62, 95.74, 94.87, 82.23, 81.50, 81.03, 75.07, 74.87, 66.77, 
66.53, 56.18, 56.10. ESI-HRMS calc. for C12H14NaO3+ [M+Na]+: 229.0841, found: 
229.0853. 
 
(1R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-yl 3,5-dinitrobenzoate (S40): To a 
solution of diastereomeric mixture of the propargylic 
alcohol 3.84 (104 mg, 500 µmol, 1.0 eq.) in dry DCM (2 
mL) were added 3,5-dinitrobenzoyl chloride (237 mg, 1.01 
mmol, 2.0 eq.), DMAP (6.15 mg, 50 mmol, 0.10 eq.) and 
NEt3 (128 mg, 1.26 mmol, 2.50 eq.), upon which the formation of HCl gas could be 
observed. The clear red solution was stirred for 14 h, quenched with saturated aqueous 
NH4Cl (5 mL) and extracted with Et2O (3 x 10 mL). The combined organic layers were 
dried over sodium sulfate and the residue was purified by flash chromatography (SiO2, 
pentane/Et2O 3:1) to furnish the ester S40 (159 mg, 0.39 mmol, 79%) as a yellowish oil. 
Rf = 0.36 (SiO2, pentane/ether 3:1). FTIR (neat): 3472, 3288, 3100, 2952, 2893, 2826, 
2359, 2129, 1983, 1738, 1629, 1600, 1544, 1495, 1458, 1343, 1267, 1155, 1102, 1076, 
1024, 966, 844, 767, 720, 647, 610 cm-1. 1H NMR (400 MHz, CDCl3) δ = 9.24 (dt, J = 
9.9, 2.1 Hz, 1H), 9.14 (dd, J = 35.8, 2.1 Hz, 2H), 7.58 – 7.33 (m, 5H), 7.24 – 7.13 (m, 
1H), 5.88 (ddd, J = 7.0, 6.0, 2.2 Hz, 1H), 5.06 (dd, J = 8.9, 6.0 Hz, 1H), 4.75 – 4.58 (m, 
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2H), 3.41 (d, J = 26.2 Hz, 3H), 2.57 (dd, J = 47.7, 2.2 Hz, 1H), 2.36 (s, 1H).13C NMR 
(101 MHz, CDCl3) δ = 161.48, 148.86, 135.93, 135.79, 133.45, 129.74, 129.72, 129.28, 
129.18, 128.73, 128.68, 128.37, 128.22, 128.01, 125.44, 122.86, 94.71, 94.59, 78.11, 
77.93, 77.06, 68.88, 56.05. ESI-HRMS calc. for C19H16N2NaO8+ [M+Na]+: 423.0805, 
found: 423.0799. 
 
(1R,2R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-yl acetate (3.91): The 
diastereomerically impure alcohol 3.84 (956 mg, 4.64 mmol, 1.0 eq.) 
was dissolved in dry hexane (20 mL) and vinyl acetate (1.39 g, 16.2 
mmol, 3.50 eq.) and immobilized lipase B from Candida antarctica 
(50 mg, >2 U/mg) were added. The mixture was stirred for 6 d, upon 
which 1H NMR indicated complete consumption of one of the diastereomeric alcohols. 
The suspension was filtered and the solvents removed. The residue was then purified by 
flash chromatography (SiO2, pentane/Et2O, 3:2) to obtain the ester 3.91 (580 mg, 2.34 
mmol, quant.) as a diastereomerically pure compound. Rf = 0.31 (SiO2, pentane/Et2O 
3:2). [α]D = –185 (c = 0.85 CHCl3). FTIR (neat): 3285, 2946, 2893, 1744, 1454, 1372, 
1226, 1152, 1104, 1021, 971, 918, 831, 765, 703, 633 cm-1. 1H NMR (400 MHz, 
CDCl3) δ = 7.46 – 7.33 (m, 5H), 5.67 (dd, J = 6.7, 2.2 Hz, 1H), 4.86 (d, J = 6.7 Hz, 1H), 
4.63 (dd, J = 25.3, 6.8 Hz, 2H), 3.41 (s, 3H), 2.41 (d, J = 2.2 Hz, 1H), 2.13 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ = 169.67, 136.59, 128.84, 128.43, 128.23, 94.55, 78.63, 
78.12, 75.44, 66.53, 55.86, 20.98. ESI-HRMS calc. for C14H16NaO4+ [M+Na]+: 
271.0938, found: 271.0941. 
 
(1R,2R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-ol (3.92): To a solution of the ester 
3.91 (330 mg, 1.33 mmol, 1.0 eq.) in a mixture of MeOH (2.4 mL) and 
water (0.6 mL) was added K2CO3 (919 mg, 6.65 mmol, 5.0 eq.). After 
1 h stirring at room temperature, TLC indicated full consumption of 
the starting material and the mixture was acidified with aqueous HCl (1 M). The mixture 
was then extracted with Et2O (3 x 20 mL) and the combined organic layers were dried 
over sodium sulfate. Evaporation of the solvent under reduced pressure furnished 
(1R,2R)-1-(methoxymethoxy)-1-phenylbut-3-yn-2-ol (3.92) (256 mg, 1.24 mmol, 94%) 
as a colorless oil. Rf = 0.25 (SiO2, pentane/Et2O 2:3). [α]D = –155.7 (c = 0.85 CHCl3). 
OMOM
O
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FTIR (neat): 3412, 3288, 3033, 2951, 2983, 2827, 2681, 2334, 2118, 1605, 1454, 1403, 
1262, 1212, 1150, 1073, 1025, 916, 846, 762, 703, 632 cm-1. 1H NMR (500 MHz, 
CDCl3) δ = 7.42 – 7.32 (m, 5H), 4.71 – 4.65 (m, 2H), 4.64 – 4.61 (m, 1H), 4.52 (dd, J = 
6.8, 2.1 Hz, 1H), 3.41 (s, 3H), 2.81 (s, 1H), 2.40 (d, J = 2.2 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ = 137.0, 128.76, 128.47, 128.10, 94.89, 81.49, 81.05, 74.88, 66.56, 
56.12. ESI-HRMS calc. for C12H14NaO3+ [M+Na]+: 229.0841, found: 229.0852. 
  
 (1R,2R,E)-1-(Methoxymethoxy)-1-phenyl-4-(tributylstannyl)but-3-en-2-ol (3.27): 
To a solution of the alkyne 3.92 (96 mg, 460 mmol, 1.0 eq.) in 
dry THF (5 mL) was added 
bis(triphenylphosphine)palladium(II) chloride (16.3 mg, 20.0 
µmol, 5 mol%) at 0 °C. Then tributyltin hydride (0.21 ml, 0.69 mmol, 1.50 eq.) was 
added slowly. After 30 min TLC indicated complete consumption of the starting 
material. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography (SiO2, Et2O/pentane/NEt3 2:3:0.05) to yield the 
stannane 3.27 (132 mg, 265 mmol, 58%, E/Z >10:1) as a dark brownish oil. The 
stannane should be used immediately as it decomposes within 2 weeks at 5 °C to an 
unknown byproduct in a 1:1 ratio. Rf = 0.34 (SiO2, Et2O/pentane/NEt3 2:3:0.1). [a]D20 = 
–29.8 (c = 0.39 CHCl3). FTIR (neat): 3465, 2924, 2851, 1603, 1456, 1376, 1341, 1255, 
1150, 1074, 1025, 921, 864, 755, 700, 664 cm-1. 1H NMR (400 MHz, CDCl3) δ = 7.36 – 
7.27 (m, 5H), 6.12 (dd, J = 19.2, 1.4 Hz, 1H), 5.78 (dd, J = 19.2, 5.3 Hz, 1H), 4.60 (d, J 
= 0.7 Hz, 2H), 4.43 (d, J = 7.5 Hz, 1H), 4.30 – 4.22 (m, 1H), 3.38 (s, 3H), 2.87 (d, J = 
2.9 Hz, 1H), 1.48 – 1.18 (m, 14H), 0.96 – 0.70 (m, 16H). 13C NMR (101 MHz, CDCl3) 
δ = 145.24, 138.14, 131.48, 128.37, 128.29, 128.13, 94.69, 82.44, 78.52, 56.03, 29.12, 
27.42, 13.82, 9.49. ESI-HRMS calc. for C24H42NaO3Sn+ [M+Na]+: 521.2054, found: 
521.2052.  
OMOM
OH
SnBu3
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Preparation of the (S)- and (R)-MTPA-diol esters 3.93 and 3.94 : To a stirred 
solution of the alcohol 3.92 (10 mg, 40.3 mmol, 1.0 eq.) and dry 
pyridine (11.9 mg, 150 mmol, 3.1 eq.) in dry DCM (1 mL) was 
added (R)-(–)-MTPACl (23.3 mg, 90.0 mmol, 1.90 eq.) at room 
temperature. After stirring for 15 h, the mixture was quenched by the 
addition of H2O (1 mL) and extracted with Et2O (3 x 5 mL). The 
combined organic layers were dried over sodium sulfate and after removal of the 
solvent, the crude product was further purified by flash chromatography (SiO2, 
Et2O/pentane, 2:3) to give the S-ester 3.94 as a colorless oil (20 mg, 40.0 µmol, 98%). 
1H NMR (600 MHz, CDCl3) δ = 7.58 – 7.54 (m, 2H), 7.44 – 7.36 (m, 3H), 7.35 – 7.30 
(m, 5H), 5.79 (dd, J = 7.9, 2.2 Hz, 1H), 4.75 (d, J = 7.9 Hz, 1H), 4.38 (dd, J = 14.8, 6.8 
Hz, 2H), 3.62 (d, J = 1.0 Hz, 3H), 3.01 (s, 3H), 2.42 (d, J = 2.2 Hz, 1H). 
In an entirely analogous fashion, the (R)-ester 3.93 was prepared using (S)-(+)-MTPACl 
with a yield of 95%. 1H NMR (600 MHz, CDCl3) δ = 7.54 (d, J = 6.9 Hz, 2H), 7.45 – 
7.33 (m, 12H), 5.74 (dd, J = 8.2, 2.2 Hz, 1H), 4.85 (d, J = 8.2 Hz, 1H), 4.60 (d, J = 6.7 
Hz, 1H), 4.54 (d, J = 6.7 Hz, 1H), 3.54 (d, J = 0.6 Hz, 3H), 3.42 (d, J = 1.1 Hz, 2H), 
3.24 (s, 3H), 2.38 (d, J = 2.2 Hz, 1H).
OMOM
O O
F3C
Ph
MeO
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7 NMR Spectra 
(R,E)-ethyl-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylhex-2-enoate (2.71): 
 
 
NMR Spectra 
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(R,E)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-methylhex-2-en-1-ol (S2): 
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(R,E)-4-(hydroxymethyl)-2-methylhex-2-enal (S3): 
 
 
  
NMR Spectra 
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(S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)butanal (S1):
 
 
  
NMR Spectra 
181 
Dimethyl ((2Z,4E,6E)-1-(4-methoxy-5-(4-((4-methoxybenzyl)oxy)phenyl)-2-oxo-
1,2-dihydropyridin-3-yl)-6,8-dimethyl-1-oxodeca-2,4,6-trien-2-yl)phosphonate 
(2.74): 
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NMR Spectra 
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3-((R,2E,4E)-6-(hydroxymethyl)-4-methylocta-2,4-dienoyl)-4-methoxy-5-(4-((4-
methoxybenzyl)oxy)phenyl)pyridin-2(1H)-one (S5): 
 
  
NMR Spectra 
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NMR Spectra 
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(–)-Pyridovericin (2.46): 
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(E)-ethyl 2-methyl-7-oxohept-2-enoate (3.31):321 
  
                                                
 
321 E. L. Richards, P. J. Murphy, F. Dinon, S. Fratucello, P. M. Brown, T. Gelbrich, Michael B. 
Hursthouse, Tetrahedron 2001, 57, 7771. 
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(E)-ethyl 7-hydroxy-2-methyl-9-(trimethylsilyl)non-2-en-8-ynoate (S7): 
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(E)-ethyl 7-methoxy-2-methyl-9-(trimethylsilyl)non-2-en-8-ynoate (3.32): 
 
 
  
NMR Spectra 
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(E)-methyl 9-methoxy-2,4-dimethyl-3-oxo-11-(trimethylsilyl)undec-4-en-10-
ynoate (S8): 
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(E)-tert-butyl 9-methoxy-2,4-dimethyl-3-oxo-11-(trimethylsilyl)undec-4-en-10-
ynoate (S9): 
 
  
NMR Spectra 
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Diethyl (1-(2,2,5-trimethyl-4-oxo-4H-1,3-dioxin-6-yl)ethyl)phosphonate (3.44): 
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2,2,5-Trimethyl-5-propionyl-1,3-dioxane-4,6-dione (S10): 
 
 
  
NMR Spectra 
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N-methoxy-N-methylmethacrylamide (S11): 
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2-Methyl-1-morpholinoprop-2-en-1-one (S12): 
 
 
  
NMR Spectra 
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(E)-3-bromo-N-methoxy-N,2-dimethylacrylamide (3.58): 
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(E)-3-bromo-2-methyl-1-morpholinoprop-2-en-1-one (3.59): 
 
 
  
NMR Spectra 
199 
tert-butyl 2,4-dimethyl-3-oxopent-4-enoate (S42):
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tert-Butyl 3-hydroxy-2,4-dimethylpent-4-enoate (S13): 
 
 
  
NMR Spectra 
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2,2,5-trimethyl-6-(prop-1-en-2-yl)-4H-1,3-dioxin-4-one (3.52):
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(E)-1-bromo-2-methylocta-1,7-dien-3-one (3.60): 
  
  
NMR Spectra 
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(E)-1-bromo-2-methylocta-1,7-dien-3-ol (S14): 
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(E)-1-bromo-3-methoxy-2-methylocta-1,7-diene (3.53): 
 
 
  
NMR Spectra 
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(E)-2-(6-bromo-4-methoxy-5-methylhex-5-en-1-yl)-1,3-dioxolane (S16): 
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(2E,8E)-9-bromo-7-methoxy-2,8-dimethylnona-2,8-dienal (S17): 
 
  
NMR Spectra 
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(4E,10E)-methyl 11-bromo-3-hydroxy-9-methoxy-2,4,10-trimethylundeca-4,10-
dienoate (3.71): 
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(E)-1-bromo-2-methyl-7-((triethylsilyl)oxy)hept-1-en-3-ol (S19): 
 
 
  
NMR Spectra 
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(E)-7-bromo-5-methoxy-6-methylhept-6-enal (3.70): 
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(E)-1-bromo-2-methyl-7-((triethylsilyl)oxy)hept-1-en-3-one (S21):
 
NMR Spectra 
211 
(R,E)-((7-bromo-5-methoxy-6-methylhept-6-en-1-yl)oxy)triethylsilane (S43):
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(4E,9R,10E)-methyl 11-bromo-3-((tert-butyldimethylsilyl)oxy)-9-methoxy-2,4,10-
trimethylundeca-4,10-dienoate (S24): 
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(4E,9R,10E)-11-bromo-3-((tert-butyldimethylsilyl)oxy)-9-methoxy-2,4,10-
trimethylundeca-4,10-dienoic acid (3.117): 
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(9R,12S)-methyl 5-((R,2E,8E)-9-bromo-7-methoxy-8-methylnona-2,8-dien-2-yl)-
12-isopropyl-9-(3-methoxy-4-((triisopropylsilyl)oxy)benzyl)-2,2,3,3,6,8-
hexamethyl-7,10-dioxo-4-oxa-8,11-diaza-3-silatridecan-13-oate (3.118): 
  
NMR Spectra 
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(5R,6R,7E,9E,11R,15E,21R,24S)-methyl 17-((tert-butyldimethylsilyl)oxy)-6-
hydroxy-21-(4-hydroxy-3-methoxybenzyl)-24-isopropyl-11-methoxy-10,16,18,20-
tetramethyl-19,22-dioxo-5-phenyl-2,4-dioxa-20,23-diazapentacosa-7,9,15-trien-
25-oate (3.120): 
 
NMR Spectra 
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Methyl (tert-butoxycarbonyl)glycinate (S25): 
 
 
  
		






 !"!#$
$

 
%


%



	
&

'
%
!
	
"








	

%

%

%


	

  





	%	%






!
 !"!#$
$

 
	

















	


  





Appendices 
 218
Methyl 2-bromo-2-[(tert-butoxycarbonyl)amino]acetate (S26):
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Methyl 2-[(tert-butoxycarbonyl)amino]-2-(dimethoxyphosphoryl)acetate (3.97):
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3-Methoxy-4-[(triisopropylsilyl)oxy]benzaldehyde (3.101):
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Methyl (Z)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl}acrylate (3.98): 
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Methyl-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(triisopropyl-silyl)oxy]-
phenyl}propanoate (3.99): 
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Methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl} propanoate (3.100): 
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Methyl-{[tert-butoxycarbonyl](methyl)amino}-3-{3-methoxy-4-[ 
(triisopropylsilyl)-oxy]phenyl}propanoate (3.105): 
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2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(triisopropylsilyl)-
oxy]phenyl}propanoic acid (3.106): 
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Methyl {2-[(tert-butoxycarbonyl)methyl]amino-3-{3-methoxy-4-
[(triisopropylsilyl)-oxy]phenyl}propanoyl}-L-valinate (3.107):
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Methyl (Z)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3-methoxyphenyl)-
acrylate (3.98):
 
 
  
		






 !!	
"














	


#


$

"






"
%


&
'
	
(
''
	
)

	
 








	
"	"




' !!








"

"
"



"
"





"










	




	




 








Appendices 
 230
3-Methoxy-4-[(4-methoxybenzyl)oxy]benzaldehyde (S30): 
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Methyl (Z)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(4-methoxybenzyl)-
oxy]phenyl}acrylate (S31): 
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Methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-{3-methoxy-4-[(4-methoxy-benzyl)-
oxy]phenyl}propanoate (S32):
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Methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-(4-hydroxy-3-methoxyphenyl)-
propanoate (S33):
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Methyl (rac)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(4-
methoxybenzyl)oxy]phenyl}propanoate (S34):
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Methyl (rac)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-[(4-
methoxy-benzyl)oxy]phenyl}propanoyl-L-valinate (S35):
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Methyl [(R)-2-{[(benzyloxy)carbonyl](methyl)amino}-3-{3-methoxy-4-[(triiso-
propylsilyl)oxy]phenyl}propanoyl}-L-valinate (S28): 
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NMR Spectra 
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Methyl (rac)-2-{[(benzyloxy)carbonyl]amino}-3-{3-methoxy-4-[(triisopropyl-
silyl)-oxy]phenyl}propanoate (3.109): 
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Methyl (rac)-2-{[(benzyloxy)carbonyl](methyl)amino}-3-{3-methoxy-4-
[(triisopropyl-silyl)oxy]phenyl}propanoate (S36):
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Methyl [(rac)-2-{[(benzyloxy)carbonyl](methyl)amino}-3-{3-methoxy-4-[(triiso-
propylsilyl)oxy]phenyl}propanoyl}-L-valinate (S37):
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Methyl {(R)-3-(3-methoxy-4-[(triisopropylsilyl)oxy]phenyl}-2-(methylamino)-
propanoyl}-L-valinate (3.104) 
Minor diastereomer: 
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Major diastereomer (3.103):
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Methyl (Z)-2-[(tert-butoxycarbonyl)(methyl)amino]-3-{3-methoxy-4-
[(triisopropyl-silyl)oxy]phenyl}acrylate (S38):
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(R)-1-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-3-(3-methoxy-4-
((triisopropylsilyl)oxy)phenyl)-N-methyl-1-oxopropan-2-aminium chloride 
(3.112):
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NMR Spectra 
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Methoxymethyl (R)-2-(methoxymethoxy)-2-phenylacetate (S39):
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(R)-2-(Methoxymethoxy)-2-phenylacetaldehyde (3.83):
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(1R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-ol (3.84):
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(1R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-yl 3,5-dinitrobenzoate (S40):
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(1R,2R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-yl acetate (3.91): 
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(1R,2R)-1-(Methoxymethoxy)-1-phenylbut-3-yn-2-ol (3.92):
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(1R,2R,E)-1-(Methoxymethoxy)-1-phenyl-4-(tributylstannyl)but-3-en-2-ol (3.27):
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S -MTPA-diol ester (3.93): 
 
R -MTPA-diol ester (3.94) 
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8 Chiral HPLC Traces 
HPLC Chromatograms 
Racemate chromatogram: 
 
 
Enantioenriched chromatogram of ester 2.70: 
 
OD-H (4.6 mm x 250 mm, Daicel Chemical Industries); 99:1 Heptane/iPrOH; 0.5 
mL/min; 20 °C 
tR= 9.50 min; tS=10.57 min  
MeO
O
SiPh Ph
t-Bu
O
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racemate chromatogram: 
 
 
 
enantioenriched chromatogram of alcohol S2: 
 
AD-H (4.6 mm x 250 mm, Daicel Chemical Industries); 99:1 Heptane/iPrOH; 0.6 
mL/min; 20 °C 
tR= 15.3 min 
tS= 17.7 min  
O
SiPh Ph
t-Bu
OH
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racemate chromatogram: 
 
 
 
enantioenriched chromatogram 2.71: 
 
 
IC (Chiralcel); 99:1 Heptane/iPrOH; 0.6 mL/min; 20 °C 
tS= 11.1 min 
tR= 11.6 min  
O
SiPh Ph
t-Bu
O
EtO
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Determination of Enantiopurity of (–)-Pyridovericin (2.46) 
Racemate whole chromatogram: 
 
Magnified  racemate chromatogram:
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Enantioenriched whole chromatogram: 
 
 
Enantioenriched magnified chromatogram: 
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IC (Chiralcel); 70:30 Heptane/iPrOH; 1.0 mL/min; 20 °C Retention times for the Z-
isomer: 
tS = 8.0 min; tR = 8.8 min 
E/Z Ratio of (–)-Pyridovericin (2.46) 
 Enantioenriched chromatogram 
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Chiral HPLC traces of racemic methylation product 3.105 (up) and enantiopure 
product 3.111 (below). Chiralpak IA, 95:5 heptane/isopropanol, 1 mL/min, injection 
vol.: 1 µL, 25 °C, tR (S): 4.12 tR (R): 4.43. 
  
O
(R)
MeOOC
NBoc
OTIPS
OMeOOC
NBoc
OTIPS
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Chiral HPLC traces of racemic alcohol S19 (up) and CBS product S41 (below). 
Chiralpak OD-H, heptane/isopropanol 99:1, 1.0 mL/min, injection vol.: 1 µL, 25 °C, 
tR (S): 7.98 min, tR  (R): 8.59 min 
  
OTESBr
OH
(R) OTES
OH
Br
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Chiral HPLC trace of racemic amino ester 3.99 (up) and asymmetric hydrogenation 
product 3.100 (below). Chiralpak IA, 95:5 heptane/isopropanol, 0.5 mL/min, injection 
vol.: 1 µL, 25°C, tR (R): 14.5 min, tR (S): 19.5 min.).
30.10.2013 10:07:11  Page 1 / 1 
D:\Data\GademannGroup\Fabian\CW-034IA1.lcd 
Pfaltz Group Analysis Report
Sample Name : CW-034IA1
Data Filename : CW-034IA1.lcd
Method Filename : Standard_Method_PDA.lcm
Vial # : 1-31
Injection Volume : 1 uL
Date Acquired : 22.10.2013 16:04:31
IA, 95:5, 0.5 mL/min, 1 uL, 25 °C
 
<Chromatogram>
min
mAU
0 5 10 15 20 25
0
100
200 PDA Multi 1 210nm,4nm
 
14
.
57
6 
 
19
.
49
4 
PDA Ch1 210nm
Peak#
 1 
 2 
Total
Ret. Time
 14.576 
 19.494 
Height
 188382 
 104166 
 292548 
Area
 4277799 
 4323462 
 8601260 
Area%
 49.735 
 50.265 
 100.000 
min
mAU
0 5 10 15 20 25
0
25
50
75 PDA Multi 2 220nm,4nm
 
14
.
57
7 
 
19
.
49
4 
PDA Ch2 220nm
Peak#
 1 
 2 
Total
Ret. Time
 14.577 
 19.494 
Height
 72351 
 39614 
 111964 
Area
 1623933 
 1636560 
 3260493 
Area%
 49.806 
 50.194 
 100.000 
28.10.2013 10:39:16  Page 1 / 1 
D:\Data\GademannGroup\Fabian\CW-037IA1.lcd 
Pfaltz Group Analysis Report
Sample Name : CW-037
Data Filename : CW-037IA1.lcd
Method Filename : Standard_Method_PDA.lcm
Vial # : 1-31
Injection Volume : 1 uL
Date Acquired : 25.10.2013 15:08:46
IA, 95:5, 0.5 mL/min, 1 uL, 25 °C
 
<Chromatogram>
min
mAU
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0
0
100
PDA Multi 1 210nm,4nm
 
14
.
47
5 
 
19
.
39
7 
PDA Ch1 210nm
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